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Abstract 
The childhood neuromuscular disease spinal muscular atrophy (SMA) is caused by 
low levels of survival motor neuron (SMN) protein. Historically, SMA has been 
characterised as a disease primarily affecting lower motor neurons. However, recent 
breakthroughs have revealed defects in other non-neuronal cells and tissues. In vivo 
analysis of peripheral nerve showed defects in Schwann cells, manifesting as 
abnormal myelination and delayed maturation of axo-glia interactions. The 
experiments in this thesis were designed to build on these observations and examine 
whether Schwann cell defects are intrinsic and occur as a primary result of low levels 
of SMN in that cell type, or rather represent a secondary consequence of pathology 
in neighbouring motor neurons.  
I initially developed a protocol to allow isolation of high-yields of purified, 
myelination-competent Schwann cells from ‘Taiwanese’ SMA mice. SMA-derived 
Schwann cells had significantly reduced SMN levels and failed to respond normally 
to differentiation cues. Increasing SMN levels restored myelin protein expression in 
Schwann cells from SMA mice. Perturbations in expression of key myelin proteins 
were likely due to failure of protein translation and/or stability rather than 
transcriptional defects. Co-cultures of healthy neurons with SMA Schwann cells 
revealed a significant reduction in myelination compared to cultures where wild-type 
Schwann cells were used. The presence of SMA Schwann cells also disrupted neurite 
stability. Perturbations in the expression of key extracellular matrix proteins, such as 
laminin α2, in SMA-derived Schwann cells suggests that Schwann cells were 
influencing neurite stability by modulating the composition of the extracellular 
matrix.  
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Previous studies have demonstrated that low levels of SMN lead to disruption of 
ubiquitin homeostasis and decreased expression of ubiquitin-like modifier activating 
enzyme (UBA1) in the neuromuscular system, driving neuromuscular pathology via 
a beta-catenin dependent pathway. Label-free proteomics analysis of SMA and 
control Schwann cells identified 195 proteins with modified expression profiles. 
Bioinformatic analysis of these proteins using Ingenuity Pathway Analysis (IPA) 
software confirmed that major disruption of protein ubiquitination pathways was also 
present in Schwann cells from SMA mice. Immunolabeling and proteomics data both 
revealed that UBA1 levels were significantly reduced in SMA-derived Schwann 
cells. However, loss of UBA1 in Schwann cells did not lead to downstream 
modifications in beta-catenin pathways. Pharmacological inhibition of UBA1 in 
healthy Schwann cells was sufficient to induce defects in myelin protein expression, 
suggesting that UBA1 defects contribute directly to Schwann cell disruption in SMA. 
I conclude that low levels of SMN induce intrinsic defects in Schwann cells, 
mediated at least in part through disruption to ubiquitination pathways. 
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Chapter 1: Introduction 
1.1 Spinal muscular atrophy 
The term “lower motor neuron” refers to a group of neurons whose cell bodies are 
located in the spinal cord of the central nervous system (CNS) and whose axons 
project into peripheral nerves to reach target muscles (Figure 1.1). Degeneration of 
these motor neurons causes muscle weakness, which is normally progressive and 
leads to paralysis or death in severe cases (Rezania & Roos, 2013).  
 
Figure 1.1 Lower motor neuron and neuromuscular junction (NMJ). Figure taken from (Thomson 
et al., 2012) to show how lower motor neurons connect the central nervous system to target 
muscle fibres. Upper motor neurons synapse onto lower motor neurons in the spinal cord. 
Lower motor neurons then send their axons out to target skeletal musculature via peripheral 
nerves. Once a lower motor neuron axon has reached its target muscle (magnified box) it will 
form neuromuscular synapses with individual muscle fibres. The motor nerve terminal (green) 
makes up the presynaptic component of the NMJ, and features numerous synaptic vesicles 
containing the neurotransmitter acetylcholine. The postsynaptic muscle fibre (orange) is also 
specialised, with accumulations of acetylcholine receptors at the motor endplate (red). The 
motor nerve terminal is insulated by one or more terminal Schwann cells (blue). A second ‘NMJ 
capping cell’– the kranocyte – also overlies the terminal Schwann cell (pink). 
Examples of the most common motor neuron diseases are amyotrophic lateral 
sclerosis (ALS), which is characterised by degeneration of both upper and lower 
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motor neurons, and autosomal-recessive spinal muscular atrophy (SMA) that 
primarily affects lower motor neurons (Lefebvre et al., 1995; Bäumer et al., 2014). 
SMA, a predominantly childhood form of motor neuron disease, was first described 
by Werdnig and Hoffmann in the 1890s.  It is the most common genetic cause of 
infant mortality, with an estimated incidence of around 1 in 6,000 to 1 in 10,000 live 
births and a carrier frequency of 1 in 50 (Lefebvre et al., 1995; Ogino et al., 2002). 
1.1.2 Clinical classification 
SMA is classified into four clinical sub-types based on age of onset and motor 
functions achieved (Munsat & Davies, 1992). Type I SMA (also known as Werdnig-
Hoffmann disease) is the most severe and common type with onset ranging from the 
prenatal period to the first 6 months of age. Patients never acquire the ability to sit 
unsupported and they have severe hypotonia, often with no head control and an 
impaired breathing pattern (Dubowitz, 1999). In the most severe cases, with perinatal 
onset, reduced intrauterine movement, joint contractures at birth, congenital bone 
fractures and chest deformities have been observed (Felderhoff-Mueser et al., 2002). 
Patients rarely survive beyond 2 years of age without intervention (D'Amico et al., 
2011). 
Type II SMA is characterised by onset between 7-18 months of age (D'Amico et al., 
2011). Patients are able to sit unaided, but they do not acquire the ability to walk 
independently. Joint contractures and kyphoscoliosis, the abnormal curvature of the 
spine in coronal and sagittal plane, are very common. Chewing ability is affected by 
weakness of masticatory muscles (D'Amico et al., 2011; Haaker & Fujak, 2013). 
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SMA type III (also known as Kugelberg-Walender disease) is a milder SMA 
phenotype with the onset after 18 months of age. Patients typically achieve all major 
motor milestones including independent walking. Based on severity some might 
need a wheelchair, while others are able to walk and live relatively normal adult 
lives. However, some patients also develop scoliosis and poor mobility disorders, 
which leads to obesity and osteoporosis (D'Amico et al., 2011; Haaker & Fujak, 
2013). 
SMA type IV is not a childhood form of the disease with an incidence of <0.5/10000 
(Liu et al., 2011). Onset occurs in individuals older than 18 years of age and is 
inherited in either an autosomal dominant or rarely autosomal recessive manner. 
Adult onset autosomal dominant SMA is caused by different genetic factors from 
childhood SMA such as vesicle-associated membrane protein/synaptobrevin-
associated membrane protein B (VABP) and senataxin (SETX) (Nishimura et al., 
2004; Rudnik-Schöneborn et al., 2012). Motor impairments are mild and patients are 
able to walk in adulthood without respiratory and nutritional problems. Patients with 
this type of SMA have a normal life expectancy (D'Amico et al., 2011).  
1.1.2 Genetics 
SMA is caused by mutations in the survival motor neuron gene (SMN gene) 
(Brzustowicz et al., 1995). The SMN gene has been mapped to chromosome 5q11.2-
13.3, where large-scale deletions have been identified, by linkage analysis in all three 
types of childhood SMA (Brzustowicz et al., 1995). Lefebvre et al. reported the 
precise location of the SMN gene within the telomeric region of chromosome 5q13, a 
20 kb gene encoding a novel protein of 294 amino acids (Lefebvre et al., 1995). This 
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gene was either lacking or interrupted in the majority of SMA patients.  The patients 
that retain this gene carry either point mutations or short deletions in the consensus 
splice sites of introns 6 or 7. They also found a highly homologous gene in the 
centromeric region of 95% of their controls (Lefebvre et al., 1995). There is one 
telomeric copy (SMN1 gene) and several centromeric copies (SMN2 gene) in the 
human genome. In SMA patients the SMN1 gene is deleted or mutated, but at least 
one copy of SMN2 is retained (Melki et al., 1994). 
Although SMN1 and SMN2 encode near identical genes, it is the homozygous 
deletion of SMN1 gene that causes SMA. The major difference between the two 
genes occurs in 5 nucleotides, with a single nucleotide C-to-T transition (at codon 
280) in an exonic splicing enhancer (ESE) responsible for differential processing of 
SMN1 and SMN2 pre-mRNAs (Lorson et al., 1999; Monani et al., 1999). Exon 7 is 
skipped from the SMN2 mRNA transcripts and results in the generation of an 
unstable version of the SMN protein, which rapidly degrades (Lorson & Androphy, 
2000). However, exon 7 is not spliced out in 10% of the SMN2 mRNA transcripts, 
resulting in the formation of a small amount of functional, full-length SMN protein 
(Figure 1.2) (Lefebvre et al., 1995). Complete loss of SMN protein is fatal to all cells 
and tissues (Wang & Dreyfuss, 2001), but generation of the full-length SMN protein 
by SMN2 gene partially compensates for the loss in SMA. The number of SMN2 
copies is variable among individuals and there is correlation between SMN2 copy 
number and the severity of disease. The majority of SMA type I patients have one or 
two copies of the SMN2 gene, while SMA II type patients have three copies. Finally, 




Figure 1.2 SMN1 and SMN2 genes, structure and splicing. SMN1 and SMN2 have identical gene 
structure and are 99.9% identical at the sequence level. The essential difference between the 
two genes is a single nucleotide change in exon 7 (C or T as indicated). This single nucleotide 
change affects the splicing of the gene. Thus, the majority of SMN transcripts from SMN2 lack 
exon 7 whereas those from SMN1 contain exon 7. However, because SMN2 does produce some 
full-length SMN it can be viewed as a gene with reduced function but not loss of function. The 
loss of amino acids that are encoded by exon 7 results in the production of SMN protein with 
severely decreased stability. (Burghes & Beattie, 2009)  
1.1.3 SMN protein function 
Ubiquitous expression of SMN protein suggests it regulates fundamental activities in 
all cells (Burghes & Beattie, 2009). The SMN protein is a multi-functional protein, 
but is heavily involved in the assembly of protein-RNA complexes (RNPs) (Eggert et 
al., 2006). SMN is found both in the cell cytoplasm and nucleus, where it is highly 
enriched within bodies called Gems (Gubitz et al., 2004). Gems are associated with 
Cajal bodies (Liu & Dreyfuss, 1996), which contain high levels of factors for 
transcription and processing of many types of nuclear RNAs, such as small nuclear 
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ribonucleoproteins (snRNPs), nucleolar ribonucleoproteins (snoRNPs), and RNA 
polymerases (Ogg & Lamond, 2002; Gall, 2003; Gubitz et al., 2004). SMN forms a 
complex with 7 proteins called gemins in the gems. The best-characterised function 
of SMN is its role in assembly of snRNPs. In eukaryotes, splicing of pre-mRNA 
transcripts is carried out by snRNPs, which recognise the splice sites of introns and 
catalyse the splicing reaction to produce mature spliced mRNAs (Nilsen, 2003; Will 
& Lührmann, 2001). Each snRNP contains a single copy of uridine-rich small-
nuclear RNAs (snRNAs) and 7 common core proteins known as Sm proteins. The 
SMN/gemin complex binds directly to snRNAs and Sm proteins to assemble the Sm 
core onto the snRNA in an ATP-dependent manner, forming snRNPs (Liu & 
Dreyfuss, 1996; Pellizzoni et al., 2002; Workman et al., 2012) (Figure 1.3).  
 
Figure 1.3 The role of SMN in snRNP biogenesis. Following transcription, snRNAs are exported 
to the cytoplasm where they are bound by Gemin5 and delivered to SMN for Sm core assembly. 
Sm proteins are methylated in the cytoplasm by PRMT5 and then transferred to pICln, which 
delivers them to the SMN complex. The SMN complex binds Sm proteins through at least 2 
binding modes: 1) SMN binds to sDMA tails on Sm B, D1 and D3, and 2) Gemin2 recognizes the 
Sm-fold of the Sm D1/D2/E/F/G pentamer. Several SMA patient mutations disrupt these binding 
activities. SMN forms oligomers and is depicted here as a tetramer for simplicity. The SMN 
complex then assembles the Sm proteins into a heptameric ring on the snRNA. Assembled 
snRNPs are then imported into the nucleus for final maturation and function in pre-mRNA 
splicing (Workman et al., 2012). 
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There are also thought to be specific roles for SMN in motor neurons, the cells most 
severely affected in SMA. Motor axon-specific pathfindings defects have been 
observed in zebrafish treated with SMN-specific antisence morpholinos to 
knockdown SMN protein (McWhorter et al., 2003). In vitro analysis of motor 
neurons isolated from a transgenic SMA mouse model has shown reduced axon 
outgrowth compared to those isolated from wild-type mice (Rossoll et al., 2003). 
SMN has also been reported to involve in transport and trafficking of specific mRNA 
molecules in motor axons, such as ß-actin mRNA (Rossoll et al., 2003). Genome-
wide analysis of RNAs present in complexes containing SMN in differentiated NCS-
34 cells has identified 200 mRNAs associated with SMN. 30% of identified RNAs 
have been localised in axons of different neuron types and SMN depletion results in 
localization deficiencies of mRNAs essential for axogenesis (Rage et al., 2013). 
Furthermore, SMN accumulation has been observed in growth cones and filopodia-
like structures in both neuronal- and glial-like cells, suggesting a role for SMN in 
neurite outgrowth and neuromuscular maturation (Fan & Simard, 2002). These 
potential motor neuron specific functions of SMN may partly explain the higher 
sensitivity of this particular cell type to SMN depletion in SMA pathology. 
Reduction in SMN levels has also been reported to lead to wider peripheral nerve 
abnormalities in SMA human patients, including reduced conduction velocities, 
abnormal axonal membrane conductance and disrupted Schwann cells/myelin (Chien 
& Nonaka, 1989; Yonekawa et al., 2013; Farrar et al., 2011).  
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1.2 Peripheral nerve components and formation 
Axons within peripheral nerve are projections of cell bodies located in the dorsal root 
ganglia (sensory neurons), autonomic ganglia (autonomic neurons) and the ventral 
horn of the spinal cord or brain stem (motor neurons) (Topp & Boyd, 2006). Three 
layers of connective tissue protect axons: the endoneurium, the perineurium, and the 
epineurium. Single large diameter axons are myelinated by myelinating Schwann 
cells. In contrast, unmyelinating Schwann cells envelop several small diameter axons 
(Jessen & Mirsky, 2005). Both Schwann cell types are surrounded by a basal lamina 
of type IV collagen, fibronectin, laminin, and heparan sulfate proteoglycan (Thomas, 
1963). Between the axons is a loose connective tissue of type I and type II collagen 
fibrils in longitudinal orientation, fibroblasts, a few mast cells, macrophages, and 
endoneurial fluid. These structures are covered by endoneurium and form 
endoneurial compartments. Capillaries are also present within the endoneurial 
compartment. Bundles of axons are grouped into fascicles by epineurium and finally, 
nerve fascicles are held together by epineurium (Topp & Boyd, 2006) (Figure 1.4). 
Motor axons are one of the major neural components of peripheral nerves. Motor 
neuron somas are located in the ventral horn of the spinal cord, from where their 
axons leave the spinal cord via ventral roots and travel through peripheral nerves to 
their target muscles. Upon entering the muscle region, single axons undergo 
intramuscular branching and ultimately innervate between 10-2000 muscle fibres. 
The neuromuscular junction (NMJ) is a specialised synapse that forms at the contact 
point of motor neuron and muscle cell (Sanes & Lichtman, 1999) (Figure 1.4).  
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Figure 1.4 Schematic diagram of peripheral nerve. Nerves are composed of nerve fascicles 
(individual fascicles eventually become branches of the nerve). The entire nerve is enveloped 
by connective tissue called epineurium. Individual fascicles are delineated by connective tissue 
called perineurium. Layers of flattened mesodermal cells, called perineural epithelium 
(epithelioid) cells, line the perineurium and offer a protective barrier. Connective tissue inside 
perineural epithelium is called endoneurium. It surrounds neurolemmocytes. Axons are either 
myelinated or non-myelinated (not shown). The latter are ensheathed (by the dozens) by 
individual neurolemmocytes, in series. Individual myelinated axons are enveloped by a series 
of myelin internodes, each formed by a single neurolemmocyte 
(http://vanat.cvm.umn.edu/neurHistAtls/pages/pns1.html). 
1.2.1 Motor neuron development 
Lower motor neuron development and pathfinding have been shown to be disturbed 
in models of SMA both in vitro (Rossoll et al., 2003) and in vivo (McWhorter et al., 
2003). Lower motor neurons originate in the ventral portion of the neural tube, with 
developing axons projecting into ventral roots. Growth cones located at the tip of 
these axonal projections are sensory and motile structures that enable axon 
pathfinding (Vitriol & Zheng, 2012). 
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Motor axons make contact with their target muscles as myoblasts are fusing to 
generate myotubes (Sanes & Lichtman, 1999). Synaptic transmission starts as soon 
as a motor axon’s growth cone contacts its myotube (Sanes & Lichtman, 1999). 
Initially, transmission efficacy is low due to the lack of both pre- and post-synaptic 
specialization. At this stage, nerve terminals are bulbous enlargements containing 
few vesicles and no recognisable active zones. Pre-synaptic specialisations then 
follow increasing synaptic vesicle number, loss of axonal cytoskeletal elements, 
generation of active zones, clustering of vesicles at the active zones, and the 
polarisation of nerve terminals (Sanes & Lichtman, 1999). Stimulation of a motor 
axon can then lead to depolarisation of pre-synaptic membranes and an influx of 
Ca2+ into the synaptic terminal. Initially, multiple motor axons innervate skeletal 
muscle fibres. In the first two weeks after birth in rodents, axonal inputs compete 
with each other and all losing axons are removed in a process known as synapse 
elimination (Lichtman & Colman, 2000). 
1.3 Neuromuscular pathology in SMA 
SMA is characterised primarily by disruption of neuromuscular connectivity that 
precedes degeneration of lower motor neuron soma from the spinal cord and atrophy 
of skeletal muscle (Dachs et al., 2011). However, sensory neuron defects have also 
been documented (Yonekawa et al., 2013). Due to the lack of suitable human tissues 
either from biopsy or post-mortem, many groups have used animal models of SMA 
to study these disease processes. Several SMA mouse models have been developed 
because of the similarities in neuromuscular function between humans and mice 
(Sleigh et al., 2011). 
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1.3.1 Mouse models of SMA 
Unlike humans, mice have only one copy of the Smn gene and homozygous deletion 
of this gene results in embryonic cell death before implantation (Schrank et al., 
1997). Cre-loxP SMA mouse models generated from deletion of Smn exon 7 from a 
conditional allele (SmnF7) produce a complete loss of cellular SMN in all target cells, 
thereby providing only limited information about SMA pathology (Sleigh et al., 
2011). In order to better recapitulate the human SMA genotype, the human SMN2 
transgene has been expressed on a Smn-null background (Sleigh et al., 2011). In 
these mice the severity of the disease correlates directly with SMN2 copy number, 
similar to what has been observed in human patients (Hsieh-Li et al., 2000; 
Feldkötter et al., 2002). 
‘Severe’ mice modelling SMA, carrying one or two copies of SMN2 transgene (Smn -
/-; SMN2+/+), are similar to controls at birth but die before postnatal day 7 (P7) 
(Monani et al., 2000). Extended life span of SMA mice model is essential to study 
molecular mechanisms of SMA pathogenesis during disease progression and to 
recapitulate the human SMA pathogenesis. Therefore, a milder mouse model known 
as SMN∆7 (Smn-/-; SMN2+/+; SMN∆7+/+) has been generated by inserting an 
additional SMN2 gene without exon 7, called the delta7 transgene (Kerr et al., 2000). 
Another milder mouse model of SMA, known as the ‘Taiwanese’ SMA model, has 
four copies of the SMN2 gene (two copies per allele) (Smn-/-; SMN2tg/+) and can 
survive for 12 days (Hsieh-Li et al., 2000; Riessland et al., 2010). 
One alternative approach that has been shown to decrease SMN levels in mice is to 
have a knock-in allele that impairs endogenous smn splicing (Smn2B/-), which results 
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in a milder phenotype with life expectancy of around 1 month (Bowerman et al., 
2009).  
1.3.2 Other SMA model organisms 
Several other SMA model organisms have been generated due to the high degree of 
SMN gene evolutionary conservation between different species (Sleigh et al., 2011). 
Depletion of Smn-1, the ortholog of human SMN in Caenorhabditis elegans has 
been shown to induce late larval arrest, reduced lifespan as well as impaired 
locomotion and pharyngeal activity (Briese et al., 2009). Drosophila SMA models 
have been generated by point mutations in Smn similar to those found in SMA 
patients (Chan et al., 2003). These flies show abnormal motor behaviour and defects 
at the NMJ. The Drosophila SMA model has also been used to screen genetic 
modifiers of Smn (drosophila SMN ortholog) phenotype and identify new genes that 
previously have not been associated with Smn (Chang et al., 2008). SMN has been 
reduced using antisense morpholino in zebrafish, showing for the first time 
perturbations in motor axon developments in vivo (McWhorter et al., 2003). 
However, mouse models are probably the best model to address fundamental 
questions in SMA pathogenesis, due to the similarities between the neuromuscular 
system in humans and mice (Sleigh et al., 2011). 
1.3.3 Motor neuron pathology in SMA 
Mouse models with low levels of SMN have been instrumental in defining 
neuromuscular pathology in SMA. For example, functional motor deficits and 
degeneration of motor neurons were reported in initial studies (Monani et al., 2000). 
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Several subsequent studies using tissue from these mice reported that reduced SMN 
protein levels play an important role in neurodevelopmental processes of the lower 
motor neuron. Primary motor neurons exhibited disrupted actin dynamics in axons 
and growth cones, resulting in shorter neurites (Rossoll et al., 2003). SMN 
knockdown in PC12 cell lines also showed similar defects in cytoskeletal integrity 
and a subsequent disruption in neuritogenesis (Bowerman et al., 2007). Moreover, 
neurosphere-derived neural stem cells (NSCs) produced from the brains of a 
hypomorphic series of SMA mice displayed morphological alterations and neuronal 
differentiation was inhibited (Shafey et al., 2008). Similarly, motor neuron 
pathfinding is deficient in SMN-depleted zebrafish (McWhorter et al., 2003). 
However, early embryonic formation of the neuromuscular system in mice revealed 
no significant abnormalities in motor axon formation, axonal projection or reduction 
in outgrowth (McGovern et al., 2008). Morphological and genetic analysis of lower 
motor neuron connectivity in pre-symptomatic severe SMA mice showed no 
significant disruption in lower motor neuron prior to the onset of symptoms (Murray 
et al., 2010). Therefore SMN depletion can influence neurodevelopmental processes 
in vitro and in lower organisms, but these defects are not sufficient to induce 
abnormal development in mammalian lower motor neurons (Murray et al., 2010). 
In mice, the NMJ shows the earliest signs of postnatal pathology in the 
neuromuscular system (Murray et al., 2008). In SMA mice, NMJ defects can be 
detected when the number of motor neuron cell bodies was not significantly reduced 
(Dachs et al., 2011). Poor terminal arborisations have been shown in two SMA 
mouse models as well as immature post-synaptic AChRs and intermediate filament 
aggregates (Kariya et al., 2008). Severe SMA NMJs release significant fewer 
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vesicles (50% reduction) from pre-synaptic terminals, which lead to NMJ functional 
abnormalities (Kong et al., 2009). A GTP-binding protein, Rab3A has been reported 
to be down-regulated in SMA muscles that are normally innervated (Dachs et al., 
2011). Rab3A contributes to the targeting of synaptic vesicles to the active zones and 
induce neurotransmitter release in the synaptic cleft (Dachs et al., 2011). 
NMJs in human patients have similar structural defects (Kariya et al., 2008). 
Abnormal accumulation of neurofilaments has been observed in nerve terminals of 
type I SMA patient’s diaphragm along with smaller endplates than controls (Kariya 
et al., 2008). Another human SMA study revealed prenatal abnormalities in 
diaphragm development, pre-terminal accumulation of vesicles and aberrant 
ultrastructure of nerve terminals (Martínez-Hernández et al., 2013).  
Widespread heterogeneity has been observed in the susceptibility of individual motor 
neurons to neurodegeneration in SMA mouse models (Ling et al., 2012; Thomson et 
al., 2012). Analysis of motor neurons innervating NMJs across a range of muscles 
that are affected and resistant to SMA revealed no significant difference in 
morphological characteristics of neurons. This suggests that either subtle molecular 
differences between motor neurons, or extrinsic factors from other cell types, 
possibly determine relative susceptibility in SMA (Thomson et al., 2012). 
1.3.4 Sensory neuron pathology in SMA 
Although motor neuron degeneration is the major hallmark of SMA pathology, 
sensory neuron involvement has also been observed. Sensory neurons from SMA 
type I patients have been shown to exhibit wallerian degeneration (Carpenter et al., 
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1978) as well as reduced fibre density, conduction velocity and sensory nerve action 
potential amplitude (Rudnik-Schöneborn et al., 2003; Yonekawa et al., 2013). 
Sensory neuron degeneration was more significant in large myelinated fibres. Unlike 
severe SMA patients, SMA type II and III patients showed no abnormalities in 
sensory neurons (Yonekawa et al., 2013). In a drosophila model of SMA, restoration 
of SMN in either muscles or motor neurons did not alter disease phenotype (Imlach 
et al., 2012). However, SMN restoration in proprioceptive neurons and interneurons 
in the motor circuit corrected neuromuscular defects. Inducing circuit excitability by 
inhibiting K+ channels also ameliorated SMN-dependent phenotypes (Imlach et al., 
2012). It has been reported that SMA motor neurons show reduced proprioceptive 
reflexes that correlate with decreased number and function of synapses on motor 
neuron somata and proximal dendrites (Mentis et al., 2011). Motor neuron loss 
followed afferent synapse loss. Treatment with highly specific and potent histone 
deacetylase inhibitor Trichostatin A (TSA), which increases SMN2 gene 
transcription, partially restored spinal reflexes and subsequently improved motor 
behaviour (Mentis et al., 2011). However, a recent study has challenged the 
causative role for proprioceptive input on motor neurons in SMA pathology 
(Gogliotti et al., 2012). Analysis of sensory neurons in severe SMA mice has 
demonstrated no widespread loss of sensory neurons in the lumbar dorsal root 
ganglion at postnatal day 3-5, when motor neuron loss was observed (Jablonka et al., 
2006). However, cultured sensory neurons had shorter neurites, smaller growth cones 
and reduced beta-actin mRNA and protein in neurite terminals. Similarly, sensory 
neuron terminals were smaller in footpads of severe SMA mouse embryos, indicating 
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that pathological alterations were not restricted to solely motor neurons (Jablonka et 
al., 2006). 
1.4 SMA therapy 
There is currently no cure for SMA, but there are several approaches being 
developed to either restore SMN in affected cells, or to protect the most vulnerable 
cells (e.g. motor neurons). Increasing the amount of full-length SMN protein from 
the SMN2 gene is one major focal point for SMA therapeutic development. High 
levels of SMN can be achieved by inhibiting SMN2 pre-mRNA splicing, increasing 
SMN2 transcription, or stabilising SMN∆7 transcripts (Avila et al., 2007; Mattis et 
al., 2009; Passini et al., 2011; Ling et al., 2012). Similarly, using viral gene therapy, 
the SMN gene can also be reintroduced to restore SMN levels in depleted cells 
(Valori et al., 2010; Foust et al., 2010; Dominguez et al., 2011). The possibility to 
replace lost motor neurons by differentiated neural stem cells is another potential 
approach (Corti et al., 2010). From a different perspective, neurotrophic agents have 
been shown to have a protective role against neurodegeneration, promoting motor 
neuron survival (Lesbordes et al., 2003; Haddad et al., 2003). These approaches are 
covered in more detail in the subsequent sections. 
1.4.1 Antisense oligonucleotides 
Modulating SMN2 pre-mRNA splicing is a direct approach to restore proper 
expression of full-length SMN protein. Antisense oligonucleotides (ASOs) can 
increase expression of SMN2 by binding to an intronic splicing silencer (ISS), which 
leads to inclusion of exon 7 in the SMN2 transcript, subsequently increasing SMN 
 17 
protein levels (Hua et al., 2010). Off-target effects are limited in this approach by 
targeting specific nucleotides. ASOSs that block intron 7 ISS in human SMN2 gene, 
termed ISS-N1, strongly enhance SMN2 exon 7 inclusion in cultured patient 
fibroblasts (Singh et al., 2006). Intracerebroventicular (ICV) infusion of ASO-10-27, 
the 18mer 2'-O-2 methoxyethyl ASO targets ISS-N1 in intron 7, has shown robust 
and long-lasting increase in SMN2 exon 7 inclusion in adult mice of type III SMA 
with no subsequent CNS inflammation (Hua et al., 2010). Embryonic ICV 
administration of ASO-10-27 significantly reduced the tail and ear necrosis in these 
mice (Hua et al., 2010). Furthermore, muscle physiology, motor neuron function and 
survival have been improved after ASO-10-27 injection into the cerebral lateral 
ventricles in severe SMA mice (Passini et al., 2011). The same study demonstrated 
that intrathecal infusion of ASO-10-27 into Cynomolgus monkeys delivered ASO to 
all regions of the spinal cord and therefore can be used as practical route for 
delivering this therapeutic in the clinic (Passini et al., 2011). 
Osman et al., has used bifunctional RNAs to obtain more efficient ASO for SMA 
treatment (Osman et al., 2012). They inhibited ISS-N1 through antisense 
oligonucleotides and at the same time recruit known activators of SMN exon 7 
inclusion: splicing factor 2/ alternative splicing factor (SF2/ASF) or transformer-2 
protein homolog ß (hTra2ß1) (Osman et al., 2012). Both of these exonic splicing 
factors have shown to promote inclusion of exon 7 to produce full length SMN 
(Cartegni & Krainer, 2002; Hofmann et al., 2000). Bifunctional RNAs elicited 
induction of SMN protein in the brain and spinal cord of neonatal SMA∆7 mice, 
leading to an increase in weight and an extension of lifespan to the extent not 
achieved by using ISS-N1 antisense alone (Osman et al., 2012).  
 18 
1.4.2 Histone deacetylase inhibitors 
Histones are proteins that promote DNA to form condense chromatin. The post-
translational modifications of histones such as methylation, acetylation and 
phosphorylation determine the accessibility of DNA for transcription (Johnson & 
Dent, 2013). Histone deacetylases (HDACs) repress transcriptional activity and 
therefore HDAC inhibitors (HDACi) increase transcription (Johnson & Dent, 2013).  
HDAC inhibitors have been shown to increase SMN levels by inducing endogenous 
SMN2 promoter activity, but this effect is not SMN2 specific and is likely to have 
detrimental off-target effects (Ling et al., 2012). It has been shown that the HDAC 
inhibitor, Trichostatin A (TSA) preserves innervation of muscles of SMN∆7 mice 
(Ling et al., 2012). A single intraperitoneal dose of TSA has been demonstrated to 
result in modest increase in SMN gene expression in an SMA mouse model. Daily 
TSA delivery after onset of weight loss and motor deficits improved survival, 
attenuated weight loss, enhanced motor behaviour, and increased myofiber size 
(Avila et al., 2007). HDAC inhibitors also improve cardiac phenotypes (Heier et al., 
2010) as well as sensorimotor connectivity in SMA mice (Mentis et al., 2011). 
1.4.3 SMN∆7 transcript stabilisation 
SMN∆7 transcript is the main transcript produced by the SMN2 gene, but it is 
unstable and rapidly degrades (Lorson & Androphy, 2000). One therapeutic 
approach for SMA is to stabilize this transcript. Aminoglycosides have been shown 
to suppress efficient recognition of stop codons, resulting in significantly enhanced 
levels of SMN protein in SMA patient fibroblasts (Mattis et al., 2009). Geneticin 
(G418) is a compound acting upon the SMN∆7 stop codon sequence and induces 
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readthrough at this site in a dose dependent manner (Heier & DiDonato, 2009). G418 
increased SMN levels in patient cell lines as well as SMA mice. Motor function was 
improved in the mice treated with G418. However, lifespan was not increased, most 
likely due to its toxicity (Heier & DiDonato, 2009). TC007, a novel aminoglycoside 
has been delivered directly to the CNS in an intermediate SMA mouse model, 
increasing SMN levels in both the brain and spinal cord (Mattis et al., 2009). It 
increased lifespan and ventral horn cell number. TC007 also enhanced SMN protein 
levels in induced pluripotent stem cell-derived SMA motor neuron cultures (Mattis et 
al., 2009).  
1.4.4 Neurotrophic and neuroprotective agents 
Developing motor neurons require trophic support from their target, the skeletal 
muscle. Cardiotrophin-1 (CT-1), an interleukin 6 cytokine is highly expressed in 
embryonic skeletal muscle (Oppenheim et al., 2001). It is secreted by myotubes and 
increases the survival of embryonic mouse motor neurons. CT-1 deficiency has been 
shown to increase motor neuron cell death in spinal cord and brainstem nuclei of 
mice in late embryonic and neonatal stages (Oppenheim et al., 2001). Systemic 
delivery of adenoviral vector expressing CT-1 improves median survival and delays 
motor defects of mutant mice lacking Smn exon 7 in neurons. It also exerts a 
protective effect against loss of proximal motor axons and aberrant cytoskeletal 
organization of motor synaptic terminals (Lesbordes et al., 2003).  
Glutamate blocking agent Riluzole has a neuroprotective effect and is the only 
medication demonstrated to be mildly effective in prolonging survival in ALS. 
Riluzole has improved median survival and exerted its protective effect against 
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aberrant cytoskeletal organization of motor synaptic terminals but not against loss of 
proximal axons in post-symptomatic SMA mutant mice model (Haddad et al., 2003). 
Riluzole has been shown to exhibit enhance expression of brain-derived neurotrophic 
factor (BDNF), which promotes neuronal survival, guides axonal pathfinding, and 
participates in activity dependent synaptic plasticity (Katoh-Semba et al., 2002). It 
recently has been shown to act via small conductance Ca2+-activated K+ (SK) 
channels to ameliorate defects in both mouse and C.elegans SMA models (Dimitriadi 
et al., 2013). However these results should be confirmed in human SMA patients. 
1.4.5 Gene therapy 
Replacement of SMN1 is the main focus of gene therapy approaches for SMA. 
Lentivector expressing human SMN has been used to restore SMN protein levels in 
SMA type 1 fibroblasts (Azzouz et al., 2004). SMN lentiviral injections to various 
muscles of SMA mice restored SMN in motor neurons, reduced motor neuron death 
and increased life expectancy 20-38% (Azzouz et al., 2004). The challenge in this 
field is effective gene delivery to the brain and spinal cord across the blood brain 
barrier (BBB). Foust et al. showed that the self-complementary adeno-associated 
virus (scAAV) 9 injected intravenously bypasses the BBB and efficiently target cells 
of the CNS (Foust et al., 2009). The same group showed neonatal delivery of SMN1 
with scAAV9 vector rescued motor neuron functions, neuromuscular physiology and 
improved life span in SMA mice (Foust et al., 2010; Valori et al., 2010; Dominguez 
et al., 2011). They also observed extensive scAAV9-mediated motor neuron 
transduction after injection into a newborn Cynomolgus macaque. The fact that 
AAV9 traverses the blood brain barrier in nonhuman primate emphasises the clinical 
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potential for scAAV9 gene therapy in SMA (Foust et al., 2010). Delivery of scAAV9 
SMN1 gene has shown to reduce severity of heart defects and improve muscle fibre 
size in SMA mice (Bevan et al., 2010; Glascock et al., 2012). 
1.4.6 Stem cell therapy 
Corti et al. have injected primary neural stem cells from spinal cord as well as ES 
cell-derived neural cell precursors into the spinal cord of SMN∆7 model mice (Corti 
et al., 2009; Corti et al., 2010). 15% of the injected cells exhibited an astrocyte 
phenotype and, to a much lesser extent, motor neuron characteristics. The transplant 
led to an improvement in disease phenotype, with a 50% increase in weight, and 40% 
increase in lifespan. One of the beneficial effects of transplantation is the release of 
growth factors from transplanted human motor neurons both in vivo and in vitro. 
Although this study demonstrates the feasibility of using stem cells for SMA therapy, 
the results are not comparable to those obtained by gene and molecular based 
therapeutic approaches (Corti et al., 2010; Zanetta et al., 2014). 
1.5 SMN-independent pathways contributing to SMA pathology 
Recently, extensive progress has been made in understanding the biology of SMA 
pathogenesis; this includes the identification of new roles and down-stream targets 




X-linked spinal muscular atrophy (SMAX2) is a genetically distinct type of SMA 
with similar clinical characteristics, such as loss of cells in ventral horn of the spinal 
cord, hypotonia and areflexia (Ramser et al., 2008). SMAX2 is caused by mutations 
in ubiquitin-like modifier-activating enzyme 1 gene (UBA1). UBA1 is an enzyme 
involved in catalysing the initial step of the ubiquitination pathway (Rubinsztein, 
2006). The de-ubiquitination enzyme, ubiquitin carboxy-terminal hydrolase L1 
(UCHL1) has also been shown to be significantly increased in fibroblasts from SMA 
type I patients (Hsu et al., 2010). Recently, it has been shown that perturbations in 
ubiquitination pathways are a robust feature of Drosophila, mouse and zebrafish 
models of SMA (Wishart et al., 2014). UBA1 levels were shown to be reduced 
dramatically in a mouse model of SMA, while UCHL1 levels increased. UBA1 and 
SMN were reported to physically interact in the neuronal cytoplasm while disruption 
in uba1 mRNA splicing was observed in the spinal cord of SMA mice (Wishart et 
al., 2014). UBA1 perturbations led to beta-catenin accumulation. Pharmacological 
suppression of beta-catenin significantly ameliorated neuromuscular pathology in 
different animal models of SMA. However, UBA1-associated disruption of β-catenin 
was restricted to the neuromuscular system in SMA mice; therefore, pharmacological 
inhibition of β-catenin in these animals failed to prevent systemic pathology in 
peripheral tissues and organs, indicating fundamental molecular differences between 
neuromuscular and systemic SMA pathology (Wishart et al., 2014). This study 
showed that reduction in UBA1 levels induced SMA neuromuscular pathology by 
modulating downstream effector beta-catenin signalling, confirming a role for the 
ubiquitination pathway in pathogenesis of SMA. 
 23 
1.5.2 Plastin-3 
Oprea et al. reported a case of female individuals with homozygous deletion of 
SMN1, who did not exhibit any SMA symptoms, despite carrying the same number 
of SMN2 copies as their affected siblings (Oprea et al., 2008). Increased levels of 
plastin-3 were observed in these individuals (Oprea et al., 2008). Plastin-3 is known 
as an actin binding protein that regulates organisation of actin filaments and 
colocalises with SMN throughout motor neuron axons. Plastin-3 levels have been 
reported to be reduced in the brain and spinal cord of SMA mice (Bowerman et al., 
2009). Furthermore, overexpression of plastin-3 in ‘Taiwanese’ SMA mice improved 
neuromuscular defects, suggesting protective role for plastin-3 (Ackermann et al., 
2013). 
1.6 Other non-neuronal cells and tissues contributing to SMA 
pathology 
SMN is a ubiquitously expressed protein, depletion of which clearly leads to 
pathology in motor neurons. However, other studies have reported SMA pathology 
in other cells and tissues, such as liver, heart, vasculature and bone (Hamilton & 
Gillingwater, 2013). 
1.6.1 Muscle 
Although muscle cells undergo pathological alterations in SMA (Monani, 2005), it is 
not known whether these alterations are due to intrinsic defects in SMA muscle or as 
a secondary consequence of motor neuron pathology. It has been shown that muscle 
biopsy extracts from SMA patients inhibit neurite outgrowth of chick spinal motor 
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neurons (Henderson et al., 1987). Co-cultures of SMA patient muscle with rat spinal 
cord explants undergo degeneration, suggesting that muscles may play a role in this 
atrophy (Braun et al., 1997). However, analysis of these co-cultures revealed no 
neurotrophin deprivation or secretion of toxic factors, suggesting intrinsic defects in 
SMA skeletal muscle (Braun et al., 1997). 
Myotubes are smaller in SMA patient fetuses, indicating a delay in muscle growth 
and maturation (Martínez-Hernández et al., 2009). Primary cultures of embryonic 
human skeletal muscle cells from SMA patients are unable to fuse correctly to form 
myotubes. AChRs are also defective in myotubes from SMA patients (Arnold et al., 
2004). Fusion defects, as well as reduced proliferation, correlate with SMN levels in 
myoblast cells (Shafey et al., 2005). Satellite cells, skeletal muscle-resident stem 
cells isolated from severe SMA mice exhibit abnormal differentiation and reduced 
efficiency in forming myotubes, indicating a role for SMN protein in the intrinsic 
regulation of muscle differentiation (Hayhurst et al., 2012). Analysis of the 
molecular composition of skeletal muscle in pre-symptomatic severe SMA mice has 
shown significant increased activity of cell death pathways in the absence of any 
detectable degenerative changes in innervating lower motor neurons (Mutsaers et al., 
2011). These molecular changes were also confirmed in skeletal muscles from type 
II/III SMA patients (Mutsaers et al., 2011). Although these data suggest a direct role 
for SMN in skeletal muscle, the extent to which such intrinsic defects contribute to 
overall SMA pathology remains unclear. 
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1.6.2 Liver 
Liver-specific deletion of murine Smn exon 7 results in severe impairment of liver 
development associated with iron overload, dramatic liver atrophy and late 
embryonic lethality of mutant mice (Vitte et al., 2004). Neonatal SMA mice have 
decreased circulating hepatic insulin-like growth factor 1 (IGF-1), confirming the 
importance of liver in SMA pathogenesis (Hua et al., 2011). IGF-1 is a neurotrophic 
factor and is necessary for normal postnatal growth, which could be restored by 
increasing SMN level systemically (Hua et al., 2011). 
1.6.3 Pancreas 
It has been shown that SMN protein has a role in glucose metabolism and pancreatic 
development (Bowerman et al., 2012). SMN-depleted mice (Smn+/-) that lack 
neuromuscular pathology showed abnormal localisation of glucagon-producing alpha 
cells in the pancreatic islets and increased hepatic insulin and glucagon sensitivity 
(Bowerman et al., 2014). Metabolism abnormalities have also been reported in SMA 
patients, including metabolic acidosis, abnormal fatty acid metabolism, 
hyperlipidemia, and hyperglycemia (Bowerman et al., 2012). 
1.6.4 Heart 
Severe SMA patients with a single SMN2 copy develop heart defects such as atrial, 
ventricular and septal defects, as well as cardiac arrhythmias (Rudnik-Schöneborn et 
al., 2008). SMA mice suffer from severe bradyarrhythmia with progressive heart 
block and impaired ventricular depolarisation (Heier et al., 2010). Structural defects 
in the heart precede motor neuron dysfunction (Shababi et al., 2010). These defects 
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can exist independently of motor neuron and muscle pathology (Gogliotti et al., 
2012). 
1.6.5 Vasculature 
Distal necrosis develops in SMA type I infants due to defects in vasculature (Araujo 
et al., 2009). Vascular defects and subsequent necrosis in tail and ear pinnae have 
also been observed in mild and severe mouse models of SMA (Hsieh-Li et al., 2000; 
Foust et al., 2010). It has been reported that a significant decrease (45%) in the 
density of the capillary bed is present in skeletal muscles of late symptomatic severe 
SMA mice (Somers et al., 2012). Capillary calibre was increased by 50% in SMA 
mice, while ramification of capillaries in muscle was reduced. This could have a 
dramatic influence on oxygen delivery to muscles and the removing of their 
metabolites, suggesting vasculature defects are likely to contribute to SMA 
pathogenesis (Somers et al., 2012). 
Taken together, these studies challenge the notion that SMA is solely a lower motor 
neuron disorder, indicating that SMA is in fact a multi-system disorder (Hamilton & 
Gillingwater, 2013). Recently, it has been suggested that there is a gradient of 
vulnerability to SMN reduction in affected cells in SMA, with motor neurons at one 
end of spectrum (Sleigh et al., 2011). Therefore, therapies aimed to increase SMN 
levels should be delivered systemically and during specific developmental time 
points in which SMN delivery could ameliorate the pathology in all affected cells 
(Sleigh et al., 2011). The identification of new target cells in SMA is of great 
importance not only for understanding the overall pathogenesis of SMA but also for 
the design of efficient treatment strategies. 
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1.7 Axon-Schwann cell interaction  
Schwann cells, the major glial cells in the peripheral nervous system (PNS) play a 
key role in maintenance and regeneration of the PNS and therefore, could be one of 
the potential target cells contributing to pathogenesis of SMA. Schwann cells are 
highly specialised glial cells that wrap axons with multi-layered myelin membrane 
essential for rapid impulse conduction. Investigations have identified the axonal 
signals that regulate Schwann cell differentiation and myelination. Schwann cells 
also maintain long-term functional integrity of the axons, which is not always 
dependent on their myelinating functions (Nave & Trapp, 2008). 
Loss of glial support leads to progressive axonal degeneration (Beirowski, 2013). 
Axonal loss independent of neuronal cell body pathology highlights the critical role 
of glia in axonal integrity (Beirowski, 2013). However, the underlying mechanisms 
remain unclear. Microarray analysis of spinal cord in the post-symptomatic SMA 
mouse model has highlighted a significant disruption in myelination pathways, 
suggesting that defects in axo-glial interactions may contribute to the pathogenesis of 
SMA (Murray et al., 2010). 
1.7.1 Schwann cell differentiation and myelination 
Glial cells in the PNS, including satellite cells in peripheral ganglia, myelinating and 
non-myelinating Schwann cells in nerve trunks, are derived from neural crest cells 
(Woodhoo & Sommer, 2008). Neural crest-derived stem cells migrate ventrally and 
differentiate to Schwann cell precursors (SCPs) at embryonic day 12-13 in mice, 
which are subsequently differentiated to immature Schwann cells at embryonic day 
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13-15 (Jessen et al., 1994; Dong et al., 1995). The postnatal fate of immature 
Schwann cells is determined by which axons they randomly associate with, with 
myelination being selectively activated in those cells that happen to envelope single 
large diameter axons (Jessen & Mirsky, 2005). These transitions are strikingly 
dependent on survival factors, mitogens and differentiation signals from the 
associating axons (Dong et al., 1995). All transitions are reversible except for the 
transition from SCPs to immature Schwann cells. The onset of myelination is the 
only step of differentiation that is linked to cell cycle exit (Stewart et al., 1993). 
Numerous molecules have now been implicated in the regulation of Schwann cell 
development. 
SRY (sex determining region Y) box10 (SOX10) is necessary for the generation of 
all peripheral glia from the neural crest (Britsch et al., 2001), whereas bone 
morphogenetic proteins (BMPs) inhibit glial differentiation (Shah et al., 1996). Type 
III isoform of axon-derived neuregulin 1 (NRG1) is required for the survival of SCPs 
in embryonic nerves as well as SCP proliferation both in vitro and in vivo. In mice 
that selectively lack this isoform, SCPs initially populate spinal nerves, but their 
numbers are severely reduced, indicating NRG1 type III is important for SCP 
survival (Wolpowitz et al., 2000).  
During the transition of SCPs to immature Schwann cells, connective tissue spaces 
open up within the nerves and become vascularised. Developing perineurium appears 
at the nerve surface. SCPs are found at the outer margin of the nerves, and inside 
them. They connect to each other through sheet-like processes that envelope a large 
number of axons. In contrast, families of immature Schwann cells ensheath large 
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groups of axons (Wanner et al., 2006; Jessen & Mirsky, 2005). Unlike SCPs, 
immature Schwann cells can support their own survival in an autocrine manner by 
secreting a cocktail of survival factors (Meier et al., 1999). NRG1 accelerates the 
conversion of SCPs to immature Schwann cells, as well as promoting SCP survival 
and proliferation (Morrissey et al., 1995). Notch has also been shown to promote the 
generation of Schwann cells from SCPs as well as mediate Schwann cell 
proliferation (Woodhoo et al., 2009) 
In a process known as radial axonal sorting, which starts around the time of birth, 
individual Schwann cells separate from Schwann cell families and adopt a 1:1 
relationship with large diameter axons (Jessen & Mirsky, 2005). At the same time, 
the number of Schwann cells and axons are matched by regulating Schwann cell 
survival and proliferation. Studies have shown that the amount of NRG1 type III 
expressed at the axonal surface is an indicator of axonal thickness and determines the 
fate of associated Schwann cells (Simons & Trotter, 2007). Overexpression of NRG1 
leads to hypermyelination of large axons or myelination of small calibre axons 
(Michailov et al., 2004). It has been shown that deletion of various laminin isoforms 
such as laminin-2 (α2, β1, γ1) and laminin-8 (α4, β1, γ1) impairs radial sorting (Yang 
et al., 2005). Similarly, Schwann cells lacking the laminin receptor, β1integrin show 
the same phenotype (Feltri et al., 2002). It has been reported that laminin/ β1integrin 
regulates Schwann cell process extension and radial sorting by mediating Rac1 
activity (Nodari et al., 2007). Another receptor for laminin is dystroglycan (DG), 
mutations in which lead to infolding of internodal myelin and late onset 
demyelination similar to that observed in L-periaxin deficient mice (Gillespie et al., 
2000). L-periaxin has been shown to be necessary for formation of the DG-
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dystrophin related protein-2 (DG-DRP2) complex, which is involved in the link 
between the extracellular matrix (ECM) and the Schwann cell cytoskeleton (Sherman 
et al., 2001). L-periaxin deficient Schwann cells exhibit disruption of Cajal bands 
and its nutritive function, resulting in reduced Schwann cell length during nerve 
growth (Court et al., 2004). These observations indicate the important role of the 
ECM in Schwann cell elongation and process extension involved in radial sorting 
(Chernousov et al., 2008). 
There are various signalling pathways that activate or inhibit myelination in 
immature Schwann cells. Myelination is promoted by the transcription factors early 
growth response 2 (EGR2, also known as Krox20), POU-domain transcription factor 
OCT6 (also known as POU3f1) and brain 2 class III POU-domain protein (BRN2) 
and inhibited by c-Jun, Notch and SRY (sex determining region Y) box 2 (SOX2) 
(Jessen & Mirsky, 2005). Deletion of OCT6 and its close relative BRN2 has been 
shown to cause severe but transient arrest at the promyelin stage, resulting in late 
onset of myelination and hypomyelinated nerves in adult animals (Jaegle et al., 
2003). OCT6/BRN2 cooperates with SOX10, the master regulator of Schwann cell 
lineage, to upregulate EGR2 in myelinating cells through the OCT6 Schwann cell 
enhancer (Jagalur et al., 2011). EGR2 is a transcription factor required for the 
myelinating phase of Schwann cell development. EGR2 null and hypomorphic mice 
exhibit reduced levels of several major myelin genes with Schwann cell arrested in 
the promyelinating stage (Le et al., 2005). Svaren and Meijer suggested a mechanism 
for OCT6 regulation, in which CAMP induces PKA signalling, leading to activation 
of NFκB to upregulate OCT6 (Svaren & Meijer, 2008). However, it is suggested that 
activation of NFκB regulates OCT6 at the posttranslational level (Svaren & Meijer, 
 31 
2008). SOX10 can also regulate myelin gene transcription directly through the 
conserved SOX10 binding sites in several myelin genes such as MPZ (myelin protein 
0) and MAG (myelin associated glycoprotein) (LeBlanc et al., 2007). 
Myelination is also negatively regulated by several transcription factors, such as 
Notch and c-Jun. It has been shown that EGR2 suppresses Notch signalling in 
myelinating cells (Woodhoo et al., 2009).  Notch has been reported to initiate 
demyelination in demyelinating neuropathies before the onset of neuronal loss. 
Notch signalling promotes generation of immature Schwann cells and maintains this 
phenotype (Woodhoo et al., 2009). Another negative regulator of Schwann cell 
myelination is c-Jun, which has been shown to mediate Schwann cell proliferation 
(Parkinson et al., 2004). There is an antagonistic relationship between EGR2 and c-
Jun that regulates the transition between nonmyelinating and myelinating Schwann 
cells (Parkinson et al., 2008). Finally, SOX2 is co-expressed with c-Jun in the nuclei 
of immature Schwann cells as well as dedifferentiated cells. It has been suggested 
that c-Jun regulates SOX2 expression (Parkinson et al., 2008). 
At the onset of myelination, Schwann cells establish an axis of polarity, which 
defines the orientation of the Schwann cell to the extracellular environment and to 
the axonal membrane (Simons & Trotter, 2007). Cell adhesion molecules of the 
nectin-like (Necl) family regulate in part the attachment of Schwann cells to the 
axonal membrane (Maurel et al., 2007). Necl4 accumulates with MAG along the 
axon-glia interface, the region forming the future internode, while neurofascin 155, 
TAG1 and gliomedin, which are essential for Schwann cell-axon interactions, 
accumulate at either side of the node of Ranvier (Simons & Trotter, 2007). Polarity is 
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established by the Par polarity complex, which localises asymmetrically to the inner 
glial membrane adjacent to the axon and recruits the P75 neurotrophin receptor to the 
axon-glia junction (Chan et al., 2006). 
Cholesterol, phospholipids and glycosphingolipids account for 70% of the dry 
weight of myelin membrane (Simons et al., 2000). The synthesis of most of these 
lipids initiate in the endoplasmic reticulum and because of the propensity of 
sphingolipids and cholesterol to form tightly packed membrane microdomains (lipid 
rafts), it is possible that some of the myelin lipids preassemble in the secretory 
pathway (Simons et al., 2000). MBP mRNA in oligodendrocytes (glial cells in the 
CNS) is transported from cell perikaryon in the form of granules to the myelin 
membrane, where the response to the stimulus of local translation occurs (Barbarese 
et al., 1999). This mechanism is to ensure that MBP exerts its adhesive function at 
the appropriate place. MBP seems to act as a clustering agent, inducing myelin 
membrane formation by bringing together the smaller preassemblies through 
secretory pathways (Simons & Trotter, 2007).  
These observations show that myelination is a complex process that involves precise 





Figure 1.5 Some of the factors that control Schwann cell development and myelination. SOX10 
is essential for generation of Schwann cells from the neural crest while BMPs inhibit glial 
differentiation. NRG1 is necessary for the survival of Schwann cell precursors (SCP). NRG1, 
fibroblast growth factor 2 (FGF2) and Notch accelerate the SCP-Schwann cell transition. In 
immature Schwann cells, survival is supported by autocrine survival factors, NRG1 and laminin, 
whereas p75 neurotrophin receptor (p75NTR) induces Schwann cell death. The transcription 
factors SOX2 and c-Jun support proliferation and ATP inhibits Schwann cell division. Prior to 
myelination NRG1, BDNF, IGFs and the p38 pathway induce Schwan cell migration and/or 
association with axons. Radial sorting is mediated by laminin and its receptor ß1 integrin. 
Myelination is promoted by the transcription factors EGR2 with NGFI-A-binding (NAB) proteins, 
OCT6 and brain 2 class III POU-domain protein (BRN2), and inhibited by c-jun and SOX2. Cell-
extrinsic signals that promote myelination include GDNF, NRG1, IGFs, BDNF and laminin. PI3K-
AKT and cyclic AMP (cAMP) activated pathways also promote myelination, whereas it is 
blocked by ATP and Notch activation (modified from Jessen & Mirsky, 2005). 
1.7.2 Terminal Schwann cells 
Terminal Schwann cells (also known as teloglia or presynaptic Schwann cells) are 
synapse-associated non-myelinating Schwann cells. The origin of terminal Schwann 
cells is similar to the axonal Schwann cells discussed in the previous section. During 
early postnatal development, terminal Schwann cells proliferate and each NMJ is 
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associated with several Schwann cells. The number of terminal Schwann cells is 
tightly regulated in the adult NMJ and depends on the size of the end-plate 
(Lubischer & Bebinger, 1999). It has been reported that muscle-derived 
neurotrophin-3 (NT-3) regulates the number of Schwann cells (Hess et al., 2007).  
Genetic studies have shown that although Schwann cells are present at the beginning 
of nerve-muscle contact, motor axons can reach target muscle cells in the absence of 
Schwann cells (Sugiura & Lin, 2011). However, nerves remain defasiculated as 
Schwann cells are essential for growth and maintenance of the developing synapses 
(Lin et al., 2000; Feng & Ko, 2008). 
Terminal Schwann cells can play an important role in restoration of the NMJ after 
motor nerve injury. They de-differentiate to immature Schwann cells and extend 
their processes at the site of muscle denervation to guide the growth of nerve sprouts 
(Reynolds & Woolf, 1992; Son et al., 1996). In partial denervation of NMJs, 
terminal Schwann cells form a ‘bridge’ from innervated to denervated NMJs to 
induce axonal sprouting (Kang et al., 2003). 
Schwann cells (SCs) are shown to play a role during synapse elimination. Their 
processes separate nerve terminals from each other and from the muscle fibre and 
contact the plaque of acetylcholine receptors, apposing this surface as closely as the 
nerve, limiting the area where synaptic transmission occurs. SCs also phagocytose 
nerve terminals contacting the muscle fibre (Smith et al., 2013). Terminal Schwann 
cells are not direct focus of this study, but its similarities in form and function with 
myelinating Schwann cells make them a good candidate for future studies of 
contributing factors in SMA pathogenesis. 
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1.7.3 Extracellular matrix contribution in Schwann cell development 
Extracellular matrix (ECM) plays an important role in peripheral nervous system 
development. In addition to having structural importance, ECM proteins also 
regulate cell behaviour through receptor interactions (Chernousov et al., 2008). 
Laminin and collagen are two major ECM proteins that regulate Schwann cell 
developmental processes in peripheral nerve including proliferation, survival, 
differentiation, polarisation and morphogenesis (Aszódi et al., 2006).  
Laminins are heterotrimeric proteins with 15 isoforms of variable numbers of α, β 
and γ chains. Laminin 2 (α2, β1, γ1), laminin 8 (α4, β1, γ1) and laminin 10 (α5, β1, 
γ1) play critical roles in Schwann cell myelination (Chernousov et al., 2008). 
Schwann cells express several laminin receptors such as α6β1, α6β4 integrins and 
dystroglycan (DG) (Previtali et al., 2003). Mutations in the laminin α2 gene 
(LAMA2) have been shown to cause peripheral neuropathy in both humans and mice 
(Helbling-leclerc et al., 1995; Shorer et al., 1995). Dystrophic mice, which have 
mutations in the α2 gene, exhibit hypomyelinated axons most obviously at the 
proximal region of the peripheral nerve (Stirling, 1975) with reduced conduction 
velocity (Rasminsky et al., 1978). Mouse models with a laminin γ1 mutation lack 
expression of all laminin isoforms and exhibit tremor, muscle weakness, and hind 
limb paralysis (Chen & Strickland, 2003; Yu et al., 2005). Nerve fibres are 
significantly smaller than controls and appear hypomyelinated. Schwann cells do not 
extend processes and therefore are unable to undergo radial sorting (Chen & 
Strickland, 2003; Yu et al., 2005). Radial axonal sorting requires Schwann cell 
proliferation and process extension. NRG1 mediates Schwann cell proliferation 
 36 
through ErbB2 and ErbB3 receptors (Morrissey et al., 1995). Mutations in laminin 
γ1 have been shown to inhibit phosphorylation and subsequent activation of these 
two receptors (Yu et al., 2005), leading to a reduced number of Schwann cells. 
Schwann cells lacking laminins or β1 integrins do not extend processes that 
interdigitate between axonal bundles through inhibition in Rac1 signalling (Yu et al., 
2005; Nodari et al., 2007). As discussed previously, laminins also induce Schwann 
cell elongation and are important for the later stages of myelination acting through 
the dystroglycan receptor by forming a complex between DG, DRP2 and periaxin 
(Gillespie et al., 2000; Sherman et al., 2001; Court et al., 2004). Finally, it has been 
shown that laminins play a role in Schwann cell long-term survival (Chernousov et 
al., 2008). PI3-kinase/Akt signalling is important in regulating Schwann cell survival 
and apoptosis (Maurel & Salzer, 2000). Interestingly, PI3-kinase activation is 
severely reduced in laminin-deficient Schwann cells (Yu et al., 2005). These 
observations reveal the importance of laminin signalling in Schwann cell 
differentiation and myelination. 
Schwann cells also produce collagens, another ECM component (Chernousov et al., 
2008). They are classified into three groups: fibril forming collagens (types I, II, and 
V), basement membrane collagens (type IV) and hybrid proteins with collagen 
domains such as gliomedin (Chernousov et al., 2008). Collagen molecules consist of 
a rod-like helical domain formed by association of three polypeptides containing 
repeating proline-rich sequences (Prockop & Kivirikko, 1995). Medium lacking 
ascorbic acid, an essential co-factor for collagen post-translational modification, fails 
to induce ECM assembly and myelination in DRG neuron-Schwann cell co-cultures 
(Chernousov et al., 1998). Dominant-negative inhibition or siRNA suppression of 
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type-V collagen assembly in Schwann cell-DRG neuron co-cultures dramatically 
inhibits myelin formation (Chernousov et al., 2006). However, in vivo analysis of 
mice with homozygous null mutations in α3(V) collagen has not confirmed these 
findings, suggesting the existence of possible compensatory mechanisms for genetic 
loss of  α3(V) collagen (Chernousov et al., 2008). Finally, basement membrane 
collagen type IV induces Schwann cell attachment and spread through α1β1 and 
α2β1 integrins on the Schwann cell surface (Chernousov et al., 2001). 
1.7.4 Axonal signals that recruit glial cells 
Axonal NRG1 binds to the Schwann cell tyrosine kinase receptor ErbB3, leading to 
heterodimerisation of ErbB3 with ErbB2 (Morrissey et al., 1995). Although NRG1 
plays a role in numerous neural functions, including neuronal migration, 
synaptogenesis, and glutamatergic neurotransmission, its best-characterised function 
is neural and axonal regulation of Schwann cell development (Britsch, 2007). The 
entire Schwann cell lineage is controlled, at least in part, by NRG1. NRG1 as a 
Schwann cell mitogen secures the necessary number of Schwann cells for normal 
ensheathment through ErbB2 and ErbB3 receptors (Jessen & Mirsky, 2005). 
NRG1/ErbB signal is amplified by the phosphatidylinositol-3 (PI3) kinase pathway 
(Ogata et al., 2004). Axon-bound NRG1 type III is required for the differentiation of 
the myelinating Schwann cell phenotype (Taveggia et al., 2005). Myelin sheath 
thickness is regulated by axonal NRG1. When exposed to the below threshold levels 
of axonal NRG1 type III, the associated axons are not sorted and myelinated but 
remain grouped together as a Remak bundle associated with a single nonmyelinating 
Schwann cell. Experimental NRG1 type III axonal overexpression is sufficient, 
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however, to trigger axonal sorting and myelination in vitro (Taveggia et al., 2005). 
According to these in vitro results, the expression level of NRG1 on the axonal 
surface may be responsible for lineage decision made by Schwann cells (Nave & 
Trapp, 2008). 
Finally, it has been reported that the axonal release of ATP inhibits Schwann cell 
differentiation and myelination via purinergic P2 receptor signalling (Fields, 2006). 
These observations have shown the importance of axonal signals in Schwann cell 
development and maintenance, but Schwann cells also provide trophic support for 
axons. This will be discussed in the subsequent section. 
1.7.5 Mechanisms of Schwann cell support of axons 
Although the presence of Schwann cell precursors is not necessary for the initial 
guidance and outgrowth of axons to their targets, SCPs are playing a role in late 
patterning events in the developing nerves (Woodhoo & Sommer, 2008). Genetic 
ablation of ErbB2 results in the loss of SCPs in the developing nerves. Although 
initial patterning events are normal, the nerves are poorly de-fasciculated and project 
abnormally within their final targets as well as making abnormal synaptic 
connections at the NMJ. In ErbB2 null mice, widespread neuron’s death has been 
observed after initial generation of normal numbers of motor and sensory neurons, 
indicating a role for SCPs in the trophic support of developing neurons. The same 
results have been observed as a result of inactivation of the Sox10, ErbB3 and NRG1 
type III genes (Woodhoo & Sommer, 2008). 
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Schwann cells express ciliary neurotrophic factor (CNTF), but the mechanisms of 
release are unclear because this cytoplasmic cytokine is not exocytosed like other 
growth factors (Nave & Trapp, 2008). In mice, CNTF is required for motor neuron 
survival and the long-term integrity of myelinated axons in the PNS (Gatzinsky et 
al., 2003). In 2% of human population, a mutation near exon 3 of the CNTF gene 
results in a truncated and biologically inactive protein without obvious altered 
phenotype (Takahashi et al., 1994). Genotyping the CNTF polymorphism in a large 
group of patients with CMT (Charcot-Marie-Tooth disease) and SALS (sporadic 
amyotrophic lateral sclerosis) have also revealed no increased frequency of CNTF 
null alleles. Therefore CNTF does not have an important role in modifying CMT and 
SALS (Van Vught et al., 2007). 
Glial cell line-derived growth factor (GDNF) is another growth factor expressed by 
Schwann cells. Hirschsprungs disease is caused by GDNF mutations, which is 
characterised by loss of enteric ganglia as a result of early glial and neural crest 
defects (Nave & Trapp, 2008). GDNF has a survival effect on dopaminergic neurons 
(Beck et al., 1995), embryonic motor neurons (Henderson et al., 1994) as well as a 
beneficial role in neuropathic pain treatment (Boucher et al., 2000). GDNF injection 
into intact peripheral nerves causes Schwann cells to proliferate and to sort and 
myelinate small-caliber C-fiber axons (Höke et al., 2003). Therefore, trophic factors 
can, in principle, overcome developmental thresholds and change the glial phenotype 
from nonmyelinating Schwann cells to myelin-forming Schwann cells, similar to 
axonal NRG1. 
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A prerequisite for trophic support of axons by Schwann cells is correct physical 
alignment between these two cell types. The axo-glial junctions are locations of 
highest probability for delivery of trophic substances (Beirowski, 2013). Axo-glial 
junctions, between myelinating Schwann cells and their underlying axons, are 
formed by various adhesion molecules, such as L1, MAG, Necl proteins, 
Neurofascin, Neural cell adhesion molecule, N-cadherin, Caspr, Contactin, and their 
associated scaffolding proteins. Deletion of some of these proteins has been shown to 
induce abnormal axo-glial contact and subsequent axon degeneration (Beirowski, 
2013). Progressive unmyelinated sensory axon degeneration has been observed in L1 
deficient mice. L1 is specifically required for establishing appropriate contact 
between non-myelinating Schwann cells and their axons (Haney et al., 1999). In 
contrast, MAG knockout mice develop late-onset axonal detachment from 
myelinating Schwann cells and neurodegeneration, but exhibit normal myelination 
(Pan et al., 2005) 
One of the mechanisms through which Schwann cells protect the axon is through 
metabolic support. The number of mitochondria is increased in dysmyelinated and 
demyelinated axons (Andrews et al., 2006). ATP is required for membrane 
repolarisation and for rapid transport of vesicle and organelles including 
mitochondria (Hollenbeck & Saxton, 2005). Mitochondria have been reported to 
pause at the nodes of Ranvier, where Na+/K+ channels are clustered and more ATP is 
required (Fabricius et al., 1993). Mitochondria are located near paranodes, the site of 
axo-glial interaction. Caspr is one of the major components of paranodes and 
mutations in this protein in mice lead to the formation of mitochondria with a 
swollen morphology, which is abnormally retained at the intra-axonal membrane 
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beneath disrupted paranodes (Alberti et al., 2007). This suggests that myelinating 
Schwann cells regulate the functioning and transport of axonal mitochondria (Nave 
& Trapp, 2008). Reduction in axonal ATP also decreases Na+/K+ ATPase and ATP-
dependent Na+/Ca2+ exchanger activity, which can operate in reverse and exchange 
axoplasmic Na+ for extracellular Ca2+, at least under pathological conditions. 
Elevated axoplasmic Ca2+ causes further damage to axonal and mitochondrial 
proteins, which introduces a second vicious pathological cycle (Li et al., 2000). 
1.7.6 Glial cell contribution to peripheral nerve pathology 
In most neurodegenerative diseases, a subpopulation of neurons is more vulnerable 
to neurotoxicity. The traditional view was that the mechanism of this action would be 
cell autonomous that is independent of mutant damage accumulated within other cell 
types that interact with affected neurons. However recent evidence from different 
mouse models of neurodegenerative diseases, including amytrophic lateral sclerosis 
(ALS) and Charcot-Marie-Tooth disease (CMT) has shaken this classic view. 
Toxicity or mutant protein expression in both neuronal and adjacent non-neuronal 
glial cells strongly influenced neurodegeneration (Lobsiger & Cleveland, 2007; 
Berger et al., 2006). 
 
ALS is a neurodegenerative disease characterized by degeneration of upper and 
lower motor neurons. ALS can be induced by mutations in the superoxide dismutase 
1 gene (SOD1) (Boillée et al., 2006). It has been shown that normal motor neurons in 
chimeric mice, containing a mixture of mutated and normal human SOD1, develop 
aspects of ALS pathology (Clement et al., 2003). The same study showed that non-
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neuronal cells that did not express mutant SOD1 delayed degeneration and 
dramatically extended survival in mutant-expressing motor neurons (Clement et al., 
2003). A reduction in mutated SOD1 levels in the microglia and astrocytes slows 
disease progression (Boillée et al., 2006; Yamanaka et al., 2008). Co-cultures of 
mouse-derived, mutant SOD1-expressing astrocytes and mouse wild-type motor 
neurons have also demonstrated that motor neuron survival reduced over a 2-week 
period (Di Giorgio et al., 2007). Replacing the entire mutant SOD1 myeloid lineage 
including microglia with normal SOD1 myeloid lineage had no influence on disease 
onset, but prolonged survival by reducing disease progression (Beers et al., 2006). 
Replacing entire myeloid lineage with mutant SOD1 cells did not produce disease in 
wild-type mice, indicating that mutant expression within microglia is not sufficient 
for motor neuron disease, but does drive rapid disease progression (Beers et al., 
2006). Reactive oxygen species (ROS) and their subsequent oxidative damage are at 
least part of the microglial-derived component of non-cell autonomous disease 
(Lobsiger & Cleveland, 2007). Astrocytic glutamate transporters play a key role in 
neuroprotection against glutamate excitotoxicity (Lobsiger & Cleveland, 2007). In 
both sporadic and mutant SOD1 mediated ALS, GLT1/EAAT2 glutamate 
transporters are focally lost (Rothstein et al., 2005). Upregulation of these 
transporters extend survival in ALS mice (Rothstein et al., 2005). It has been 
suggested that mutant damage in the motor neurons is driving disease initiation and 
the role of both glial cell types is accelerating disease progression (Lobsiger & 
Cleveland, 2007). Finally, a decline in Schwann cell-derived IGF1 (insulin growth 
factor 1) and other growth factors accompanying axon degeneration was reported in 
SOD1 mice (Lobsiger et al., 2009). 
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Charcot-Marie-Tooth disease (CMT) represents a large group of inherited peripheral 
neuropathies, which involves mainly both motor and sensory neurons and induce 
muscular atrophy and weakness (Juárez & Palau, 2012). More than 40 genes have 
been identified to be associated with CMT. CMT is caused by mutations in genes 
that encode proteins involved in Schwann cell functions such as compaction and 
maintenance of myelin, transport through myelin, cell signalling, cytoskeleton 
formation, axonal transport, mitochondrial dynamics, vesicle and endosomal 
trafficking, and chaperones. Autosomal dominant demyelinating CMT or CMT1 is 
caused by duplication in PMP22 (peripheral myelin protein 22) that is expressed 
predominantly in the compact myelin of Schwann cells (Lupski et al., 1991). 
Overexpressed PMP22 reaches late endosomes and forms protein aggregates that are 
ubiquitinated (Fortun et al., 2006). Heat shock response also influences protein 
aggregation. However, excess PMP22 overloads the protein degradation machinery, 
leading to a disruption in Schwann cell intracellular sorting of PMP22 and other 
proteins (Fortun et al., 2006). Mouse models with a PMP22 mutation exhibit 
minimal or abnormal myelination and reduced axonal diameter (Adlkofer et al., 
1997). Clinical signs of the disease are demyelination, progressive weakness, 
reduced axonal conduction velocity and sensory loss (Krajewski et al., 2000). 
CMT1B is caused by mutations in the MPZ gene, encoding a major myelination 
component, myelin protein zero. Patients show two distinct phenotypes: the first 
group exhibits a delayed motor development, slow nerve conduction and the second 
group shows late-onset neuropathy that allows myelin production, but eventually 
leads to axonal degeneration with minimal demyelination (Shy et al., 2004). There 
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are other subtypes for CMT disease that affect both axonal and Schwann cell 
expressed genes and disrupt axon-Schwann cell interactions (Juárez & Palau, 2012). 
Therefore, Schwann cells play key role in axonal survival and maintenance and this 
makes them a potential suspect in peripheral nerve disorders. 
1.8 Aims 
Based on the critical role of Schwann cells in regulating peripheral neuropathies, I 
will address the following questions in this thesis: 
1) Are there any intrinsic defects in SMA Schwann cells? (Chapter 4) 
2) Do these defects contribute to SMA pathogenesis? (Chapter 4) 
3) What molecular pathways control Schwann cell defects in SMA? (Chapter 5) 
In order to answer these questions, I developed a technique to isolate primary 
Schwann cells from SMA mouse model (Chapter 3) 
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Chapter 2: Materials and methods 
2.1 Mouse colony 
2.1.1 Ethics statement 
All animal experiments were approved by a University of Edinburgh internal ethics 
committee and were performed under license by the UK Home Office (Project 
License number 60/3891). 
2.1.2 Animal maintenance  
‘Taiwanese’ SMA mice, Smn-/-; SMN2tg mice (originally obtained as breeding pairs 
from Jackson Labs, strain no. 005058) on a congenic FVB background were 
maintained as heterozygous breeding pairs under standard SPF conditions in animal 
care facilities in Edinburgh.  All animal procedures and breeding were performed in 
accordance with Home Office and University of Edinburgh guidelines.  The 
‘Taiwanese’ SMA model has two copies of SMN2 per allele and has a mean age of 
survival of 11 days (Hsieh-Li et al., 2000; Riessland et al., 2010). Retrospective 
genotyping was carried out using standard PCR protocols detailed below. 
Wild-type CD1 mice were obtained from in-house breeding stocks at the University 
of Edinburgh. 
2.1.3 Genotyping 
5mm tail tips were taken from sacrificed mice for genotyping.  Tail tips were 
digested in Tail Tip Lysis Buffer + 5 µl/ml proteinase K at 55oC overnight.  The next 
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day, the tail tips were further lysed by vortexing before centrifugation at 14000rpm 
for 5 minutes.  The supernatant was added to a new 1.5 ml eppendorf containing 500 
µl isopropanol. This mixture was centrifuged at 14000 rpm for 5 minutes to pellet the 
DNA.  The DNA pellet was washed twice in 70% ethanol and then dried for one 
hour at 37oC to evaporate all traces of ethanol. The DNA was then re-suspended in 
200 µl autoclaved deionised water. 
SMA mice were genotyped by using the following primers: 
SMN wild-type (1,150 bp)    Forward (F1): 5’-ATAACACCACCACTCTTACTC-3’ 
                                              Reverse (R1): 5’-GTAGCCGTGATGCCATTGTCA-3’ 
SMN knock-out (950 bp)     Forward (F1): 5’-ATAACACCACCACTCTTACTC-3’ 
                                             Reverse (R2): 5’-AGCCTGAAGAACGAGATCAGC-3’ 
Product was amplified by using the following thermo cycler program (Table 2.1): 
Step Temperature (°C) Time (Seconds) 
1 95 180 
2 94 30 
3 59 30 
4 68 (35 cycles) 60 
5 68 300 
6 4 Indefinite 
Table 2.1 PCR genotyping program 
PCR products were separated by gel electrophoresis. Samples were resolved on a 1% 
agarose gel at 100 V for 30 minutes with a 100 bp DNA ladder (Promega Express) 
and genotype was assessed by size of bands observed (Figure 2.1) 
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Figure 2.1 Genotyping Taiwanese SMA mice. A) Diagram of a section of wild-type mouse smn 
gene B) Smn exon 7 were replaced with Hypoxanthine phosphoribosyltransferase (HPRT) 
cassette to produce smn null allele (Hsieh-Li et al., 2000).  Three PCR primers were used for 
genotyping: F1 (5′-ATAACACCACCACTCTTACTC-3′) and R1 (5′-GTAGCCGTGATGCCATTGTCA-
3′) were used to detect wild-type allele (1,150 bp), while F1 and R2 (5′-
AGCCTGAAGAACGAGATCAGC-3′) were used to detect knockout alleles (950 bp). C) 
Representative PCR gel scan. Lanes with 2 bands at 950 and 1,150 bp represent control 
samples and those with one band at 950 bp are SMA samples. 
2.2 Isolation of mouse Schwann cells 
Mouse Schwann cell isolation was performed by modifying protocols described by 
Honkanen et al (Honkanen et al., 2007) and Arthur-Farraj et al (Arthur-Farraj et al., 
2011). Wild type CD1 mice were used to establish modified protocol to isolate 
Schwann cells (details will be discussed in chapter 3). In order to calculate number 
of CD1 mouse Schwann cells obtained from each treatment, 12 mice were sacrificed 
and total number of 24 sciatic nerves was isolated per preparation. Three 
preparations were used for each treatment and the average number of Schwann cells 
was used to compare different treatments efficiency. 
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2.2.1 Dissection and plating nerve fragments 
100 µg/ml poly-L-lysine (PLL, Sigma) was deposited to 60 mm dishes and kept for 
45 minutes at room temperature. PLL was washed 3 times with sterile water and left 
to be air- dried. A solution of 30 µl neat laminin (Invitrogen) in 3 ml PBS 
(Invitrogen) was added to PLL coated dishes and maintained for an hour. Dishes 
were washed once with PBS and used as wet coating. 
Postnatal day 8 (P8) control and SMA mice were sacrificed by cervical dislocation, 
according to University of Edinburgh guidelines. Sciatic nerves and brachial 
plexuses were extracted and connective tissues were removed under sterile 
conditions. Cleaned nerves were shredded in PBS and were lysed with 0.125% 
trypsin (Invitrogen) and 0.05% Collagenase A (Roche) for 30 minutes at 37°C. 
Nerves were washed three times with Dulbecco’s modified eagle medium (DMEM, 
Invitrogen) containing 10% horse serum (HS, Invitrogen) and were re-suspended in 
basic growth medium (Table 2.2). Nerves were plated in PLL/ laminin coated dishes 
and incubated at 37°C with 5% CO2 for two days. After two days, medium including 
any unattached nerves were transferred to another coated dish. Fresh basic growth 
medium was added to the original dish and left for two additional days in the 
incubator. 
2.2.2 Purification of Schwann cells 
Four days after plating nerves, nerve-containing dishes were washed once with 
Hanks balanced salt solution (HBSS, Invitrogen) in 20 mM Hepes buffer 
(Invitrogen) and once more with HMEM (Table 2.2). Complement-mediated 
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cytolysis medium (Table 2.2) was added and incubated for 15 minutes at 37°C in a 
tissue culture incubator. Human leucocyte-associated antigen A, B, C (HLA-ABC) 
complement sera (Invitrogen) was then added and dishes were incubated for 2 hours 
at 37°C. Rinsing the cells twice with HBSS in 20 mM Hepes buffer terminated 
cytolysis. Schwann cell growth medium was then added.  
2.2.3 Expansion of Schwann cells 
Schwann cell medium was changed daily for 2 days until cells reached ~80% 
confluency. Confluency was estimated qualitatively based on the percentage of dish 
surface area covered by cells. Cells then were rinsed with 20 mM Hepes buffer in 
HBSS and were detached from the surface of the dish by 1X trypsin versene 
(Sigma). Trypsinisation was terminated by rinsing cells three times with DMEM 
containing 10% HS and re-suspended in Schwann cell growth medium. Cell 
suspension solution was plated on PLL/ laminin coated 60-mm dishes at the density 
of 1.5 X 105. 
 
2.3 Mouse Schwann cell differentiation 
The Schwann cell differentiation technique was adapted from a protocol published 
by Arthur-Farraj et al. (Arthur-Farraj et al., 2011). Cells were passaged and re-
suspended in supplemented defined medium (Table 2.2) containing 10-6 M insulin 
(DM, Roche). They were plated on PLL/Laminin coated 24-well plate dishes and 
kept at 37°C overnight. The following day, 20 ng/ml NRG-1 (or Heregulin) and 
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1mM 2'-O-dibutyryladenosine 3': 5' cyclic monophosphate (dbcAMP) were added to 
cultures and kept for either 72 hours or 120 hours. 
Culture medium  
Basic growth medium High-glucose Dulbecco’s modified eagle medium (DMEM, 
Invitrogen) 
 10% v/v inactivated Horse serum (HS, Invitrogen) 
 4 mM L-glutamine (Invitrogen) 
 100 units/mL penicillin/ streptomycin (Invitrogen) 
 0.5 µM forskolin (Sigma) 
 2 ng/mL human heregulin-β1 (Sigma) 
 10-6 M insulin (Roche) 
Schwann cell growth 
medium 
High-glucose DMEM (Invitrogen) 
 10% v/v inactivated HS (Invitrogen) 
 4 mM L-glutamine (Invitrogen) 
 100 units/mL penicillin/ streptomycin (Invitrogen) 
 0.5 µM forskolin (Sigma) 
 2 ng/mL human heregulin-β1 (Sigma) 
 10 ng/mL human basic fibroblast growth factor (Invitrogen) 
 20 µg/mL bovine pituitary extract (Sigma) 
 10-6 M insulin (Roche) 
HMEM High-glucose DMEM (Invitrogen) 
 20 mM Hepes (Invitrogen) 
 10% v/v inactivated HS (Invitrogen) 
 4 mM L-glutamine (Invitrogen) 




 4 µg/ mL anti mouse CD90 anti Thy-1.2 (ABD Serotec) 
Schwann cell D-
medium 
50% v/v High-glucose DMEM (Invitrogen) 
 50% v/v Ham F12 (Sigma) 
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Culture medium  
 1% v/v N2 supplement (Invitrogen) 
 1% v/v L-glutamine (Invitrogen) 
 1% v/v penicillin/ streptomycin (Invitrogen) 
 10-6 M insulin (Roche) 
Schwann cell 
differentiation medium 
Schwann cell D-medium 
 1 mM N6, 2'-O-Dibutyryladenosine 3', 5'-cyclic monophosphate 
sodium salt (dbcAMP, Sigma) 
 20 ng/mL human heregulin-β1 (Sigma) 
Table 2.2 Schwann cell media composition and concentrations 
2.4 Dorsal root ganglion (DRG) neuron-Schwann cell co-cultures 
This technique was modified from the protocol published by Päiväläinen et al. 
(Päiväläinen et al., 2008). All media compositions are described in Table 2.3. 
2.4.1 DRG dissection and isolation 
One part of matrigel (BD biosciences) was diluted in 4 parts of EMEM and a drop of 
matrigel was deposited on each coverslip (VWR). Matrigel was gelatinised for 45 
minutes at 37°C. 
Embryonic day 14 (E14) mouse embryos were removed from CD1 female mice, 
sacrificed with CO2 exposure and cervical dislocation. DRGs were dissected from 
spinal cords of the embryos and kept in cold Leibovitz medium (L-15, Life 
technologies) under sterile conditions. Pooled DRGs were cleaned and were plated 
on matrigel-coated dishes in DRG growth medium (Table 2.3). 
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2.4.2 DRG neuron purification 
Non-neuronal cells were eliminated from DRG neuron cultures by replacing DRG 
growth medium with DRG purification medium (Table 2.3) at day 2. Purification 
medium contained anti-mitotic drugs uridine and deoxyuridine to inhibit 
proliferation of dividing cells such as fibroblasts and Schwann cells. Non-dividing 
DRG neurons could survive in this media. After 2 days, cultures were grown in DRG 
growth medium. This process was repeated 2 more times over a period of 2 weeks. 
DRG neurons were maintained in DRG growth medium for an additional week 
before Schwann cell addition. Purity was assessed by immunocytochemistry against 
anti-S100 and anti-neurofilament 160 kDa (neurofilament medium chain) antibodies 
(Table 2.4) (Jessen et al., 1990; Hyden & McEwen, 1966). 
2.4.3 Schwann cell addition, differentiation and myelination 
80% confluent Schwann cell cultures were trypsinised and washed (as discussed in 
2.2.3). Schwann cell pellets were re-suspended in DRG growth medium. In order to 
count cells, 10 µl of cell suspension was loaded to haemocytometer (VWR) and cells 
were counted from 4 selected areas. These data were averaged and rounded to 100. 
50000 purified Schwann cells were added to each DRG neuron culture in a 24-well 
plate in DRG growth medium and were allowed to attach overnight. DRG neuron-
Schwann cell co-cultures were then maintained in differentiation medium (Table 2.3) 
for 7-10 days to induce alignment of Schwann cells. 
Differentiation medium was replaced by myelination medium containing L-ascorbic 
acid (Table 2.3). Ascorbic acid enables Schwann cells to produce components of the 
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basal lamina necessary for myelination. The medium was changed every other day 
for 3-4 weeks until luminescent myelin sheaths were observed in cultures under a 
phase contrast microscope. 
Culture medium  
DRG growth medium EMEM (Sigma) 
 4 g/L D-glucose (Sigma) 
 50 ng/mL nerve growth factor (NGF, R&D systems) 
 10% v/v HS (Invitrogen) 
 2 mM L-glutamine (Invitrogen) 
 100 U/mL pencillin/ streptomycin (Invitrogen) 
DRG purification medium EMEM (Sigma) 
 4 g/L D-glucose (Sigma) 
 50 ng/mL NGF (R&D systems) 
 10 µM uridine (Sigma) 
 10 µM deoxyuridine (Sigma) 
 2 mM L-glutamine (Invitrogen) 
 1% v/v N2 supplement (Invitrogem) 
 100 U/mL pencillin/ streptomycin (Invitrogen) 
Differentiation medium 50% v/v high-glucose DMEM (Invitrogen) 
 50% v/v F-12 Ham nutrient (Sigma) 
 50 ng/mL NGF (R&D systems) 
 1% v/v N2 supplement (Invitrogem) 
 2 mM L-glutamine (Invitrogem) 
 100 U/mL pencillin/ streptomycin (Invitrogem) 
Myelinating medium EMEM (Sigma) 
 4 g/L D-glucose (Invitrogem) 
 50 ng/mL NGF (R&D systems) 
 5% v/v HS (Invitrogem) 
 2 mM L-glutamine (Invitrogem) 
 1% v/v N2 supplement (Invitrogem) 
 50 µg/mL ascorbic acid (Sigma) 
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Culture medium  
 20 µg/mL bovine pituitary extract (Sigma) 
 0.5 µM forskolin (Sigma) 
 2 mM L-glutamine (Invitrogen) 
Table 2.3 DRG neuron-Schwann cell co-culture media compositions 
2.5 Immunocytochemistry 
2.5.1 Schwann cell immunocytochemistry 
Schwann cells were rinsed 3 times with PBS and fixed with 4% v/v PFA for 10 
minutes at room temperature. Cells were then permeabilised with ice-cold methanol 
for 15 minutes at -20°C. After rinsing cells 3 times with PBS, fixed cells were 
incubated first with blocking buffer containing 1% v/v Bovine serum albumin (BSA, 
Invitrogen) in PBS for one hour and then with primary antibody diluted in blocking 
buffer for 1 hour. Cells were rinsed with blocking buffer for 6 times and incubated 
with secondary antibody diluted in blocking buffer. For nuclear staining, TOPRO3 
(1:500, Life technology) was applied for 10 minutes followed by washing cells 6 
times with PBS. Finally, coverslips were mounted with mowiol (Calbiochem) and 
left to air-dry overnight. Table 2.4 describes all primary and secondary antibodies 
that were used with applied concentrations. 
In order to check Schwann cell proliferation, cells were labelled with 10 µM BrdU 
(Sigma) 24 hours before fixation. Cells were then fixed, permeabilised and 
immunostained with mouse anti-BrdU antibody (Table 2.4) and cell marker 
TOPRO3 as described above. The percentage of BrdU-labelled cells were calculated. 
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2.5.2 DRG neuron-Schwann cell co-culture immunocytochemistry 
DRG neurons are very sensitive to physical disruption; therefore cold methanol was 
replaced with 0.25 % v/v Triton X-100 (Fisher chemicals) in PBS for 30 minutes as a 
permeablisation step. Fixation and immunostaining were performed as described in 
section 2.5.1. 
2.6 Immunohistochemistry 
Sciatic nerves from SMA ‘Taiwanese’ mice were fixed for 30 minutes in 4% v/v 
PFA and incubated overnight in 30% sucrose in 4°C. Sciatic nerves were embedded 
in a 1:1 solution of 30% sucrose and OCT (CellPath). For immunostaining on 
intercostal nerves, whole rib cages were fixed, halved at the sternum and each half 
embedded separately. 10 µm sections were cut with a cryostat and mounted on 
Superfrost slides.  
Sections were permeabilised in 0.025% v/v Triton X-100 solution for 30 minutes to 
break down cell membranes. Blocking solution of 0.025% v/v Triton X-100 + 1% 
v/v BSA was added to each section for 30 minutes to minimize non-specific protein 
binding. Primary antibody was diluted in blocking solution to required 
concentrations  (Table 2.4) and incubated for one hour at room temperature. After 6 
times washes (each wash for 5 minutes) in PBS, sections were incubated with 
secondary antibodies in blocking buffer for 2 hours (Table 2.4). Following 6 times 
washes (each wash for 5 minutes) in PBS, slides were mounted with Mowiol. 
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Antibody Concentration Host Company 
Sox10 1:50 Goat Santa Cruz sc-17342 
Sox2 1:500 Rabbit Chemicon AB5603 
MPZ 1:1000 Mouse Gift (Dr. Archelos) 
EGR2 1:100 Rabbit Covance PRB-236P 
POU3F1 1:50 Goat Santa Cruz sc-11661 
UbaI 1:50 Mouse Abcam ab89647 
Beta-catenin 1:50 Mouse BD-transduction 610153 
Neurofilament (2H3) 1:200 Mouse Developmental studies hybridoma 
bank 
Caspase-3 1:50 Rabbit Cell signalling 9662 
BrdU 1:100 Mouse BD biosciences 347580 
LAMA2 1:100 Rat Abcam AF1060 
S100 1:100 Mouse Abcam ab4066 
GFAP 1:1000 Rabbit Abcam ab7260 
MBP 1:1000 Rabbit Gift (Prof. Brophy) 
Collagen type IV 1:100 Rabbit Millipore AB756P 




1:200 Goat Jackson Research laboratories  
112-095-003 
Fluorescein (FITC)–
anti- rabbit conjugated 
IgG (H+L) 
1:40 Swine Dako F0205 
Cy3-conjugated anti-
mouse IgG (H+L) 
1:250 Donkey Jackson Research laboratories 
715-165-151 
Cy3-conjugated anti-
goat IgG (H+L) 
1:250 Donkey Jackson Research laboratories 
705-165-003 
Table 2.4 Primary and Secondary antibodies used in this study 
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2.7 SMN transfection 
2.7.1 pMPZ-SMN construct generation 
The pMPZ-SMN construct was made by Dr. Gillian Hunter. Briefly a full-length 
human SMN1 plasmid construct (gift from Prof. Brunhilde Wirth) was amplified and 
ligated to an intermediate plasmid (pGL4.13, Promega) (Hunter et al., 2014). An 
MPZ-promoter plasmid (gift from Professor Brophy) was used to specifically target 
Schwann cells. The SMN-containing plasmid and the MPZ-promoter plasmid were 
digested and ligated to form pMPZ-SMN (Hunter et al., 2014). The plasmids were 
stored at -80°C. Figure 2.2 shows the diagram of plasmids that were used in the 
SMN transfection experiment. 
 
Figure 2.2 Plasmids involved in SMN transfection to Schwann cells. A) SMN1 was expressed 
under the induction of Schwann cell-specific promoter MPZ (Hunter et al., 2014). B) PEHHG 
plasmid was used as control GFP-expressing (EGFP), non-SMN transgene carrying plasmid to 
identify transfection efficiency (Hamilton et al., 2012). 
2.7.2 Plasmid purification 
The plasmid colony was transferred to LB-medium containing 100 µg/ml ampicillin 
and incubated overnight at 37°C with vigorous shaking. The plasmid was purified 
using a Qiafilter plasmid purification kit (Qiagen). DNA was precipitated with 
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isopropanol and washed with ethanol. The pellet was air-dried to remove any traces 
of alcohol. DNA was re-suspended in sterile water. Its concentration and purity were 
measured using a nanodrop (Thermo Scientific). 
2.7.3 Transfection of Schwann cells with pMPZ-SMN 
70,000 SMA and control Schwann cells were plated and differentiated as described 
previously. 90 hours post differentiation, Schwann cells were transfected with either 
control GFP-expressing, non-SMN transgene carrying plasmid, PEHHG (Hamilton 
et al., 2012) or PEHHG with pMPZ-SMN (Figure 2.2). A total amount of 1 µg DNA 
was used per reaction, with 2.4 µl Lipofectamine 2000 (Invitrogen) in all transfection 
studies. 1:1 ratio of PEHHG: pMPZ-SMN construct was used in SMA-derived 
Schwann cells. Transfection was terminated after 4 hours by changing media to fresh 
one. Cells were then fixed and immunostained at 120 hours post-differentiation with 
MPZ and TOPRO3 to measure expression levels. 
2.8 Ubiquitin E1 inhibitor UBEI-41 experiment 
15,000 Schwann cells were plated in D-media on each 13 mm coverslip and kept 
overnight to settle down. The next day, D-medium was replaced by differentiation 
medium and kept for either 72 or 120 hours. 24 hours before termination of 
differentiation 10 µM UBEI-41 drug (Biogenova) was added to the medium. Control 
and SMA Schwann cells were fixed and immunostained to study MPZ levels. 
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2.9 Neurite density 
In order to study the stability of DRG neurons in Schwann cell-DRG neuron co-
cultures, neurite density was calculated in each culture. Purified DRG neurons 
cultured for 72 hours either with or without control Schwann cells or SMA Schwann 
cells. Neurons were immunocytochemically labeled with antibody to NF medium 
(Table 2.4). Three images were captured approximately 250 µm from the DRG core 
in each culture. Each image was converted to binary and the total area covered by 
neurites quantified using ImageJ software. 
2.10 Conditioned medium experiment 
DRG neurons from wild-type CD1 embryonic mice were purified and grown for 3 
weeks. Purified control and SMA Schwann cells were also incubated in Schwann 
cell D-media (Table 2.2). Conditioned media were collected after 72 hours and 50 
ng/ml NGF was added to the media prior to their addition to DRG neurons. Three 
phase contrast pictures were taken approximately 250 µm from the DRG core in 
cultures treated with SMA and control condition media after 6, 24 and 72 hours. 
Each image was converted to binary and the total area covered by neuritis quantified 
using ImageJ software. 
2.11 Microscopy and image analysis 
Fluorescent images were taken using a Zeiss 710 laser-scanning confocal microscope 
(40 X or 20 X objective; 1.4NA) or a standard epi-fluorescence microscope equipped 
with a chilled CCD camera (20 or 40 X objective; 0.8NA; Nikon IX71 microscope; 
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Hammamatsu C4742-95). Images were taken at identical confocal microscope 
settings to compare protein expression levels between control and SMA Schwann 
cell cultures. To measure protein expression levels for each immunostaining, 
confocal images were captured from 4 subcultures from single preparation per 
genotype (N=4). Images were captured from 2 fields of view on coverslip. Pictures 
with 2 overlaid channels (blue channel: TOPRO3-labeled nuclei, red or green 
channel: immunostaining of interest) were exported as tif files and opened with 
ImageJ software. Initially 2 channels were separated and the colour intensities of 
cells were measured in channel with immunostaining of interest. Colour intensity in 
ImageJ was measured as mean pixel intensities in a rectangular selection around cell 
nuclei. Using the same size rectangle, Colour intensity of all cells of both genotypes 
was measured. The average of colour intensity measurements from each coverslip (2 
fields of view) was calculated and therefore 4 readings were obtained per genotype 
(n= 4 readings). Graph of protein expression levels were plotted using GraphPad 
prism from the average ± SEM of these 4 readings between SMA and control 
Schwann cells. 
2.12 mRNA expression analysis 
2.12.1 Purification of total RNA from Schwann cells 
Cells were detached by incubating in pre-warmed Trypsin for up to 5 minutes. 
Trypsinisation was terminated by washing cells three times in 10% v/v Horse serum 
in DMEM. Pelleted cells were rinsed with 5ml cold PBS and following 
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centrifugation were re-suspended in 1ml cold PBS. Cells were centrifuged in 4°C 
and the supernatant was removed. 
mRNA was extracted from Schwann cells using an RNeasy Microkit (Qiagen). 10 µl 
beta-Mercaptoethanol was added to 1ml RLT buffer prior to its addition to cells. 
Cells were re-suspended in 350 µl of RLT buffer and homogenised for 30 seconds 
(pellet mixer, VWR). 350 µl of 70% ethanol was added to the lysate and mixed well. 
700 µl of the solution was transferred to an RNease spin column and centrifuged at 
10000 rpm for 15 seconds. Flow-through was discarded and 700 µl buffer RW1 was 
added and centrifuged at 10000 rpm for 15 seconds. 10 µl DNaseI was added to 70 
µl RDP buffer (RNase-free DNase set, Qiagen) and mixed gently. The mix was 
deposited directly onto the column and left to incubate at room temperature for 15 
minutes. After centrifugation and discarding the flow-through, 500 µl buffer PPE 
was added to spin columns. This was repeated and tubes were centrifuged for 2 
minutes at 10000 rpm. 30 µl RNase-free water was added directly onto the 
membrane and centrifuged for 1 minute at 10000 rpm. This eluate was collected and 
stored at -20°C. 
2.12.2 cDNA synthesis 
RNA samples were defrosted and quantified using a nanodrop spectrophotometer. 
A260/230 and A260/280 ratios were recorded as an indication of sample purity. 
cDNA was made using a high Capacity cDNA reverse transcription kit (Invitrogen). 
100 ng of RNA was added to each tube and made up to 10 µl with RNAse free water. 
2 RT-PCR master mixes were made per sample: one with reverse transcriptase and 
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the other without reverse transcriptase. The master mix composition is described in 
Table 2.5. 
10 µl PCR mix was added to 10 µl RNA tubes. Samples were run in a PCR machine 
with the following program: 1) 25°C for 10 minutes 2) 37 °C for 2 hours 3) 85 °C for 
5 minutes 4) 4°C pause. cDNA samples were quantified using a Nanodrop and were 
stored at -20°C. 
10XRT buffer 2 µl 
25X dNTP 0.8 µl 
10X RT random primer 2 µl 
Reverse transcriptase 1 µl (or 0 µl for negative RT control) 
Nuclease free water 4.2 µl (or 5.2 µl for negative RT control 
Table 2.5 cDNA synthesis master mix composition 
2.12.3 qPCR primer design and optimisation 
qPCR primers were designed by Dr. Gillian Hunter. Briefly, each mouse gene cDNA 
sequence were checked on NCBI website. The corresponding genomic regions 
(exons) were identified by UCSC genome browser. Couple of exons were selected 
with their intervening introns. Genomic sequence was downloaded from these areas 
and those exons that were separated by small intronic sequence were selected so that 
cDNA and genomic DNA will have significant different PCR product lengths. This 
strategy will help to identify any cDNA contamination of genomic DNA. cDNA was 
uploaded into Primer 3 to design primers spanning suitable introns. Table 2.6 shows 
the forward and reverse primers that were used. 
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To ensure that primers were amplified correctly and reproducibly between 
experiments, each cDNA was serially diluted up to 5 orders of magnitude. PCR was 
performed on cDNA samples. The standard curve is constructed by plotting the log 
of the starting quantity of template for each dilution (log of dilution/concentration) 
against the average Ct values obtained during amplification of each dilution. Ideally, 
the dilution series will produce amplification curves that are evenly spaced and 
generate a linear standard curve. The slope of a standard curve is indicative of PCR 
efficiency. Efficiency percentage is calculated using the equation:  E=(10(-1/slope)-1) X 
100. This is the amount of PCR product increased after each cycle and should be 
between 90-110%. 
Gene (Accession number) Primer sequence Exon 
MPZ (NM_008623)  F: 5’- CTGGTCCAGTGAATGGGTCT -3’ 234-400 
R: 5’- ATGACAATGGAGCCATCCTT -3’ 401-416 
LAMA2 (NM_008481) F: 5’- CTCGAAGGCTCCCAGACTC -3’ 1-246 
R: 5’- GCATTGGTTGTGATGAGTGC -3’ 247-417 
SOX2 (NM_011443.3) 5’- GAACGCCTTCATGGTATGGT -3’ 1-2457 
5’- TCTCGGTCTCGGACAAAGT -3’ 1-2457 
SOX10 (NM_011437) 5’- GACCAGTACCCTCACCTCCA -3’ 210-715 
5’- GGATGGTCCTTTTTGTGCTG -3’ 716-984 
OAZ1 (NM_008753) 5’-ATCCTCAACAGCCACTGCTT -3’ 1-250 
5’- CGGACCCAGGTTACTACAGC -3’ 251-396 
Table 2.6 qPCR pimers 
2.12.4 Quantitative RT-PCR 
All cDNA samples and -RT controls were diluted to 5ng/µl. Each sample was 
amplified in triplicate with primers amplifying gene of interest and two house 
keeping genes: OAZ1 and GAPDH. Two master mixes were made to minimize 
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pipetting error between samples. Master mixes composition for one sample is 
detailed in Table 2.7. 
Master mix 1 (10 µl) Master mix 10 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
Water 2 µl 
Master mix 2 (6 µl) Rox 0.4 µl 
cDNA 1 µl 
Water 4.6 µl 
Table 2.7 quantitative RT-PCR master mixes composition 
Master mixes were added to 96-well plate. The plate was placed in preheated 
ABI7000 machine (Applied Biosystems). The appropriate program was selected 
from computer and the wells to be analysed were chosen. SYBR green was selected 
as dye and the volume was set. The PCR program was set as follows: a) 95°C for 7 
min b) 95°C for 10 s c) 60°C for 30 s (repeat b and c steps 40 times) d) dissociation 
curve. 
2.12.5 Quantitative RT-PCR data analysis 
The Ct values were extracted and exported to an excel spread sheet. The standard 
curve values from section 2.12.3 including slope of the line and Y intercept were also 
imported to calculate log quantity.  
Log quantity=(CT value-Y intercept)/slope.  
Anti-log values were calculated by following formulae: 
Quantity= 10Log quantity 
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Quantity and Ct means were calculated to measure standard deviation for quantity 
means and Ct means. 
Data was normalised to reference genes OAZ1 and GAPDH. Geometric means 
(Geomean) for each sample were calculated by averaging the quantity means of 
OAZ1 and GAPDH. To establish the normalising factor for each sample, the value 
for each sample Geomean was divided to all Geomeans average. The gene of interest 
quantity mean was then divided by the normalising factor for each sample to 
calculate the relative expression levels for the gene of interest.  
2.13 Label-free proteomics 
2.13.1 Cell preparations 
Three separate Control and 3 SMA Schwann cell cultures were differentiated for 120 
hours after one passage (P1). To terminate differentiation, cells were trypsinised and 
washed once with 10% HS in DMEM. After centrifugation, cell pellets were washed 
twice with ice cold PBS and centrifuged. All PBS was removed from pellets and the 
samples were snap-frozen on dry ice. Samples were stored at -80°C. 
2.13.2 Protein extraction 
Protein samples were extracted in SDT lysis buffer containing 100 mM Tris-HCl (pH 
7.6), 4% (W/V) Sodium dodecyl sulphate (VWR) and 0.1 M D/L-dithiothreitol 
(Sigma). For efficient protein extraction, lysates were freeze-thawed and 
homogenised in SDT buffer several times. Protein concentrations were determined 
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by bicinchoninic acid assay (BCA; Thermo Scientific Pierce) according to 
manufacturer’s instructions. 
Three samples per genotype were sent to Douglas Lamont at the ‘Fingerprint’ 
proteomics facility at the University of Dundee for Mass Spectrometry. All three 
samples for each genotype were pooled together and then separated to three technical 
replicates to reduce variability between samples. Sample processing steps for the 
label-free experiment are summarised in Figure 2.3. 
 
Figure 2.3 Summary of experimental design for label-free proteomics. Picture was modified 
from (Wang et al., 2012) 
2.13.3 Label-free proteomics data analysis 
Raw MS data files were sent back for analysis. Progenesis LC-MS (version 4.0) 
software was used to determine individual peptide sequences and their protein 
identities. 
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LC-MS data from 6 samples were imported to Progenesis software and data were 
aligned automatically. In this process, all experimental runs were compared to every 
other run. The run with the greatest similarity to all other runs was selected as the 
alignment reference. Quality of alignment vectors was manually reviewed. 
Data were then filtered before starting comparative analysis. The minimum and 
maximum retention times for ion elution were manually set to more than 16.589 
minutes and less than 138.961 minutes. Maximum ion charge was set to 5. These 
modifications gave 67,883 MS/MS spectra in total. Software automatically 
established which run was ‘least different’ from all the other runs for selection as the 
Normalising reference. The experiment design was set as between-subject design: 
control versus SMA Schwann cells.  
Based on the study done by Mutsaers et al., peptides were filtered initially by their 
Anova p value of more than 0.05 and power of more than 0.08 (Mutsaers et al., 
2013). Power is the probability of finding real difference and is calculated based on 
expression variance, sample size and difference between the means. Application of 
these filters gave 14,295 peptides. Peptide statistics was performed on selected 
features to determine existence of any outliers in the data by principal component 
analysis (PCA). Features were grouped according to the similarity in their expression 
profiles (Figure 2.4). 
MS/MS peak lists were exported to the Mascot (v2.4.0) search engine to perform ion 
searches and to identify specific peptide sequences. 663 proteins were identified 
which were re-imported to Progenesis software to resolve conflict by excluding 
peptides that were associated with more than one protein. Any peptides with Lysine 
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or Arginine mid-sequence or not having Lysine or Arginine at the end were also 
removed from data since they were products of improper cleavage by trypsin. 195 
proteins remained after further filtering data for p value of less than 0.05, 
identification of more than 2 peptides and more than 20% up- or down regulation of 
protein expression compared to control samples. 
2.14 Ingenuity pathway analysis (IPA) 
Lists of differentially expressed proteins were imported to IPA (Ingenuity systems) 
software to identify interactions from known relationships between genes, proteins 
and diseases. The majority of information in the IPA database is extracted from peer-
reviewed journals. Proteins with more than 1.2 fold change in their expression 
compared to wild type (195 proteins) were uploaded to IPA, out of which 12 could 
not be mapped. IPA generated networks were limited to a maximum of 35 members. 
The biological interaction scores were defined by p values calculated by right tailed 
Fisher’s exact test. This value is not a direct indicator of biological relevance, but 
provides a starting point for software to approximate how relevant the network is to 
the analysis. 
2.15 Statistical analysis 
All data were exported from Microsoft Excel and analysed by GraphPad Prism 
software. Statistical tests for each comparison are described in the text. All data are 




Figure 2.4 Filtering process. A) Principal components analysis before filtering. B) Expression 
profile before filtering. C) Principal components analysis after filtering. D) Expression profile 




Chapter 3: Development of primary Schwann cell culture 
techniques for use with neonatal SMA mice 
3.1 Introduction 
Spinal muscular atrophy (SMA) is often classified as a motor neuron disease. 
However, SMN protein is ubiquitously expressed and therefore other cells may 
contribute to SMA pathology (Hamilton & Gillingwater, 2013). One of the potential 
cells that may be involved in SMA pathology is the Schwann cell, the predominant 
glial cell in the peripheral nervous system (PNS). Schwann cells deposit myelin 
sheaths, which helps neurons to conduct faster electrical pulses (Rasband, 2011). 
They have also been reported to have protective effects on neurons (Rasband, 2011).  
Schwann cell defects in development and myelination are observed in several 
peripheral neuropathies including Charcot-Marie-Tooth disease (CMT) (Berger et 
al., 2006). However, no previous studies have investigated the contribution of 
Schwann cells in SMA disease pathogenesis. 
Primary isolated Schwann cell cultures from SMA mouse models are required in 
order to study Schwann cell development and differentiation in the absence of 
neurons. Myelination could then also be studied using co-cultures of wild-type dorsal 
root ganglion (DRG) with pre-purified SMA Schwann cells. However, to our 
knowledge, there is no protocol suitable for extraction of Schwann cells from SMA 
mice. Most studies of PNS myelination have been performed using rat DRG neuron-
Schwann cell co-cultures. Kleitman’s method is generally used to isolate Schwann 
cells from sciatic nerves (Kleitman et al., 1997). Sciatic nerves are enzymatically 
dissociated and purified with antibody and complement serum treatment. However, 
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there is no rat model for SMA. In contrast, several mouse models of SMA have been 
developed (Bebee et al., 2012).  
It is difficult to isolate and purify a sufficient amount of myelination competent 
Schwann cells from mice with existing protocols designed for use with rat models. 
Therefore, most of the previous work using mouse models has been performed with 
DRG explant cultures in which Schwann cells and neurons are extracted from the 
same tissue (Liu et al., 2005). Explant cultures therefore limit the potential to 
generate co-cultures of neurons and Schwann cells from mice with different genetic 
modifications. 
 Several protocols have been developed to study myelination in mouse DRG-
Schwann cell co-cultures. Although reported Schwann cell purities were satisfactory, 
the number of Schwann cells generated and their myelination capability were not 
sufficient for our experiments in SMA mice (Verdú et al., 2000; Seilheimer et al., 
1989; Kim et al., 1997). The only protocol suitable for modification for use with 
SMA mice was published in 2007 by Honkanen et al (Honkanen et al., 2007). They 
proposed a co-culture protocol in which they used the basics of the Kleitman method 
with less harsh treatment for sciatic nerve dissociation. Horse serum was replaced by 
fetal calf serum and fibroblasts were removed by Thy1.1 antibody instead of Thy1.2 
and cytosine arabinoside. The Thy 1.2 antigen is expressed on mouse fibroblasts but 
not Schwann cells, which provides more efficient and less cytotoxic agent for 
Schwann cell purification (Dong et al., 1999). They also used a Schwann cell 
mitogenic factor, adenylate cyclase activator forskolin, that was also reported to 
inhibit fibroblast proliferation (Yamada et al., 1995). They compared collagen type 
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1, poly-L-lysine and laminin as substrata on which cultures were grown. They found 
that Schwann cells plated on either collagen or PLL had a similar proliferation rate 
that was higher than that observed using laminin alone.  Due to economical reasons 
they chose to use PLL as coating material. This protocol generated 1.9-3.3 X 106 of 
95% purified Schwann cells that were myelination competent from sciatic nerves 
from 12-15 4-day-old wild-type CD1 mice (Honkanen et al., 2007). 
Although the Honkanen et al. study confirmed that it is possible to isolate Schwann 
cells from mice, further modifications are required to use this protocol for SMA 
mice. SMA Schwann cell yields would not be sufficient due to the smaller size of 
sciatic nerves from SMA mice compared to wild-type mice. Older pups are also 
required to distinguish between healthy and SMA mice before pooling their sciatic 
nerves for experiments. 
In this chapter, I have adapted the Honkanen et al. protocol for generating Schwann 
cells from wild-type CD1 mice with parameters suitable for subsequent use with 
SMA mice. The number of Schwann cells initially obtained was not sufficient for 
quantitative studies. I therefore modified the substrata, medium composition, number 
of pups used, and the age of animals for better Schwann cell yields. Purity of 
Schwann cells was assessed by double immunostaining with S100 and GFAP 
antibodies. I adopted this protocol to generate SMA Schwann cells from sciatic 
nerves of 8-day-old ‘Taiwanese’ SMA mouse pups. Approximately 400,000 cells per 
preparation were obtained with around 95-98% purity. Finally, I assessed the 
capability of the Schwann cells to express myelin markers in DRG neuron-Schwann 
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cell co-cultures. The resulting protocol was then used for studying Schwann cell 
development and myelination in subsequent chapters. 
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3.2 Results 
3.2.1 Schwann cell generation from CD1 mice 
CD1 mice were used initially because they are more economical to maintain and they 
produce large litters in which all pups have the same genotype. The protocol by 
Honkanen et al was used (Honkanen et al., 2007) as a template that could 
subsequently be modified. Sciatic nerves were collected from 12 4-day-old mouse 
pups and plated on 10 µg/ml poly-l-lysine coated dishes. Schwann cells emerged 
from sciatic nerves after a day in culture. Schwann cells were distinguishable from 
fibroblasts by their elongated bi- or tri-polar cell morphology with an oval 
luminescent cell body. Fibroblasts display a round, large non-luminescent nucleus, 
which is flattened and polymorphic (Kaewkhaw et al., 2012). Schwann cells were 
purified with anti-Thy 1.2 antibody and rabbit complement to remove fibroblasts. 
Cells were left to become nearly 80% confluent. Schwann cell number was 
calculated after first passage. 80,000 Schwann cells were obtained by this method, 
which was not enough for future experiments. Figure 3.1 shows phase contrast 
pictures of Schwann cells emerging from sciatic nerves, purified and expanded. 
Modifications were therefore required to generate higher cell yields. Note that in 
order to calculate number of CD1 mouse Schwann cells obtained from each 
treatment to modify isolation protocol, 12 mice were sacrificed and total number of 
24 sciatic nerves was isolated per preparation. Three preparations were used for each 
treatment and their average number of Schwann cells was used to compare different 
treatments efficiency.  
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Figure 3.1 Schwann cell isolation, purification and expansion. Schwann cells emerge from 
sciatic nerves (Day 2), were purified by Thy 1.2 antibody (Day5) and expanded (Day 8). 
3.2.2 Coating substrate optimisation 
It was observed that the sciatic nerves were loosely attached to the plate and this may 
have contributed to the low yield of Schwann cells. Higher concentrations of Poly-L-
lysine were therefore tested: a 10-fold higher concentration of poly-L-lysine (100 
µg/ml) was used. The number of Schwann cells in 60 mm dish was increased to 
100,000 cells (Figure 3.2). 
 
Figure 3.2 Substratum optimisation. Representative phase contrast micrographs of Schwann 
cell cultures at day 2, 5 and 8. Original poly-L-lysine (PLL) concentration 10 µg/ml (Top panel) 
was compared to 100 µg/ml (Bottom panel). Applying more concentrated PLL for coating the 
plates increased the average number of Schwann cells. 
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For further optimisation of coating substrates, I examined whether concentrated PLL 
could be used in combination with other coating material. To develop the original 
protocol, Honkanen et al. tried several other substrates and compared the Schwann 
cell numbers. The coating materials were PLL, laminin and collagen type 1. 
Although all 3 substrates supported Schwann cell proliferation, they found that cells 
cultured on collagen type 1 and PLL had significantly higher proliferation rates 
compared to those grown on laminin. Collagen could not be used with laminin since 
it needs acidic pH to prepare. The PLL/ laminin coating is also used routinely in rat 
Schwann cell co-cultures. Therefore, dishes were first coated with concentrated PLL 
and then with laminin. 198,000 cells were obtained with these coating conditions, 
representing a notable improvement compared to PLL alone. 
3.2.3 Medium composition 
In the paper published by Arthur-Farraj et al. insulin was used after purification of 
Schwann cells (Arthur-Farraj et al., 2011). Insulin is a hormone that is used as a 
differentiation factor in Schwann cell cultures. However insulin in combination with 
forskolin could increase cyclic adenosine monophosphate (cAMP) levels, which was 
shown to induce Schwann cell proliferation (Stewart et al., 1996).  10-6 M insulin 
was therefore added to the Schwann cell growth medium post-purification (Arthur-
Farraj et al., 2011). Schwann cell number was increased to an average of 245,000 
cells. 
Based on this success, obtaining higher numbers of Schwann cells upon addition of 
insulin, it was added to the cultures from day 1. Schwann cell number was nearly 
doubled; insulin treated cultures had an average of 422,500 cells (Table 3.1). 
 77 
 
Treatment Average Schwann cell number ± SEM 
Original protocol 80,000 ± 2309.4 
10X Poly-L-lysine 100,000 ± 6110.1 
10X Poly-L-lysine/ laminin 198,000 ± 3214.5 
Insulin after purification 245,000 ± 4582.6 
Insulin before purification 422,500 ± 6427.5 
Table 3.1 CD1 mouse Schwann cell culture optimisation. Changing substratum and medium 
composition increased Schwann cell numbers 
3.2.4 Mouse age  
The majority of protocols for both rat and mouse Schwann cell cultures use early 
postnatal pups (day 0-4). Given the need to pool sciatic nerves from several mice of 
the same genotype for culturing in SMA experiments, there was a need to be able to 
genotype mouse pups before dissection. However postnatal day 4 SMA mice are pre-
symptomatic and do not show significant differences in their gross phenotype 
compared to wild-type littermates. Postnatal day 7-8 is the time point when I was 
first able to reliably distinguish between SMA and littermate controls. I initially 
modified the protocol to use older CD1 mouse pups (day 8) to compare number of 
Schwann cells compared to previous readings. The average number of cells was 
approximately 400,000 cells similar to those obtained from P4 mouse pups. 
3.2.5 Isolation of Schwann cells from ‘Taiwanese’ SMA mice 
The modified protocol was then tested on litters of SMA ‘Taiwanese’ mice and 
littermate controls. SMA mice have reduced body weight, longer righting times and 
necrosis in their tails (Somers et al., 2013; Hsieh-Li et al., 2000). Pups were 
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segregated at P8 based on this phenotype. The number of cells obtained from SMA 
and littermate animals was calculated after first passage. Given using the whole litter 
for experiments, the plated number of sciatic nerves from control and SMA mice 
might be different for each preparation. Therefore in order to compare the number of 
Schwann cells obtained from each genotype, I calculated Schwann cells per mouse. 
68,734 control and 48,478 SMA Schwann cells were obtained per mouse (from 4 
separate preparations). The lower number of SMA Schwann cells might be due to 
their smaller sciatic nerve sizes. 
3.2.6 Purity of Schwann cells 
Purity of Schwann cells are routinely quantified by double immunostaining with anti 
calcium-binding protein S100 antibody (Schwann cell marker, (Hyden & McEwen, 
1966)) and anti-glial fibrillary acidic protein (GFAP) antibody, an intermediate 
filament protein in embryonic and non-myelinating Schwann cells (Jessen et al., 
1990; Honkanen et al., 2007). Control and SMA Schwann cells were double-
immunostained with these antibodies. Schwann cell purity was calculated as a 
percentage of cells that were immunostained for all three markers (TOPRO-3 as a % 




Figure 3.3 Schwann cell purity. Representative confocal micrographs of Schwann cells 
immunostained with S100 (red), GFAP (green) and TOPRO3 (blue) show that most of the cells in 
culture were Schwann cells. The graph compares the Schwann cell purification between control 
and SMA cultures (Two-tailed, unpaired nonparametric t-test; N = 4 subcultures from one 
preparation per genotype, 2 fields of view imaged per culture, > 150 cells quantified per field of 
view, n = 4 readings). 
3.2.7 Myelination competent Schwann cells 
Finally, I needed to establish whether Schwann cells isolated using the new protocol 
were capable of myelination. Schwann cells from wild-type mice were co-cultured 
with pre-purified DRG neurons. Myelination was induced by addition of medium 
supplemented by L-Ascorbic acid. Ascorbic acid induces Schwann cells to produce 
collagen fibrils necessary for myelination (Eldridge et al., 1989). Cells were 
immunostained after 4 weeks in myelination medium. Myelin basic protein (MBP), a 
marker for late myelination was expressed around approximately 80% of neurons 
(Figure 3.4). Therefore the new protocol could be used for isolation of myelination-
competent Schwann cells from SMA and wild-type mice. 
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Figure 3.4 Induction of myelination by Taiwanese mouse Schwann cells in DRG neuron-
Schwann cell co-cultures. Representative phase-contrast pictures of DRG-neurons 
immunostained with anti-neurofilament medium antibody show that majority of neurons were 
co-immunolabled with late myelin marker MBP and therefore capable of myelin production.  
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3.3 Discussion 
In this chapter established protocols were modified to allow isolation of a high yield 
of Schwann cells from SMA mice. Based on the prior success of the Honkanen et al. 
(Honkanen et al., 2007) protocol to achieve high-yield, purified Schwann cells, it 
was adopted as the basis for this study. However, I could not obtain the same number 
of Schwann cells using their protocol with our proposed methodology for SMA 
mice. Therefore modifications were performed on the culture substratum and 
medium composition. Also I used P8 mice pups instead of P4, in order to distinguish 
SMA from healthy mice prior to pooling their sciatic nerves. After applying these 
modifications, I obtained 68,734 control and 48,478 SMA Schwann cells per mouse 
with 95-98% purity. The generated Schwann cells are capable of myelination and 
could therefore be used in our subsequent experiments. 
Although SMA is often considered as a motor neuron disease, alterations have been 
demonstrated in both motor and sensory axons (Jablonka et al., 2006). Defective 
myelination was also shown in our previous data in a mixed population of motor and 
sensory neurons (Hunter et al., 2014). Myelination studies are frequently performed 
in well-established Schwann cell-DRG neuron co-cultures (Honkanen et al., 2007). 
Therefore sensory DRG neurons were considered to be the best source of robust 
neurons for co-culture experiments.  
Here, I developed a protocol for isolation of myelination-competent Schwann cells 
from SMA mice. This protocol can also be used to study peripheral neuropathies 
such as Charcot-Marie-Tooth disease. The main advantage of DRG neuron-Schwann 
cell co-culture is the potential to use Schwann cells and neurons from different 
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genotypes to study cell type-specific bimolecular and cellular events taking place 
during normal and pathological myelination. For instance, DRG neuron can be 
extracted from healthy control mice and Schwann cells from SMA or other 
peripheral neuropathy mouse models to investigate the intrinsic defects in Schwann 
cells development and myelination. To my knowledge, no DRG neuron-Schwann 
cell co-culture experiments have been carried out in mouse models of Charcot-
Marie-Tooth disease. Although rat model of human CMT1A has been generated 
(Nobbio et al., 2006), the in vitro study of other subtypes of CMT disease was 
limited to DRG explant cultures (Liu et al., 2005). The limitation of this system is 
that both neurons and Schwann cells are from the same animal and therefore it is 
impossible to dissect the cell-type specific defects in abnormal myelination. 
Therefore, the protocol that I developed has the potential to be used in diseases with 




Chapter 4: SMN-dependent Schwann cell intrinsic defects in 
mouse models of spinal muscular atrophy  
4.1 Introduction 
Low levels of SMN are traditionally thought to selectively target lower motor 
neurons, but SMN has recently been shown to have effects on multiple other cell 
types (Hamilton & Gillingwater, 2013). Glial cells are essential for the form, 
function and maintenance of neurons. Defects in glia were observed as a contributing 
factor in several neurological conditions, such as Parkinson’s disease (Fellner et al., 
2011), Alzheimer’s disease (Nagele et al., 2004) and amyotrophic lateral sclerosis 
(Lobsiger & Cleveland, 2007). Genetic defects targeting myelin proteins in Schwann 
cells, the major glia in the peripheral nervous system (PNS), are also associated with 
peripheral neuropathies such as Charcot-Marie-Tooth disease (CMT) (Berger et al., 
2006). Given the importance of Schwann cells for the maintenance of lower motor 
neurons, I wanted to determine if they contribute to SMA pathology.  
Previous microarray analysis on late symptomatic P5 severe Smn-/-; SMN2 mouse 
spinal cord revealed significant alterations in myelin gene expression compared to 
littermate controls. There was a 6.5 and 3.7 fold decrease in expression of myelin 
protein zero (MPZ) and peripheral myelin protein 22 (PMP22) in SMA mouse spinal 
cords, respectively (Murray et al., 2010). This suggests disruption in core myelin 
protein expression in SMA mice.  
Myelination has also been examined in the ‘Taiwanese’ and severe SMA mouse 
models in vivo (Hunter et al., 2014). Ultrastructural analysis of myelination in 
intercostal nerves from P5 severe SMA mice revealed that there were more axons of 
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large calibre (>1 µm) that remained unmyelinated or had thinner myelin sheaths, 
with no signs of axonal degeneration. The average G-ratio, the ratio of axon diameter 
to myelinated axon diameter, was increased in SMA intercostal nerves. No reduction 
in axonal diameter was observed. Abnormal peripheral myelination was also 
confirmed in milder ‘Taiwanese’ SMA mouse models at early (P7) and late 
symptomatic stages (P11). However upper motor neuron tracts in the spinal cord and 
distal peripheral nerves did not show any difference in their myelination compared to 
control littermates. Expression of key myelin proteins such as myelin protein zero 
(MPZ), peripheral myelin protein 22 (PMP22) and myelin basic protein (MBP) were 
also disturbed in ‘Taiwanese’ SMA mice intercostal and sciatic nerves (Hunter et al., 
2014). Together, these data suggest that myelination is abnormal in SMA mice. 
In vivo studies could not rule out the possibility that the observed defects in 
myelination were occurring as a secondary consequence of pathology in 
neighbouring motor neurons. Therefore I wanted to isolate Schwann cells from 
‘Taiwanese’ SMA mice in order to examine whether reduced levels of SMN caused 
intrinsic defects in the absence of pathological neurons. Isolated Schwann cells were 
extracted from post-symptomatic (P7) mice and so they would have been in 
association with pathologically affected neurons. There is therefore a possibility that 
observed defects in Schwann cell differentiation are not intrinsic. However, isolated 
Schwann cells are thought to be reprogrammed to Schwann cell precursors in culture 
without differentiation medium (Arthur-Farraj et al., 2011) increasing the likelihood 
that any observed effect is intrinsic.  
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In this Chapter, I first confirmed that isolated SMA-derived Schwann cells were 
stable in culture and that SMN protein levels were reduced significantly in these 
cells. I showed that Schwann cells from SMA mice developed normally at 
undifferentiated stages. Next, I induced myelination in isolated Schwann cells in the 
absence of neurons and observed that SMA-derived Schwann cells did not respond 
normally to myelination cues. Restoring SMN levels was shown to rescue 
myelination defects. Using co-cultures of wild-type dorsal root ganglion (DRG) 
neurons with SMA-derived Schwann cells, I showed abnormal myelination with 
SMA Schwann cells. SMA-derived Schwann cells were also shown to promote 
instability in neighbouring healthy neurons. Finally, I showed that extracellular 
matrix (ECM) was disrupted in Schwann cells from SMA mice and it was to some 




4.2.1 Schwann cell stability in culture 
Schwann cells derived from SMA ‘Taiwanese’ mice were de-differentiated to an 
immature, non-myelinating phenotype in vitro.  
 
Figure 4.1 (A) Representative confocal micrographs of isolated Schwann cells immunollabeled 
with antibodies against the apoptotic marker CASP3 (green) and nuclei labeled with TOPRO3 
(blue), showing no significant difference in percentage of CASP3 expressed cells between SMA-
derived and control Schwann cells pre-differentiation.  (B) Bar graph showing no significant 
difference in percentage of CASP3 of SMA-derived Schwann cells compared to control cells 
pre-differentiation (two-tailed, unpaired nonparametric t-test; N = 4 subcultures from single 
preparation per genotype, 2 fields of view imaged per culture, > 150 cells quantified per field of 
view, total n = 4 readings).  
 87 
SMA-derived Schwann cells were found to be stable in culture, as immunolabelling 
for the apoptosis marker caspase 3 (CASP3,Table 2.4) showed no significant change 
in percentage of apoptotic Schwann cells derived from SMA mice compared with 
control cells (Figure 4.1). 
Cell proliferation was also compared between control and SMA-derived Schwann 
cells by BrdU labelling (see methods). There was no significant difference in the 
percentage of BrdU labelled cells between SMA and control Schwann cells (Figure 
4.2). These data indicated that immature SMA-derived Schwann cells were stable in 
vitro. 
 
Figure 4.2 Schwann cells proliferation assay. Isolated Schwann cells from control and SMA 
mice were labelled with mouse BrdU and immunostained with anti-BrdU antibody and nuclei 
marker TOPRO3 to assess cell proliferation in these two cultures. Number of BrdU labelled cells 
was quantified in each field of view and percentage of BrdU-labelled cells was compared 
between two genotypes. Bar graph showed a similar incorporation of BrdU into control and 
SMA-derived Schwann cells (two-tailed, unpaired nonparametric t-test; N = 4 subcultures from 
one preparation per genotype, 2 fields of view imaged per subculture, > 25 cells quantified per 
field of view and total n = 4 readings) 
4.2.2 SMN protein levels in vitro 
SMN protein expression levels in isolated Schwann cells were examined by 
immunostaining with an anti-SMN antibody (Table 2.4). SMN expression levels in 
 88 
cells derived from SMA mice were significantly decreased in comparison with 
littermate controls (Figure 4.3).  
 
Figure 4.3 SMN expression levels. (A) Representative confocal micrographs of isolated 
Schwann cells from ‘Taiwanese’ SMA mice and littermate controls, immunolabelled to reveal 
SMN protein. SMN was strongly expressed in Schwann cells from control mice, but was 
markedly reduced in primary cultures of SMA-derived Schwann cells (B) (*** P < 0.001; N = 4 
subcultures from single preparation per genotype, 2 fields of view imaged per culture, > 150 
cells quantified per field of view; unpaired two-tailed t-test, n = 4 readings). 
4.2.3 SMA-derived Schwann cells develop normally pre-differentiation 
Several transcription factors control Schwann cell development and their transition 
from an undifferentiated to a myelinating phenotype.  Examples of these 
transcription factors are SRY-box containing gene 10 (SOX10), SRY-box containing 
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gene 2 (SOX2), and POU domain class 3 transcription factor 1 (POU3F1 or OCT6).  
SOX10 is a lineage marker for Schwann cell development and is present at all stages 
of Schwann cell development (Britsch et al., 2001). Immature Schwann cell marker 
SOX2 is important for maintaining the undifferentiated state and is a negative 
regulator of myelination (Nam et al., 2005). 
 
Figure 4.4 (A) Representative confocal micrographs of isolated Schwann cells showing no 
significant difference in Schwann cell marker, Sox10 in SMA-derived Schwann cells compared 
to cells from control littermates. (B) Bar graph showing no significant difference in SOX10 
expression in SMA- and control-derived Schwann cells (Unpaired two-tailed t-test; N = 4 
subcultures from single preparation per genotype, 2 fields of view imaged per culture > 150 
cells quantified per field of view, n = 4 readings). 
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POU3F1 transiently increases before myelination to regulate early myelination 
transcription factors such as early growth response 2 (EGR2) (Jaegle et al., 2003). 
Prior to the induction of differentiation, transcription factor levels SOX10 (Figure 
4.4), SOX2 (Figure 4.5), and POU3F1 (Figure 4.6) were similar between SMA-
derived and control Schwann cells. These results show that pre-differentiated 
Schwann cells isolated from SMA mice expressed the normal complement of 
immature Schwann cell markers.  
 
Figure 4.5 (A) Representative confocal micrographs of isolated Schwann cells showing no 
significant difference in late marker of Schwann cell differentiation, SOX2 in SMA-derived 
Schwann cells compared to cells from control littermates. (B) Bar graph showing no significant 
difference in SOX2 expression in SMA- and control-derived Schwann cells (Unpaired two-tailed 
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t-test; N = 4 subcultures from one preparation per genotype, 2 fields of view imaged per culture 
> 150 cells quantified per field of view, n = 4 readings). 
 
Figure 4.6 (A) Representative confocal micrographs of isolated Schwann cells showing no 
significant difference in Schwann cell differentiation marker, POU3F1 (red) in SMA-derived 
Schwann cells compared to cells from control littermates. (B) Bar graph showing no significant 
difference in POU3F1 expression in SMA- and control-derived Schwann cells (Unpaired two-
tailed t-test; N = 4 subcultures from one preparation per genotype, 2 fields of view imaged per 
culture > 25 cells quantified per field of view, n = 4 readings). 
4.2.4 SMA-derived Schwann cells fail to respond normally to 
myelination cues 
Arthur-Farraj et al showed that immature Schwann cells could be differentiated in 
vitro by addition of dbCAMP and NRG1 to induce the myelinating Schwann cell 
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phenotype (Arthur-Farraj et al., 2011). They reported strong expression of myelin 
markers, such as early growth response 2 (EGR2 or Krox20) and myelin protein zero 
(MPZ) after 72 and 120 hours, respectively. 
 
Figure 4.7 (A) Representative confocal micrographs of differentiated Schwann cells 
immunolabelled with antibodies against myelin protein MPZ. MPZ levels were noticeably lower 
in SMA-derived Schwann cells. (B) Bar graph showing significant reduction of MPZ level 
expression in SMA-derived Schwann cells 120 hours post-differentiation (*** P < 0.001 ; two-
tailed, unpaired t-test; N = 4 subcultures from one preparation per genotype, 2 fields of view 
imaged per culture, > 25 cells quantified per field of view, n = 4 readings). (C) Bar graph 
showing significant reduction in number of cells expressing MPZ in SMA-derived Schwann 
cells 120 hours post-differentiation (*** P < 0.001; two-tailed, unpaired nonparametric t-test; N = 
4 subcultures from single preparation per genotype, 2 fields of view imaged per culture, > 25 
cells quantified per field of view, n = 4 readings) 
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I used this model to establish whether observed in vivo myelination defects in SMA 
mice were due to differences in the intrinsic ability of Schwann cells to respond to 
differentiation signals. MPZ levels were measured in SMA- and control-derived 
Schwann cells 120 hours after differentiation. MPZ levels were significantly less 
elevated in SMA-derived Schwann cells compared to control cells (Figure 4.7).  
 
Figure 4.8 Significantly   reduced   EGR2   expression   in   isolated   SMA-derived   Schwann   
cells post-differentiation.  (A) Representative confocal micrographs of differentiated Schwann 
cells immunolabelled with antibody against early myelin marker EGR2 (green) and nuclei 
staining TOPRO3 (blue).  (B) Bar graph showing significant reduction of EGR2 expression in 
SMA-derived Schwann cells (** P < 0.01; two-tailed, unpaired t-test; N = 2 cultures/ genotype, 2 
fields of view imaged per culture, > 25 cells quantified per field of view, n = 8 readings) 
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Similarly, EGR2 levels were significantly lower in SMA Schwann cells 72 hours 
after differentiation (Figure 4.8). The EGR2 immunostaining of SMA-derived 
Schwann cells revealed altered cell morphology compared to control Schwann cells. 
To ensure that the altered morphology was not due to experimental errors, the EGR2 
immunostaining was repeated and the similar results were obtained. However, the 
underlying possible mechanisms are still unknown.  
These data indicated intrinsic defects in SMA-derived Schwann cells, leading to a 
failure to respond normally to differentiation signals occurring in the absence of any 
influence from pathological neurons. 
4.2.5 SMN-dependent myelination defects in SMA-derived Schwann 
cells 
Next I wanted to determine whether Schwann cell differentiation defects were SMN 
dependent and reversible. SMA-derived Schwann cells were transfected with a SMN 
expression construct under the control of a Schwann cell specific promoter (pMPZ-
SMN) (Shorer et al., 1995) and pEHHG (a GFP-expression, non-SMN carrying, 
control construct, see methods) (Hamilton et al., 2012) at 90 hours post-
differentiation. Control and SMA-derived Schwann cells were also transfected with 
control pEHHG. Transfection efficiency was 100% for both control and SMA-
derived Schwann cells. MPZ levels were quantified at 120 hours post-differentiation. 
MPZ levels in SMA-derived Schwann cells were restored to levels observed in 
healthy control Schwann cells. This result indicated that myelination defects in 
SMA-derived Schwann cells occurred as a direct result of reduced SMN levels. It 
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also demonstrated that these defects were reversible upon SMN restoration (Figure 
4.9). 
 
Figure 4.9 (A) Representative confocal micrographs of primary Schwann cell cultures 
transfected with pEHHG (non-SMN transgene) alone (Control and SMA) or pEHHG/pMPZ-SMN 
(SMA). Cells were immunolabelled with antibodies against MPZ (red) and cell nuclei were 
labeled with TOPRO3 (blue). GFP expression was used to confirm the expression from the 
pEHHG plasmid (green). (B) Bar chart showing a significant restoration of MPZ levels in SMA-
derived Schwann cells transfected with pMPZ-SMN compared with pEHHG alone (* P ≤ 0.05;) (At 
120 hours post-differentiation; two-tailed, unpaired t-test; N = 4 subcultures from single 
preparation per genotype, n = 4 readings). 
It is interesting to observe SMN transfection effect on SMA Schwann cell 
differentiation at later time-points, when Schwann cell proliferation will dilute the 
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amount of SMN construct available to each cell. However Schwann cell’s 
mechanism of action for differentiation has not been studied after 120 hours in wild-
type cells (Arthur-Farraj et al., 2011) and therefore I did not check those time-points. 
4.2.6 Perturbations in expression of myelination transcription factors 
Levels of myelin gene transcription factors SOX10, SOX2, POU3F1 and NOTCH1 
were quantified 72 hours post-differentiation to examine whether SMN-dependent 
defects in transcription were responsible for the observed changes in MPZ and EGR2 
protein levels. SMA-derived Schwann cells expressed significantly lower SOX10 
levels compared to control cells (Figure 4.10). 
SOX2 levels were also significantly reduced in SMA-derived Schwann cells (Figure 
4.11). In contrast, POU3F1 levels remained unchanged (Figure 4.12). The negative 
regulator of myelination, NOTCH1 levels were increased in SMA-derived Schwann 
cells (Figure 4.13). This data showed that perturbations in levels of several 
myelination regulating transcription factors were present in SMA Schwann cells. 




Figure 4.10 (A) Representative confocal micrographs of differentiated Schwann cells showing 
reduced levels of Schwann cell lineage marker SOX10 in SMA-derived Schwann cells. (B) Bar 
graph showing significant reduction in SOX10 expression levels in SMA-derived Schwann cells 
post-differentiation (* P < 0.05; at 72 hours post-differentiation; two-tailed, unpaired t-test; N = 4 
subcultures from single preparation per genotype, 2 fields of view imaged per culture, > 25 cells 
quantified per field of view, n = 4 readings). 
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Figure 4.11 (A) Representative confocal micrographs of differentiated Schwann cells showing 
reduced levels of Schwann cell marker SOX2 in SMA derived-Schwann cells. (B) Bar graph 
showing significant reduction in SOX2 expression levels in SMA-derived Schwann cells post-
differentiation (*** P < 0.001 respectively; at 72 hours post-differentiation; two-tailed, unpaired t-
test; N = 4 subcultures from single preparation per genotype, 2 fields of view imaged per 
culture, > 25 cells quantified per field of view, n = 4 readings). 
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Figure 4.12 (A) Representative confocal micrographs of differentiated Schwann cells showing 
no change in levels of Schwann cell differentiation marker POU3F1 in SMA derived Schwann 
cells. (B) Bar graph showing no significant alterations in POU3F1 expression levels in SMA-
derived Schwann cells post-differentiation (at 72 hours post-differentiation; two-tailed, unpaired 
t-test; N = N = 4 subcultures from single preparation per genotype, 2 fields of view imaged per 
culture, > 25 cells quantified per field of view, n = 4 readings). 
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Figure 4.13 (A) Representative confocal micrographs of differentiated Schwann cells showing 
significant increase in Schwann cell differentiation marker NOTCH1 in SMA-derived Schwann 
cells. (B) Bar graph showing significant increase in NOTCH1 expression levels in SMA-derived 
Schwann cells post-differentiation (* P< 0.05; at 72 hours post-differentiation; two-tailed, 
unpaired t-test; N = 4 subcultures from single preparation per genotype, 2 fields of view imaged 
per culture, > 25 cells quantified per field of view, n = 4 readings). 
4.2.7 Low MPZ levels were not due to transcriptional defects 
Next, I wanted to establish whether the reduction in myelin marker MPZ levels in 
SMA-derived Schwann cells was a direct result of disruption in gene transcription. 
qPCR analysis of gene transcription at 120 hours post-differentiation revealed that 
MPZ mRNA levels were the same in SMA-derived Schwann cells compared with 
control cells (Figure 4.14). Therefore, low levels of SMN were not regulating MPZ 
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protein levels by modulating gene transcription. This data suggests that SMN likely 
mediates MPZ expression in Schwann cells by regulating protein translation and/or 
stability. 
 
Figure 4.14 No significant difference in the MPZ gene expression levels in control and SMA 
differentiated Schwann cells (at 120 hours post-differentiation; two-tailed, unpaired t-test; N = 3 
mice per genotype, each sample analysed in triplicate). 
4.2.8 Deficient myelination of wild-type neurons by SMA-derived 
Schwann cells in vitro 
Next, I used dorsal root ganglion (DRG) neuron-Schwann cell co-cultures (see 
methods) to establish whether intrinsic deficiencies observed in SMA-derived 
Schwann cells could induce defective myelination of healthy neurons. Motor neurons 
are severely affected in SMA, but alterations were also observed in sensory axons 
(Jablonka et al., 2006). Our previous data in a mixed population of motor and 
sensory neurons was shown defective myelination (Hunter et al., 2014). Myelination 
studies are frequently performed in well-established Schwann cell-sensory DRG 
neuron co-cultures (Honkanen et al., 2007) and we use this model for the 
myelination experiments instead of using motor neuron-Schwann cell co-cultures.  
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Myelination was induced in co-cultures for 40 days and cells were immunolabelled 
with antibodies against neurofilament medium protein (neurite marker) and myelin 
basic protein (MBP, compact myelin marker). It was observed that there was 
significant decrease in the percentage of neurites with corresponding myelin protein 
expressing in co-cultures of SMA-derived Schwann cells with wild-type neurons, 
compared to those with Schwann cells from littermate controls (Figure 4.15). 
This observation suggested that myelination abnormalities observed in SMA mice in 
vivo were, at least in part, due to intrinsic defects in Schwann cells. 
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Figure 4.15 Defective ability of SMA-derived Schwann cells to generate myelin protein when co-
cultured with healthy neurons. (A) Representative micrographs of DRG-Schwann cell co-
cultures immunolabelled with antibodies against neurofilaments (NF-M; left panel) and a myelin 
marker MBP (right panel) 30 days after induction of myelination. Although some neurite 
processes were associated with a corresponding MBP signal from SMA-derived Schwann cells 
(indicating that myelination processes were not completely abolished), many neurite processes 
lacked a corresponding MBP signal compared with control littermates (white arrows). (B) Bar 
graph showing a significant reduction in the percentage of neurite processes with a 
corresponding MBP signal in co-cultures with SMA Schwann cells (**** P ≤ 0.0001; two-tailed, 
unpaired t-test; N=3 co-cultures per genotype, four fields of view imaged per culture, 5–20 
neurites quantified per field of view). 
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4.2.9 Influence of SMA Schwann cells on neuronal stability  
Next, I wanted to examine whether SMA-derived Schwann cells influenced the 
stability of neighbouring healthy neurons. Neurite densities were quantified in DRG 
neuron-Schwann cell co-cultures established with SMA-derived Schwann cells- 
control DRG neurons and were compared to co-cultures with control cells (see 
methods). There was a significant reduction in neurite density in co-cultures 
established with SMA-derived Schwann cells (Figure 4.16). However no axonal 
fragmentation was observed suggesting a lack of Wallerian-like neurodegeneration. 
The reduction in neurite density was considered more likely to have happened 
gradually over time, as seen in dying-back pathways, which have been shown in 
SMA mice (Murray et al., 2008). 
 
Figure 4.16 (A) Representative micrographs of purified DRG neurites (before addition of 
Schwann cells), DRG neurites from co-cultures with control Schwann cells and DRG neurites 
from co-cultures with SMA-derived Schwann cells. Neurites were immunolabelled with 
antibodies against NF-M. (B) Bar chart showing that neurite densities were maintained after 42 
days of co-cultures when healthy DRG neurons were combined with control Schwann cells. In 
contrast, there was a significant reduction in neurite densities when healthy DRG neurons were 
cultured with SMA-derived Schwann cells (* P ≤ 0.05; N = 7 co-cultures per genotype, three 
independent fields of view quantified per culture). 
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I next investigated the mechanism through which SMA-derived Schwann cells might 
de-stabilise neighbouring healthy neurons. It has been shown that astrocytes regulate 
neuron stability by secreting neurotoxic factors in ALS (Lasiene & Yamanaka, 
2011). Therefore I examined the ability of SMA-derived Schwann cells to produce 
neurotoxic factors. Healthy purified DRG neurons were exposed to conditioned 
medium (see methods) from isolated SMA and control Schwann cells. Phase-contrast 
pictures were taken at 6, 24 and 72 hours after addition of the conditioned medium. 
Neurite densities I measured for both cultures and no significant changes were 
observed (Figure 4.17). Thus, neuronal viability was not being modulated by 
secretion of a toxic factor from SMA Schwann cells. 
 
Figure 4.17 (A) Representative tracings from phase contrast micrographs of DRG neurites 
cultured for 72 hours with conditioned media from either control or SMA Schwann cells. (B) 
Time-course graph demonstrating no significant change in neurite densities following 
treatment with conditioned media derived from control (black) or SMA (red) Schwann cells at 6, 
24 or 72 h (P > 0.05 at all time points; one-way ANOVA with Tukey’s post hoc analyses; N = 10 
co-cultures per genotype). 
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Schwann cells could also potentially influence neuronal stability in SMA via 
disruption to the extracellular matrix (ECM). Microarray analysis on post-
symptomatic P5 SMA mouse spinal cord has shown perturbations in extracellular 
matrix components such as laminin alpha 2 (LAMA2) (Murray et al., 2010). 
Laminin signalling plays an important role in Schwann cell proliferation and 
differentiation (Chernousov et al., 2008). Laminin signalling has also reported to be 
disrupted in SMA motor neurons (Rathod et al., 2012). Local translation of β-actin in 
growth cones of motor neurons has shown to be regulated by laminin signalling, 
which is disturbed in SMA (Rathod et al., 2012). 
Laminin protein expression was quantified both in vivo and in vitro. LAMA2 
expression levels were examined in intercostal and sciatic nerves representing 
severely affected and less affected neurons, respectively. At early-symptomatic stage 
(P7), LAMA2 expression levels in SMA sciatic nerves did not show any difference 
with control littermates, but it was already significantly decreased in intercostal 
nerves. At a late symptomatic time point (P11), LAMA2 expression showed a 
modest reduction in SMA sciatic nerves compared to control nerves. 
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 Figure 4.18 Representative fluorescence micrographs of sciatic (A and B) and intercostal (C) 
nerves from ‘Taiwanese’ SMA mice and littermate controls immunolabelled with antibodies 
against LAMA2. All panels were taken with identical microscope settings. (A) There was no 
difference in LAMA2 levels in sciatic nerve at an early-symptomatic (P7) time point, (B) but 
there was a modest reduction at P11 (late-symptomatic). LAMA2 levels were already notably 
reduced in intercostal nerves (white arrows) of SMA mice at an early-symptomatic (P7) time 
point (C). Note how LAMA2 levels were also reduced in surrounding intercostal muscle fibres in 
SMA mice.  
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Analysis of LAMA2 expression in isolated Schwann cells showed significant 
reduction in SMA-derived Schwann cells compared to control cells at both pre- and 
post-differentiation stages (Figure 4.19). Therefore reduction in LAMA2 expression 
in Schwann cells appears to be partly responsible for the LAMA2 deficits observed 
in peripheral nerve from SMA mice in vivo. 
 
Figure 4.19 (A) Representative confocal micrographs of pre-differentiated Schwann cells 
immunolabelled with antibodies against LAMA2 (green) and nuclei labeled with TOPRO3 (blue). 
(B and C) Significant reduction in LAMA2 expression in SMA-derived Schwann cells both pre-
differentiation (B) and post-differentiation (C) (* P<0.05, ** P<0.01, respectively; both tests two-
tailed, unpaired t-test; N = 4 subcultures from single preparation per genotype, two fields of 
view imaged per culture, 150 cells quantified per field of view, n = 4 readings).  
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LAMA2 mRNA levels were also examined in 120 hours post-differentiated Schwann 
cells, but no significant reduction was observed in SMA-derived Schwann cells. As 
for MPZ, this suggests a role for translational regulation or stability of LAMA2. 
 
Figure 4.20 No significant difference in LAMA2 gene expression levels in control and SMA 
differentiated Schwann cells (at 120 hours post-differentiation; two-tailed, unpaired t-test; N = 3 
mice per genotype, each sample analysed in triplicate). 
These results suggest that defects in Schwann cell expression of ECM components 
could play a role in the observed reduced neurite stability in the co-cultures. 
Defective expression of ECM proteins in peripheral nerves in SMA may be 
mediated, at least in part by, defective expression of ECM proteins by Schwann cells. 
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4.3 Discussion 
In this chapter I demonstrated that isolated SMA-derived Schwann cells developed 
normally prior to differentiation. However, they failed to respond normally to 
differentiation upon induction of myelination. Abnormal expression of a key myelin 
protein (MPZ) in SMA Schwann cells could be rescued by SMN restoration. It was 
shown that SMA-derived Schwann cells were unable to induce myelination in co-
cultures with healthy neurons. SMA Schwann cells also influenced the stability of 
neighbouring wild-type neurons. This effect was not due to secretion of a neurotoxic 
factor, but was likely mediated by defects in the ECM core component, laminin. This 
study suggests that low SMN levels induce intrinsic defects in Schwann cells which 
lead to abnormal myelination, neurite instability and defective ECM. 
Although low levels of SMN are often considered to selectively affect lower motor 
neurons in SMA, several recent lines of evidence have suggested that SMN depletion 
also influences other cells and tissues such as muscle, liver, brain, heart, pancreas, 
bones and vasculatures (Hamilton & Gillingwater, 2013). Therefore, SMA is in fact 
a multi-system disorder and it is essential to identify the targeted tissues and their 
pathological alterations in response to low levels of SMN. Our study also confirms 
this notion and adds Schwann cells to the list of cells that are affected by SMN 
depletion. 
There are several promising therapies for SMA such as gene therapy to replace 
SMN1 or modification of SMN2 splicing, but the major challenge is to effectively 
target all cells and tissues contributing to the pathology. For instance, it has been 
shown that increasing SMN specifically in either motor neurons or skeletal muscle 
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was not sufficient to inhibit SMA pathology (Martinez et al., 2012). Another study 
compared systemic versus CNS restoration of SMN in severe SMA mouse model 
and showed that peripheral SMN restoration is essential for long-term rescue of 
SMA. Systemic SMN restoration improved liver function by increasing insulin-like 
growth factor (IGF1) to normal levels and extend lifespan by 25 fold (Hua et al., 
2011). Schwann cells play an essential role in form and function of neurons and 
targeting Schwann cells alongside motor neurons may lead to more efficient 
treatments.  
 It could be still argued that some of the defects I observed in Schwann cells occurred 
as a secondary consequence of neuronal pathology. In order to further examine the 
consequence of neuronal pathology for Schwann cells and vice versa, co-cultures 
with healthy Schwann cells and SMA-derived DRG neurons may give more insight 
about their mutual interactions 
Schwann cell differentiation and myelination have a complex machinery involving 
collaboration of several transcription factors. SOX10 and EGR2 are essential 
transcription factors to promote myelination by MPZ transcription (Svaren & Meijer, 
2008). I showed perturbations in their levels in SMA-derived Schwann cells. 
However, our MPZ mRNA analysis indicated no significant difference in MPZ 
transcription between SMA and control differentiated Schwann cells. Therefore 
SMN reduction may exert its effect by regulating key myelin protein translation 
and/or protein stability. Interestingly, SMN has been shown recently to be a 
transcriptional regulator (Sanchez et al., 2013). SMN has been reported to be present 
along axonal projections of motor neurons and associates with granular foci, the 
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structures that mediate the transport of specific mRNAs and regulate mRNA 
localisation, stability and translation. It has been demonstrated that SMN acts 
through polyribosomes to regulate translation of mRNAs such as arginine 
methyltransferase CARM1. The mutations in the Tudor domain of SMN have been 
shown to inhibit translational repression (Sanchez et al., 2013). Similarly, SMN may 
inhibit translation of myelin gene mRNAs as well as laminin and induce intrinsic 
defects in Schwann cells.  
The extracellular matrix plays an important role in Schwann cell development and 
myelination. Laminin, one major ECM component and its receptor integrins were 
shown to have fundamental effects on Schwann cell proliferation, survival, process 
extension and elongation (Chernousov et al., 2008). Neurons are also dependent on 
laminin for their development and stability, as previously reported in SMN-deficient 
motor neurons (Rathod et al., 2012). Our observation of LAMA2 reduction in both 
peripheral nerves and Schwann cells suggests potential ECM-dependent pathways 
through which Schwann cells influence neuronal development and stability in SMA. 
Reduction in LAMA2 levels was observed at a pre-differentiation stage, suggesting a 
core defect in the Schwann cells, regardless of their myelination status. 
Although this study showed that a reduction in SMN levels leads to intrinsic defects 
in Schwann cells, the precise molecular mechanisms through which SMN exerts its 
effect remain unclear. For this reason, I analysed protein expression profiles of 
differentiated SMA and control Schwann cells in the next chapter. 
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Chapter 5: Label-free quantitative proteomic profiling 
identifies disruption of ubiquitin pathways as a key driver of 
intrinsic defects in SMA Schwann cells 
5.1 Introduction 
In Chapter 4, I demonstrated that depleted SMN levels led to intrinsic defects in 
Schwann cells from SMA mice. However, the molecular mechanisms through which 
SMN influenced Schwann cells remained unclear. To specifically address this 
question, protein expression profiles were quantified and compared in differentiated 
Schwann cells from SMA and littermate control mice, using label-free proteomics 
technology. 
Proteomics, the large-scale analysis of protein expression, is routinely used to 
understand molecular alterations during development, pathogenesis and following 
drug treatments (Tyers & Mann, 2003). Proteomic analysis is important because 
proteins are the final products of genes that directly influence cell functions. Proteins 
are a product of mRNA translation, but mRNAs are not always translated into 
proteins (Adams, 2008). Proteins also undergo different post-translational 
modifications depending on the physiological state of the cell suggesting that 
proteomic analysis is a more sensitive approach to study biologically-relevant 
molecular events in cells and tissues. 
Major quantitative proteomic techniques are currently based either on two-
dimensional gel electrophoresis (2-DE) or liquid chromatography combined with 
mass spectrometry (LC-MS) (Messana et al., 2013). Proteins are separated from each 
other by their charge and molecular weight in 2-DE gel based techniques (Görg et 
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al., 2004). Recently, however there has been more interest in LC-MS methods 
because of their relative high-throughput and reproducibility compared to 2-DE 
approaches. In LC-MS methods, peptides are tagged by stable isotopes or remain 
label-free before separation with chromatography (Messana et al., 2013; Wang et al., 
2012). 
Proteomic analysis has been used in previous SMA studies. Proteomic analysis of 
embryonic stem (ES) cells derived from severe SMA mice revealed reduction in 
SMN-activated cellular stress pathways, disrupted energy metabolism and 
cytoskeletal stability upon differentiation to motor neurons (Wu et al., 2011). 
Proteomic analysis of the hippocampus in mice with severe SMA revealed 
widespread modifications in expression levels of proteins necessary for cellular 
proliferation, migration and development (Wishart et al., 2010). Proteomic analysis 
has also been used to identify drug targets in SMA. Proteomic screens have been 
performed on a SMA cell line treated with valproate, one potential drug for SMA 
treatment. It has been observed that valproate treatment reduced collagen I synthesis, 
resulting in bone loss (Fuller et al., 2010). Label-free proteomics have been also 
performed to identify molecular biomarkers in pathologically-affected skeletal 
muscle from SMA mice, revealing calreticulin and GRP75/mortalin as biomarkers 
for reporting on disease progress in samples of muscle and skin (Mutsaers et al., 
2013). In another study, protein biomarkers have been identified in plasma by 
iTRAQ (isobaric tag for relative and absolute quantitation) proteomics in human 
patients (Finkel et al., 2012). Therefore, proteomic analysis is a powerful and 
established tool for examining the molecular pathogenesis of SMA. 
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Although proteomic experiments can identify specific proteins with altered 
expression profiles, details concerning protein interactions and the molecular 
pathways that they participate in require further bioinformatics approaches. For this 
purpose, Ingenuity Pathway Analysis (IPA) software has been developed. IPA 
collects data from the published literature and generates functional networks of 
proteins based on their interactions and/or shared molecular pathways (for more 
details see: http://www.ingenuity.com). In silico pathway analysis of proteomic data 
has been performed in other SMA studies to identify direct and indirect molecular 
interactions, pathway associations and functional assessments involving proteins of 
interest (Wishart et al., 2010). 
SMN’s best-characterised role is in RNA processing pathways (Pellizzoni et al., 
2002; Lotti et al., 2012). However, whether defects in these pathways contribute 
directly to disease pathogenesis remains unclear (Bäumer et al., 2009; Praveen et al., 
2012). Other potential non-canonical roles for SMN may therefore contribute to 
disease pathogenesis, including functions in translational regulation (Sanchez et al., 
2013), axonogenesis (Rossoll et al., 2003; Rage et al., 2013), and modulation of 
ubiquitin homeostasis (Wishart et al., 2014). To determine the molecular 
consequences of SMN depletion in Schwann cells, proteomic analysis was used. Our 
proteomic analysis, unlike previous proteomic screens, was performed in a 
homogenous cell population and was cell type-specific.  Another advantage of our 
system was that both SMA and healthy control Schwann cells were derived from the 
same litter and therefore, the experimental variability was reduced.  
 116 
In this chapter, I undertook a label-free proteomic assessment of differentiated 
Schwann cells from SMA mice to identify proteins differentially expressed 
compared to control Schwann cells. Using Ingenuity Pathway Analysis (IPA), I 
showed that differentially expressed proteins contributed to known muscular and 
neurological disorders, by influencing cell death and survival pathways as well as 
glucose metabolism and ubiquitination pathways. Next, I confirmed that 
ubiquitination pathways were disrupted in differentiated Schwann cells from SMA 
mice by examining UBA1 levels. I showed that, unlike in the neuromuscular system, 
UBA1 disruption in Schwann cells did not lead to downstream defects in β-catenin 
signalling. Finally, I demonstrated that inhibition of UBA1 protein in healthy 




5.2.1 Label-free proteomic analysis of Schwann cells revealed 
molecular differences in SMA-derived Schwann cells 
Label-free proteomic analysis was used to quantify the molecular composition of 
Schwann cells isolated from control and SMA mice 72-hours post-differentiation 
(n=3 cultures per genotype, n=5 mice per culture; for detailed description of label-
free proteomics see Chapter 2). Briefly, the raw mass spectrometry data was 
uploaded to Progenesis software for analysis. For each genotype three replicate runs 
were performed. Sample number 3 from SMA Schwann cells was selected as a 
reference dataset, based on its minimum distortion pattern. All other runs were 
initially aligned with the reference run automatically by the software and then 
manually where required. All ions with retention time of less than 19.589 and more 
than 138.961 minutes were excluded. The runs were grouped into control and SMA 
datasets.  
The MS/MS data of candidate peptides were exported to the Mascot database for 
comparison to known peptides and identification of corresponding proteins. 663 
proteins were identified and were re-imported to Progenesis software for further 
filtering by removing data with conflicts (see chapter 2). 195 proteins identified by 
two or more unique peptides and more than 20% up- or down-regulated in SMA 
Schwann cells were selected for further analysis. Figure 5.1 shows the filtering 
process performed on proteomics data from differentiated Schwann cells. 83 proteins 
out of 195 filtered proteins were up regulated, whereas 112 proteins were down 
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regulated more than 20% compared to control Schwann cells (Table 5.1 & Table 
5.2). 
 
Figure 5.1 Scatter plot showing the process of filtering on the raw label-free proteomics data. 
663 proteins were initially identified (left panel) in control and SMA Schwann cells, with the fold 
change in expression levels between samples represented as a ratio (SMA/Control). 195 
proteins were identified after resolving conflicts and filtering based on peptide counts of more 
than 1 and more than 1.2 fold (20%) change in the expression profile in SMA versus control 
(right panel). Red lines indicate the 20% cut off threshold for being up- or down regulation in 
SMA-derived Schwann cells compared to controls. 83 proteins were more than 20% up 
regulated, whereas 112 proteins down-regulated in SMA compared to control Schwann cells. 
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Table 5.1 Schwann cell proteins that were up regulated by >20% in SMA mice compared with 
littermate controls (all peptide counts are >1) 
Gene 
name 
Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Rab11b Ras-related protein Rab-11B IPI00135869 2 41.92432611 2.25E-06 
Ptrf Polymerase I and transcript release 
factor 
IPI00117689 2 28.47467306 1.29E-05 





Histone H2B type 1-F/J/L IPI00114642 3 20.20495492 1.10E-07 
Nap1l1 Nucleosome assembly protein 1-like 1 IPI00123199 4 12.40327996 3.38E-05 
Surf4 Surfeit locus protein 4 IPI00133249 2 10.1735082 7.08E-05 
Crlf1 Cytokine receptor-like factor 1 IPI00408751 2 8.2599662 6.22E-06 
Cald1 caldesmon 1 IPI00122450 6 8.135485259 2.29E-05 
Uchl1 Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 
IPI00313962 3 6.6846993 2.89E-06 
Prdx1 Peroxiredoxin-1 IPI00121788 7 6.674709044 4.52E-06 
Hyou1 Hypoxia up-regulated protein 1 IPI00123342 2 5.972535207 0.000311039 
S100a10 Protein S100-A10 IPI00222555 2 5.835460334 0.000119939 
Cct2 T-complex protein 1 subunit beta IPI00320217 3 5.033899684 4.44E-05 
Kpnb1 Importin subunit beta-1 IPI00323881 2 4.438902892 3.72E-05 
Hspa9 Stress-70 protein, mitochondrial IPI00133903 4 3.66186703 0.000129191 
Inf2 Isoform 1 of Inverted formin-2 IPI00678133 3 3.624115204 0.000613975 
Sod1 Superoxide dismutase [Cu-Zn] IPI00130589 2 3.525442066 7.83E-06 
Sorbs2 Uncharacterized protein IPI00177047 2 3.420079863 0.000185545 
Dbn1 Isoform A of Drebrin IPI00135475 4 3.385909332 0.001227799 
S100a4 Protein S100-A4 IPI00124096 2 3.33814045 0.000426471 
Hadha Trifunctional enzyme subunit alpha, 
mitochondrial 
IPI00223092 3 3.198565292 3.97E-05 
Gpi1 Glucose-6-phosphate isomerase IPI00228633 2 3.1833332 0.000124524 
Dnaja2 DnaJ homolog subfamily A member 2 IPI00136251 3 3.158031031 0.0018338 
Psmc1 26S protease regulatory subunit 4 IPI00133428 3 3.136066408 9.42E-05 
Rtn4 Isoform 1 of Reticulon-4 IPI00469392 6 3.086615884 0.00015073 
Mtap S-methyl-5'-thioadenosine 
phosphorylase 
IPI00132096 2 3.072450003 0.000287106 
Aldh1a1 Retinal dehydrogenase 1 IPI00626662 6 3.060914815 4.87E-05 
Anxa1 Annexin A1 IPI00230395 5 3.034787054 7.18E-05 
Spna2 Isoform 2 of Spectrin alpha chain, brain IPI00753793 15 2.901825983 6.87E-05 




Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Gnb2 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
IPI00162780 2 2.666925059 5.53E-05 
Alb Serum albumin IPI00131695 3 2.652972168 4.69E-05 
Capg Macrophage-capping protein IPI00136906 4 2.612293025 1.23E-05 
Fmr1 Isoform ISO3 of Fragile X mental 
retardation protein 1 homolog 
IPI00227005 2 2.598339962 0.0021798 
Lasp1 LIM and SH3 domain protein 1 IPI00125091 2 2.515416379 0.000184415 
Txnrd1 Isoform 2 of Thioredoxin reductase 1, 
cytoplasmic 
IPI00469251 2 2.511175994 0.019966376 
Hk1 Isoform HK1-SA of Hexokinase-1 IPI00283611 2 2.508571096 0.000119071 
Serpinb6a Serpin B6 IPI00121471 4 2.476229472 8.35E-07 
Cfl1 Putative uncharacterized protein IPI00407543 2 2.471950687 0.000588488 
Ctnna1 Catenin alpha-1 IPI00112963 2 2.369663732 0.000663734 
Plod2 Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2 isoform 1 
IPI00123758 2 2.34678508 0.000104885 
Hspd1 Isoform 1 of 60 kDa heat shock protein, 
mitochondrial 
IPI00308885 4 2.146343945 0.000931687 
Lamc1 laminin subunit gamma-1 precursor IPI01027808 2 2.145005815 0.000143953 
Dnaja1 DnaJ homolog subfamily A member 1 IPI00132208 2 2.135632218 0.000199456 
Spnb2 Isoform 1 of Spectrin beta chain, brain 
1 
IPI00319830 18 2.0347355 7.28E-05 
Actr3 Actin-related protein 3 IPI00115627 4 2.012104304 5.79E-05 
Atp5a1 ATP synthase subunit alpha, 
mitochondrial 
IPI00130280 4 1.936860813 4.07E-05 
Aldoa fructose-bisphosphate aldolase A 
isoform 1 
IPI00856379 6 1.893735544 2.87E-05 
Txnl1 Thioredoxin-like protein 1 IPI00266281 2 1.813438628 0.000853125 
Rpn2 Dolichyl-diphosphooligosaccharide-
protein glycosyltransferase subunit 2 
IPI00475154 3 1.749661854 0.000237411 
Clic1 Chloride intracellular channel protein 1 IPI00130344 2 1.747078355 0.003417362 
Asah1 Acid ceramidase IPI00125266 3 1.739801778 0.001747757 
Hist1h41 Histone H4 IPI00407339 4 1.712462933 0.000218369 
LOC10004
7183 
Protein AHNAK2-like IPI00988375 5 1.681956919 0.002009435 
Col1a1 Isoform 1 of Collagen alpha-1(I) chain IPI00329872 10 1.635632601 4.97E-05 
Gstp1 Glutathione S-transferase P 1 IPI00555023 2 1.617550528 0.000770036 
                                                
1Proteins included are: Hist1h4m; Hist1h4c; Hist1h4k; Hist1h4h; Hist2h4; Hist1h4b; Hist1h4j; Hist1h4i; 




Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Cdc42 Isoform 2 of Cell division control 
protein 42 homolog 
IPI00113849 2 1.606802482 0.00205437 
Dhx9 Uncharacterized protein IPI00339468 2 1.587679615 0.008874274 
Anxa2 Annexin A2 IPI00468203 10 1.580207437 0.000108256 
Hnrnpm Uncharacterized protein IPI00918137 3 1.546543537 0.000598341 
Anxa6 Annexin A6 IPI00554894 11 1.544715439 0.000874632 
Eif4a1 Eukaryotic initiation factor 4A-I IPI00118676 4 1.513761013 0.000196588 
Cct8 T-complex protein 1 subunit theta IPI00469268 2 1.505322427 0.004745693 
Anxa5 Annexin A5 IPI00317309 6 1.501770651 0.021745556 
Pfn1 Profilin-1 IPI00224740 4 1.466299712 0.000268083 
Gsn Isoform 1 of Gelsolin IPI00117167 6 1.458467523 0.000563686 
Atp5b ATP synthase subunit beta, 
mitochondrial 
IPI00468481 7 1.447429818 0.000256396 
Ywhag 14-3-3 protein gamma IPI00230707 2 1.419361866 0.00209086 
Plec Plectin isoform 1b2alpha IPI00229509 27 1.414294926 0.000882755 
Pgd 6-phosphogluconate dehydrogenase, 
decarboxylating 




40S ribosomal protein SA IPI00123604 2 1.384561569 0.000822485 
Nedd4 E3 ubiquitin-protein ligase NEDD4 IPI00462445; 
IPI00403303 




Uncharacterized protein IPI00467841 3 1.353000447 0.000384019 
Akap12 Isoform 1 of A-kinase anchor protein 
12 
IPI00123709 11 1.33846113 0.002122168 
- 36 kDa protein IPI00988228 3 1.333575392 0.002495454 
Hnrnpk Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein K 
IPI00224575 2 1.323203786 0.000885776 
Lmna Isoform A of Prelamin-A/C IPI00620256 8 1.321923792 0.001971639 
Canx Calnexin IPI00119618 2 1.314824795 0.000676768 
Tcp1 Isoform 1 of T-complex protein 1 
subunit alpha 
IPI00459493 5 1.282134418 0.013821566 
Rab1 Ras-related protein Rab-1A IPI00114560 1 1.247558101 0.004760429 
Flna Isoform 1 of Filamin-A IPI00131138 11 1.240737269 0.018528294 
Serpinh1 Serpin H1 IPI00114733 7 1.227110277 0.00120822 
Hspa5 Isoform 1 of General vesicular transport 
factor p115 
IPI00319992 8 1.206477959 0.019930791 
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Table 5.2 Schwann cell proteins that were down regulated by >20% in SMA mice compared with 
littermate controls (all peptide counts are >1) 
Gene 
name 
Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Krt78 Keratin Kb40 IPI00348328 2 8.580116604 1.79E-08 
Wdr1 WD repeat-containing protein 1 IPI00314748 3 8.555523292 6.40E-05 
Adh5 Alcohol dehydrogenase class-3 IPI00555004 2 7.343104438 6.56E-06 
Gorasp2 Isoform 1 of Golgi reassembly-stacking 
protein 2 
IPI00165716 2 6.142796566 9.25E-05 
Dsg1b Desmoglein-1-beta IPI00380460 3 5.704337338 5.19E-05 
Rps8 40S ribosomal protein S8 IPI00466820 2 5.622876477 0.000365601 
Jup Junction plakoglobin IPI00229475 7 5.454108812 2.30E-07 
Rnh1 Ribonuclease inhibitor IPI00313296 3 5.092790463 1.92E-06 
Pgam1 Phosphoglycerate mutase 1 IPI00457898 4 4.834587974 7.21E-07 
Dsp Desmoplakin IPI00553419 10 4.724196176 2.39E-06 
Psap Sulfated glycoprotein 1 IPI00321190 4 4.687623262 3.80E-06 
Rpl10 60S ribosomal protein L10 IPI00474637 3 4.634438831 8.18E-05 
Fhl2 Four and a half LIM domains protein 2 IPI00118205 3 4.593067921 0.000239729 
Eef1g Elongation factor 1-gamma IPI00318841 3 4.569295108 6.51E-07 
Rpl12 60S ribosomal protein L12 IPI00849793 5 4.493647854 3.39E-06 
Pls3 Plastin-3 IPI00115528 2 4.055721326 0.000240097 
Prmt1 Isoform 1 of Protein arginine N-
methyltransferase 1 
IPI00120495 2 3.999241168 8.71E-05 
Sqstm1 Isoform 1 of Sequestosome-1 IPI00133374 2 3.937072326 0.001039479 
Glud1 Glutamate dehydrogenase 1, 
mitochondrial 
IPI00114209 3 3.881609805 6.57E-06 
Uggt1 UDP-glucose:glycoprotein 
glucosyltransferase 1 
IPI00762897 2 3.800575965 0.000201465 
Gnb2l1 Guanine nucleotide-binding protein 
subunit beta-2-like 1 
IPI00317740 3 3.759440568 0.000123855 
Hsph1 Isoform HSP105-alpha of Heat shock 
protein 105 kDa 
IPI00123802 4 3.752562932 0.000109693 
Gfpt1 Isoform 1 of Glucosamine--fructose-6-
phosphate aminotransferase 
[isomerizing] 1 
IPI00406371 2 3.582872971 0.007213633 
Vdac2 Voltage-dependent anion-selective 
channel protein 2 
IPI00122547 2 3.565192632 0.000291753 
Vwa5a Von Willebrand factor A domain-
containing protein 5A 
IPI00221817;
IPI00460122 
4 3.556067789 0.000116706 
Add1 Isoform 1 of Alpha-adducin IPI00136000 3 3.47734116 2.58E-05 




Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Sugt1 Suppressor of G2 allele of SKP1 
homolog 
IPI00408957 2 3.349300452 0.000699473 
Mtap1b Microtubule-associated protein 1B IPI00130920 3 3.280621143 0.00036261 
Coro1c Coronin-1C IPI00124820 2 3.248513565 0.000236454 
Fn1 Fibronectin IPI00113539 2 3.235657278 0.000460348 
Dnm2 Isoform 1 of Dynamin-2 IPI00131445 3 3.064780713 0.00018545 
Stat3 Isoform Stat3B of Signal transducer 
and activator of transcription 3 
IPI00227814 2 3.053813233 0.000131014 
Copg Coatomer subunit gamma IPI00223437 2 3.02780233 0.000368061 
Nars Asparaginyl-tRNA synthetase, 
cytoplasmic 
IPI00223415 5 3.02573343 1.38E-05 
Aldh7a1 Isoform 1 of Alpha-aminoadipic 
semialdehyde dehydrogenase 
IPI00230084 2 3.002360735 5.72E-05 
Sacm1l Phosphatidylinositide phosphatase 
SAC1 
IPI00109221 2 2.987224133 0.005108555 
Lta4h Leukotriene A-4 hydrolase IPI00229527 2 2.980163218 0.005458829 
Slc25a1
2 




2 2.957860267 0.000128222 
Eif2s3x Eukaryotic translation initiation factor 2 
subunit 3, X-linked 
IPI00230415; 
IPI00230416 
2 2.952531868 1.90E-05 
Rpl10a 60S ribosomal protein L10a IPI00849927 2 2.928729656 1.82E-07 
Hnrnpu Heterogeneous nuclear 
 ribonucleoprotein U 
IPI00458583 2 2.867782152 3.16E-06 
Ddah2 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 
IPI00336881 2 2.865538719 5.08E-05 
Pcbp1 Poly(rC)-binding protein 1 IPI00128904 2 2.853011693 2.86E-06 
Cttn Src substrate cortactin IPI00118143 2 2.838307296 4.32E-05 
Ap2a2 AP-2 complex subunit alpha-2 IPI00310131 2 2.814409781 0.00049384 
Mdh1 Malate dehydrogenase, cytoplasmic IPI00336324 3 2.787307843 7.42E-05 
Npc2 Epididymal secretory protein E1 IPI00129186 2 2.784195535 6.63E-06 
Adam10 Disintegrin and metalloproteinase 
domain-containing protein 10 
IPI00131881 2 2.748016221 8.39E-05 
Capzb Isoform 2 of F-actin-capping protein 
subunit beta 
IPI00269481 3 2.739484682 1.11E-05 
Sncg Gamma-synuclein IPI00271440 3 2.7130939 1.58E-06 
Sec23a Protein transport protein Sec23A IPI00123349 4 2.707184398 7.27E-05 
Fkbp10 Peptidyl-prolyl cis-trans isomerase 
FKBP10 
IPI00122493 2 2.704312293 0.000135942 
Lepre1 Isoform 1 of Prolyl 3-hydroxylase 1 IPI00109205 2 2.699075181 7.44E-05 




Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Ass1 Argininosuccinate synthase IPI00134746 6 2.654662427 1.17E-06 
Sucla2 Succinyl-CoA ligase [ADP-forming] 
subunit beta, mitochondrial 
IPI00261627 2 2.622878616 7.02E-06 
Psma4 Proteasome subunit alpha type-4 IPI00277001 2 2.61647652 4.78E-06 
P4ha2 Isoform IIb of Prolyl 4-hydroxylase 
subunit alpha-2 
IPI00120100 5 2.564663288 2.28E-05 
Itgb1 Integrin beta-1 IPI00132474 2 2.551411055 7.82E-05 
Copa Coatomer subunit alpha IPI00229834 3 2.547852787 0.003549081 
Eif3c Eukaryotic translation initiation factor 3 
subunit C 
IPI00321647 3 2.503656699 0.0003898 
Eif2s2 Eukaryotic translation initiation factor 2 
subunit 2 
IPI00116302 3 2.459285924 0.000170835 
Tpp2 Isoform Short of Tripeptidyl-peptidase 
2 
IPI00227843 2 2.45657187 0.002863989 
Erp44 Endoplasmic reticulum resident protein 
44 
IPI00134058 2 2.442842887 0.00046811 
Rpl4 60S ribosomal protein L4 IPI00111412 3 2.441677869 0.000305099 
Myl6 Isoform Smooth muscle of Myosin light 
polypeptide 6 
IPI00354819 3 2.402047476 2.18E-06 
Nsf Vesicle-fusing ATPase IPI00656325 2 2.401586278 0.000115937 
Epb4.1l2 Band 4.1-like protein 2 IPI00309481 3 2.390794065 0.000285233 
Sec31a Isoform 2 of Protein transport protein 
Sec31A 
IPI00853859 2 2.38311104 9.61E-06 
Igf2r Cation-independent mannose-6-
phosphate receptor 
IPI00308971 2 2.346499417 0.004459201 
Pdcd6ip Isoform 3 of Programmed cell death 6-
interacting protein 
IPI00323483 2 2.345054217 6.97E-06 
Ap2a1 Isoform A of AP-2 complex subunit 
alpha-1 
IPI00108780 2 2.325042415 0.001261129 
Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
IPI00273646 5 2.300796427 2.01E-05 
Golgb1 Golgi autoantigen, golgin subfamily b, 
macrogolgin 1 
IPI00929857 2 2.285155195 0.001018217 
Rplp2 60S acidic ribosomal protein P2 IPI00139795 2 2.275680059 6.98E-05 
Anxa7 Annexin A7 IPI00114017 2 2.261234738 6.06E-05 
Nucks1 Nuclear ubiquitous casein and cyclin-
dependent kinases substrate 
IPI00341869 2 2.243500575 0.000103702 
Rps3 40S ribosomal protein S3 IPI00134599 2 2.240970509 0.002182785 
Rplp0 60S acidic ribosomal protein P0 IPI00314950 4 2.230476629 2.44E-05 




Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
mitochondrial 
Prx Isoform 1 of Periaxin IPI00469952 2 2.180933796 0.000278402 
Uso1 Isoform 1 of General vesicular transport 
factor p115 
IPI00128071 4 2.156768388 0.000698575 
P4ha1 Isoform 2 of Prolyl 4-hydroxylase 
subunit alpha-1 
IPI00399959 6 2.15164726 0.001068814 
Hnrnpa3 Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein A3 
IPI00269661 2 2.056178629 0.001598363 
Uba1 Ubiquitin-like modifier-activating 
enzyme 1 
IPI00123313 4 1.990801394 4.40E-05 
Gnb1 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
IPI00120716 3 1.870269364 0.000958904 
Rps17 40S ribosomal protein S17 IPI00465880 3 1.825844017 0.000914371 
Nomo1 Nodal modulator 1 IPI00222429 2 1.711952764 0.000377668 
Prdx2 Peroxiredoxin-2 IPI00117910 2 1.699377508 0.001276595 
Rab6 Isoform 1 of Ras-related protein Rab-
6A 
IPI00116697 2 1.653058678 0.004742902 
Vcp Transitional endoplasmic reticulum 
ATPase 
IPI00622235 7 1.635592784 4.81E-05 
Txndc5 Thioredoxin domain-containing protein 
5 
IPI00163011 4 1.612167497 0.002283254 
Eef1b2 Elongation factor 1-beta IPI00320208 3 1.59498509 0.0016289 
Mvp Major vault protein IPI00111258 2 1.590509535 0.00508647 
Copb1 Coatomer subunit beta IPI00120503 3 1.562702879 0.000186958 
Sept2 Septin-2 IPI00114945 4 1.549793666 1.64E-05 
Tkt Transketolase IPI00137409 3 1.547902755 1.32E-05 
Psmd1 26S proteasome non-ATPase regulatory 
subunit 1 
IPI00267295 3 1.538023248 0.000101076 
Pdia4 Protein disulfide-isomerase A4 IPI00271951 4 1.518737235 2.50E-05 
Gdi2 Isoform 1 of Rab GDP dissociation 
inhibitor beta 
IPI00122565 3 1.506890798 0.002116667 
Ywhaz 14-3-3 protein zeta/delta IPI00116498 5 1.485200853 0.000535741 
Hsp90b1 Endoplasmin IPI00129526 4 1.478765174 0.002531193 
Hspa4 Heat shock 70 kDa protein 4 IPI00331556 4 1.460867498 0.000924191 
Rcn2 Putative uncharacterized protein IPI00474959 2 1.427991178 0.019124064 
Pgk1 Phosphoglycerate kinase 1 IPI00555069 6 1.411842176 0.000262416 
Eef2 Elongation factor 2 IPI00466069 10 1.374994769 0.000209352 
Myo1c Isoform 2 of Myosin-Ic IPI00467172 2 1.351928536 0.003620869 
Krt79 Keratin, type II cytoskeletal 79 IPI00124499 1 1.347811428 0.00352169 




Protein name Accession 
number 
Peptides Fold change Anova 
(P-value) 
Vdac1 Isoform Pl-VDAC1 of Voltage-
dependent anion-selective channel 
protein 1 
IPI00122549 2 1.305955275 0.005548413 
Pcyox1 Prenylcysteine oxidase IPI00460063 2 1.206665779 0.01029442 
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5.2.2 Ingenuity Pathway Analysis (IPA) revealed differentially expressed 
proteins in SMA-derived Schwann cells are implicated in muscular and 
neurological disorders  
To establish any functional clustering of differentially expressed proteins in Schwann 
cells isolated from SMA mice, a systems level analysis of the proteomics data was 
performed using Ingenuity Pathway Analysis (IPA) software. This software collects 
data from the published scientific literature to analyse proteins of interest with 
respect to their known functions in biological systems (Wishart et al., 2010). 183 out 
of 195 proteins were mapped for data mining of published literature to establish 
functional clustering. IPA analysis revealed that approximately 43% of identified 
proteins modified in SMA Schwann cells were previously implicated in skeletal and 
muscular disorders and 37% of mapped proteins were known to contribute to 
neurological pathologies. These data indicate that many of the differentially 
expressed proteins in Schwann cells from SMA mice are known “pathological” 
proteins contributing to myopathies and neurological disorders (Table 5.3). 
Name P-value #  Proteins 
Neurological Diseases 2.13E-10 - 4.03E-03 64 
Developmental Disorder 1.34E-09 - 4.03E-03 39 
Hereditary Disorder 1.34E-09 - 4.03E-03 32 
Skeletal and Muscular Disorders 1.34E-09 - 4.03E-03 75 
Dermatological Diseases and Conditions 1.28E-08 - 3.47E-03 43 
Table 5.3 Top ranked diseases and disorders that are associated with differentially expressed 
proteins identified in SMA-derived Schwann cells by IPA analysis 
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5.2.3 Functional clustering analysis revealed disruption of cellular assembly, death 
and survival pathways in Schwann cells from SMA mice 
Approximately half of the proteins with more than a 20% change in their expression 
in SMA Schwann cells were identified to participate in cell assembly and 
organisation pathways (84 proteins). The laminin receptor, β1 integrin (ITGB1) was 
shown to be down-regulated in SMA Schwann cells (Feltri et al., 2002) (Table 5.2). 
As shown earlier in this thesis, defective laminin protein production is an important 
intrinsic defect observed in SMA Schwann cells. Therefore, reduction in SMN levels 
may exert its effect on laminin expression through modulation of β1 integrin 
signalling. This further supports the hypothesis that extracellular matrix defects 
contribute to SMA pathology (Table 5.4, for detailed tables of each molecular 
function see Appendices 1-5).  
Name P-value #  Proteins 
Cellular Growth and Proliferation 1.10E-13 - 3.31E-03 96 
Cell Death and Survival 6.60E-13 - 4.03E-03 95 
Molecular Transport 2.29E-11 - 3.40E-03 52 
Protein Trafficking 2.29E-11 - 8.60E-04 28 
Cellular Assembly and Organisation 3.44E-11 - 4.03E-03 84 
Table 5.4 Molecular and cellular functions that altered significantly in Schwann cells from SMA 
mice 
IPA analysis also revealed that 95 differentially expressed proteins are involved in 
cell death pathways. Apoptotic cell death has previously been reported in SMN-
depleted neuroblastoma hybrid (NSC-34) cell lines (Parker et al., 2008), muscle 
satellite cells in a severe SMA mouse model (Dachs et al., 2011), and lower motor 
neurons in SMA fetuses (Ito et al., 2011). Similarly it has been shown that human 
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SMN protein prolonged cell survival in PC12 cells deprived of trophic support (Vyas 
et al., 2002).   
 
Figure 5.2 (A) Representative confocal micrographs of isolated Schwann cells immunolabelled 
with antibodies against the apoptotic marker CASP3 (green) and nuclei labeled with TOPRO3 
(blue), showing significant increase in CASP3 expression levels in SMA-derived Schwann cells 
compared to littermate controls 120 hours post-differentiation.  (B) Bar graph showing 
significant increase in levels of CASP3 in SMA-derived Schwann cells compared to control cells 
120 hours post-differentiation (*** P< 0.001; two-tailed, unpaired non-parametric t-test; N = 4 
subcultures from single preparation per genotype, 2 fields of view imaged per culture, > 150 
cells quantified per field of view, n = 4 readings). 
To confirm that apoptosis pathways were being activated in SMA Schwann cells, 
CASP3 immunostaining was performed on SMA and control Schwann cells 120 
hours post-differentiation. CASP3 levels were significantly increased in SMA-
 130 
derived Schwann cells representing activation of apoptosis pathways (Figure 5.2). 
These data therefore validate the IPA results suggesting apoptosis pathway activation 
in differentiated SMA Schwann cells. 
5.2.4 Molecular perturbations in glucose metabolism and ubiquitination 
pathways in Schwann cells from SMA mice  
IPA analysis also revealed modifications in several canonical functional pathways in 
SMA Schwann cells. Disruption in glucose metabolism was identified as one of 
these pathways (Table 5.5). Perturbations in glucogenesis have previously been 
observed in both SMA mouse models and type I SMA patients (Bowerman et al., 
2012; Bruce et al., 1995; Kunkel et al., 2011).  
Name P-value Ratio Proteins 





8.03E-07 14/270 (0.052) DNAJA1, HSP90B1, HSPA4, 
HSPA5, HSPA9, HSPD1, HSPH1, 
PSMA4, PSMC1, PSMD1, SUGT1, 




1.38E-06 8/85 (0.094) ALB, COPA, COPB1, COPG1, 
DNM2, FLNA, ITGB1, PTRF 
Huntington’s 
Disease Signalling 
3.39E-05 11/252 (0.044) AP2A2, ATP5B, CTSD, DNM2, 
GNB1, GNB2, GNB2L1, HSPA4, 
HSPA5, HSPA9, NSF 
EIF2 Signalling 3.42E-05 10/201 (0.05) EIF2S2, EIF3C/EIF3CL, EIF4A1, 
RPL4, RPL12, RPL10A, RPLP0, 
RPLP2, RPS3, RPS4X 
Table 5.5 Top canonical pathways containing significant numbers of mapped differentially 
expressed proteins; Ratio represents the ratio of differentially expressed proteins number to 
the total number of proteins that contribute to the pathway in the IPA database. 
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Similarly, 14 proteins were identified in our analysis contributing to ubiquitination 
pathways (Table 5.5). In eukaryotic cells, proteins are degraded by the ubiquitin-
proteasome system (UPS), but ubiquitination also regulates different cellular 
functions such as cell signalling and post-translational modifications (Rubinsztein, 
2006). Ubiquitin, a 76 amino acid polypeptide, is activated by E1 enzymes in an 
ATP-dependent manner. The ubiquitin-conjugating enzyme E2, binds to activated 
ubiquitin and E3 ubiquitin ligases catalyse ubiquitin transfer to protein substrates. 
Finally, ubiquitinated protein is degraded by the 26S proteasome (Hershko & 
Ciechanover, 1998; Kleiger & Mayor, 2014). 
Previous studies have reported that ubiquitination pathways are important drivers of 
disease pathogenesis in SMA (Wishart et al., 2014) with additional contributions to 
SMN protein turnover (Kwon et al., 2013; Han et al., 2012; Chang et al., 2004; 
Burnett et al., 2009). It has also been reported that ubiquitination regulates 
neuromuscular junction development (Liu et al., 2009) as well as synaptic growth 
and function (DiAntonio et al., 2001), processes known to be disrupted in SMA 
(Murray et al., 2008; Kariya et al., 2008). 
IPA analysis of ubiquitination pathway proteins indicated that ubiquitin carboxyl-
terminal hydrolase L1 (UCHL1) was up-regulated in SMA Schwann cells, while 
ubiquitin activator-like modifier E1 (UBA1) was down regulated (Figure 5.3). 
Interestingly, SMN expression levels have been shown to be directly regulated by 
UCHL1 in primary SMA fibroblasts, where over-expression of UCHL1 reduced 
SMN expression levels (Hsu et al., 2010). Mutations in the UBA1 gene also cause X-
linked spinal muscular atrophy (SMAX2), which is characterised by motor neuron 
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impairments similar to SMN-dependent SMA (Ramser et al., 2008; Dlamini et al., 
2013). Importantly, a recent study has revealed major perturbations in ubiquitination 
pathways in Drosophila, mouse and zebrafish models of SMA (Wishart et al., 2014).  
 
Figure 5.3 Protein-interactions of ubiquitination pathways in SMA derived-Schwann cells. Red 
nodes represented up-regulated proteins in SMA mice compared to littermate controls, while 
green nodes represented down-regulated proteins. Grey nodes represented proteins that either 
not changed in SMA Schwann cells or unidentified in our proteomic screen due to filtering 
process. 
This study showed that reduction in UBA1 levels induced SMA neuromuscular 
pathology by modulating beta-catenin signalling. The ubiquitin-proteasome system 
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has also been shown to mediate a variety of cellular physiological events in Schwann 
cells. For instance, Schwann cell differentiation and myelination have been reported 
to be mediated by proteasome inhibition after nerve injury (Lee et al., 2009). 
5.2.5 Disruption in UBA1 protein levels following SMN depletion exerts 
its effect on SMA Schwann cells via ß-catenin independent pathways 
As discussed earlier, UBA1 protein levels have been shown to decrease significantly 
in animal models of SMA (Wishart et al., 2014). Therefore I wanted to validate and 
extend our proteomic data showing reduced levels of UBA1 in differentiated SMA 
Schwann cells. Schwann cells were differentiated for 72 hours and immunostained 
with anti-UBA1 antibody. UBA1 protein levels were significantly reduced in SMA-
derived Schwann cells compared to littermate controls (Figure 5.4), thereby 
confirming and validating the proteomic data. These data confirm that reduction in 
SMN protein levels disrupts ubiquitination pathways, at least in part by reducing 




Figure 5.4 (A) Representative confocal micrographs of Schwann cells showing reduced levels 
of UBA1 in SMA derived Schwann cells compared to control cells 72 hours post-differentiation. 
(B) Bar graph showing significant reduction in UBA1 expression levels in SMA-derived 
Schwann cells 72 hours post-differentiation (*** P < 0.001; at 72 hours post-differentiation; two-
tailed, unpaired t-test; N = 4 subcultures from single preparation per genotype, 2 fields of view 
imaged per culture, > 25 cells quantified per field of view, n = 4 readings). 
Previous studies in the neuromuscular system have demonstrated that UBA1 levels 
caused neuromuscular pathology in SMA, at least in part, by modulating beta-catenin 
dependent pathways (Wishart et al., 2014). Beta-catenin is one of the downstream 
targets of ubiquination pathways (Clevers & Nusse, 2012) and beta-catenin has been 
reported to accumulate in both spinal cord and skeletal muscles in SMA mice 
(Wishart et al., 2014). Pharmacological inhibition of beta-catenin also has been 
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shown to robustly ameliorate neuromuscular pathology in zebrafish, Drosophila and 
mouse models of SMA (Wishart et al., 2014). Therefore, Schwann cells were 
immunostained with beta-catenin antibody 72 hours post-differentiation to determine 
whether reduction in UBA1 protein levels exerted its effect through modulating 
levels of beta-catenin protein.  
 
Figure 5.5 (A) Representative confocal micrographs of differentiated Schwann cells showing no 
significant change in beta-catenin levels in SMA derived Schwann cells compared to control 
Schwann cells. (B) Bar graph showing no significant difference in Beta-catenin expression 
levels in SMA-derived Schwann cells compared to littermate controls post-differentiation (at 72 
hours post-differentiation; two-tailed, unpaired t-test; N = 4 subcultures from single preparation 
per genotype, 2 fields of view imaged per culture, > 25 cells quantified per field of view, n = 4 
readings). 
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No significant difference in beta-catenin protein levels were observed in control and 
SMA Schwann cells (Figure 5.5) suggesting the reduction in UBA1 did not lead to 
corresponding modifications in beta-catenin pathways, similar to other non-neuronal 
tissues and organs (Wishart et al., 2014). 
5.2.6 UBA1 inhibition phenocopied SMA by reducing myelin protein 
expression levels 
To identify whether the disruption to ubiqutination pathways I identified, contributed 
directly to intrinsic defects I observed in Schwann cells from SMA mice, UBA1 
protein was pharmacologically inhibited in healthy Schwann cells by treatment with 
10 µM UBEI-41 96 hours post-differentiation (see methods). Myelin marker MPZ 
expression decreased significantly in healthy Schwann cells after inhibition of UBA1 
protein compared to control cells, with MPZ levels similar to those observed in 
untreated SMA Schwann cells (Figure 5.6). Therefore, pharmacological inhibition of 




Figure 5.6 (A) Representative confocal micrographs of differentiated Schwann cells showing 
reduced levels of MPZ in SMA derived Schwann cells. UBA1 blocking of healthy Schwann cells 
reduced significantly the MPZ level (B) Bar graph showing significant reduction in MPZ 
expression levels in healthy Schwann cells treated with UBA1 blocker post-differentiation 
(***P<0.001 and **P<0.01; at 72 hours post-differentiation; two-tailed, unpaired t-test; N = 4 
subcultures from single preparation per genotype, 2 fields of view imaged per culture, >25 cells 
quantified per field of view, n = 4 readings).  
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5.3 Discussion 
In this chapter, I used highly sensitive label-free proteomics technology to identify 
differentially expressed proteins in SMA-derived Schwann cells. Using Progenesis 
software, 195 proteins were identified with > 1.2-fold change in their expression 
compared to control Schwann cells. Proteins were functionally clustered by IPA 
analysis. Identified proteins were predicted to be involved in muscular and 
neurological disorders. Differentially expressed proteins were demonstrated to 
contribute to cellular functions such as cell proliferation, death and assembly. I also 
demonstrated that apoptosis was increased in SMA-derived Schwann cells and 
revealed that proteins contributing to glucogenesis and ubiquitination pathways were 
modified in SMA-derived Schwann cells. I examined whether disruption in 
ubiquitination pathways influenced intrinsic defects I observed in Schwann cells 
from SMA mice. Differentiated SMA Schwann cells showed reduction in UBA1 
levels, which induced its effect on SMA Schwann cells via beta-catenin independent 
signalling. I showed that UBA1 inhibition reduced myelin protein expression in 
healthy Schwann cells. I conclude that reduction in SMN levels perturbs 
ubiquitination pathways, and UBA1 in particular, leading to intrinsic defects in 
Schwann cells from SMA mice. 
The extracellular matrix component LAMA2 was shown in Chapter 4 to have 
decreased expression in SMA-derived Schwann cells. Laminins act as signals to 
influence Schwann cell survival, proliferation and myelination (Yu et al., 2005). 
Laminins can exert their effects through their receptors such as integrins 
(Chernousov et al., 2008). Interestingly, β1 integrin (ITGB1) was identified in our 
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proteomics data to be down-regulated 2.5-fold in SMA-derived Schwann cells. 
Schwann cells lacking laminin-β1 integrin signals are unable to extend processes to 
interdigitate between axonal bundles (axonal sorting) for proper myelination (Feltri 
et al., 2002). β1 integrins have also shown to be a key factor in axo-glia interactions 
in central nervous system (CNS) myelination (Câmara et al., 2009). Similarly, axo-
glia interactions have been shown to be disrupted in SMA mice (Hunter et al., 2014) 
suggesting a likely role for β1 integrin in normal axo-glial maturation observed in 
SMA mice. 
The ability of Laminins to induce β-actin mRNA translation has been shown to be 
disrupted in SMN-deficient motor neurons (Rathod et al., 2012). Inverted formin-2 
(INF2) protein is one of the actin mediators with dual functions of accelerating both 
polymerisation and depolymerisation (Chhabra & Higgs, 2006). INF2 was 
significantly increased (3.6-fold) in SMA Schwann cells compared to control cells. It 
has been shown that mutations in INF2 induce a rare form of Charcot-Marie-Tooth 
(CMT) disease with renal dysfunction. Abnormal accumulation of β-actin in 
Schwann cell cytoplasm induced myelination abnormalities (Mathis et al., 2014). 
Therefore, further studies may be warranted to examine the influence of INF2 on β-
actin polymerisation and subsequent myelination in SMA pathology. 
The actin-binding protein plastin-3 (PLS3) was also down-regulated 4-fold in 
Schwann cells from SMA mice. Oprea et al. demonstrated that PLS3 acts as a 
protective modifier of SMA through increasing F-actin levels (Oprea et al., 2008). 
PLS3 protein levels have been shown to be SMN-dependent in a zebrafish model of 
SMA (Hao le et al., 2012). SMN exerted its effect by regulating PLS3 translation 
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(Hao le et al., 2012). Overexpression of PLS3 in SMA mice has been shown to 
stabilize axons and increase muscle fiber size (Ackermann et al., 2013). F-actin has 
been observed to regulate the Schwann cell cytoskeleton and myelination (Susuki et 
al., 2011). This suggests a potential mechanism through which a reduction in SMN 
levels decreases PLS3 levels in SMA Schwann cells, resulting in defects in the 
cytoskeleton and myelination through perturbations in F-actin levels. 
37% of the proteins I identified with altered expression in SMA Schwann cells have 
previously been shown to contribute to neurological disorders. Superoxide dismutase 
1 (SOD1) protein, a genetic cause of ALS, was one of the altered proteins in our 
proteomic analysis. It was down-regulated by 2.1-fold in SMA-derived Schwann 
cells. It has been demonstrated that mutant SOD1 alters the localization of SMN 
protein by preventing its recruitment to Cajal bodies (Kariya et al., 2012). SMN 
protein was also shown to protect cells against oxidative stress and subsequent cell 
death caused by mutant SOD1 in vitro (Zou et al., 2007). This suggests that SMN 
and SOD1 proteins may interact, through still unknown mechanisms, to induce 
motor neuron disorders. Reductions in SMN could therefore be causing perturbations 
in SOD1 protein levels in Schwann cells from SMA mice.  
Glucogenesis pathways were also shown to be disrupted in our proteomics data. 
Metabolism abnormalities such as hyperglycemia have been observed in SMA 
patients (Crawford et al., 1999). It was reported that SMA type I patients display 
more pancreatic glucagon-producing cells and abnormal glucose levels (Bowerman 
et al., 2012). Bowerman et al. reported that SMN-depleted mice showed increased 
hepatic insulin and glucagon sensitivity (Bowerman et al., 2014). Malic enzyme 1 
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(ME1) was among the differentially expressed proteins in glucogenesis pathways 
with a significant 25-fold decrease in expression in SMA-derived Schwann cells. 
ME1 has been shown to regulate adiposity and insulin sensitivity (Al-Dwairi et al., 
2012), suggesting that reductions in ME1 may lead to metabolism defects observed 
in SMA pathology. 
Functional clustering analyses revealed that more than half of the proteins with 
altered expression are involved in regulating cell death and survival pathways. One 
of these proteins was acid ceramidase (ASAH1), with 3-fold down-regulation in 
Schwann cells from SMA mice. SMA with progressive myoclonic epilepsy (SMA-
PME) is a rare form of SMA caused by mutations in ASAH1 (Zhou et al., 2012). 
Mutations in ASAH1 cause defects in motor neuron axonal branching and a dramatic 
increase in apoptosis in the spinal cord of zebrafish (Zhou et al., 2012). In human 
patients, motor deficits were observed around three years of age after normal 
developmental milestones. Lower motor neurons are known to be affected, leading to 
respiratory muscle involvement and severe handicap or death occurring before 20 
years of age (Zhou et al., 2012). The finding that ASAH1 levels were altered in 
Schwann cells deficient in SMN protein suggests potential shared molecular 
mechanisms linking SMN-dependent and SMN-independent forms of SMA. 
Previous studies have shown an important regulatory role for the ubiquitin-
proteasome system in SMN protein stability (Burnett et al., 2009; Chang et al., 2004; 
Kwon et al., 2013), as well as pathogenesis of a genetically distinct form of SMA, X-
linked spinal muscular atrophy (Ramser et al., 2008). In addition, a direct role for 
dysregulation of ubiquitin homeostasis has recently been reported in SMA, where 
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SMN reduction induced neuromuscular pathology through targeting of UBA1 levels 
(Wishart et al., 2014). Our study extends our understanding of the role of 
ubiquitination pathways in SMA pathology by showing a specific role in Schwann 
cells.  
As well as UBA1, the E3 ubiquitin ligase NEDD4 (neural precursor cell expressed 
developmentally down-regulated gene 4) has been shown to regulate form and 
function of neuromuscular junctions in mice (Liu et al., 2009). NEDD4 deficient 
mice die prenatally with reduced skeletal muscle fibre size and motor neuron 
numbers. Although ultrastructural analysis of NEDD4 mutants revealed an increase 
in pre-synaptic nerve terminal branches, nerve diameters were decreased compared 
to littermate controls (Liu et al., 2009). Interestingly, our proteomic analysis revealed 
that NEDD4 protein expression was increased 1.4-fold in SMA-derived Schwann 
cells. It has been observed that NEDD4 is not expressed in motor neurons, but is 
strongly expressed in Schwann cells and skeletal muscles and exerts its regulatory 
effect on NMJs via non-cell autonomous mechanisms (Liu et al., 2009). NEDD4 has 
also been reported to induce axon branching through PTEN (phosphatase and tensin 
homolog deleted on chromosome ten) down-regulation in developing xenopus retinal 
ganglion cells (Drinjakovic et al., 2010). Reduction in PTEN levels has been shown 
to rescue axonal growth defects and restore beta-actin levels in axonal growth cones 
of SMN-deficient motor neurons (Ning et al., 2010), This suggests that NEDD4 up-
regulation in SMA-derived Schwann cells could influence NMJ form and function 
through PTEN degradation. 
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I found that UBA1 disruption in SMA Schwann cells did not lead to downstream 
changes in beta-catenin signalling, confirming the findings of previous study in 
which UBA1-associated disruption of β-catenin was shown to be restricted to the 
neuromuscular system in SMA mice (Wishart et al., 2014). Inactive beta-catenin is 
in complex with APC (adenomatous polyposis coli), axin and GSK3 beta (glycogen 
synthase kinase-3). Upon binding of Wnt to its receptor frizzled, an associated 
protein dishevelled 2 (Dvl2) releases beta-catenin from the complex (Yost et al., 
1996). An isoform of NEDD4, NEDD4L has also been shown to induce poly-
ubiquitination and degradation of Dvl2 (Ding et al., 2013). Increase in NEDD4 
protein levels may inhibit beta-catenin accumulation in the SMA Schwann cells 
through Dvl2 degradation. More studies are therefore required to characterise 
NEDD4 function and its effect on inhibition of beta-catenin accumulation in 
Schwann cells from SMA mice. 
Heat shock proteins (HSPs) are involved in folding, maintenance and degradation of 
proteins in response to cell stresses including hyperthermia, oxygen radicals and 
heavy metals (De Maio, 1999). HSPs are known to contribute to protein degradation 
induced by ubiquitination pathways. Our proteomics screen revealed differential 
expression in several heat shock proteins such as HSP70 and HSP90 in SMA-derived 
Schwann cells compared to control cells. HSP90, which localises on the cell surface 
in the nervous system, has been shown to be involved in cell migration (Sidera et al., 
2004). Inhibition of HSP90 in migrating Schwann cells in culture revealed that 
HSP90 is associated with lamellipodia formation and actin cytoskeleton organisation 
(Sidera et al., 2004). In vitro studies have also shown HSP90 binds directly to 
fibronectin in breast cancer cells and HSP90ß inhibition increases formation of 
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extracellular fibronectin matrix (Hunter et al., 2014). Interestingly, fibronectin 
expression levels were shown to decrease 3.2-fold in SMA Schwann cells. HSP90 
reduction in SMA Schwann cells (1.48-fold) may therefore influence abnormal 
myelination by inhibiting proper migration of Schwann cells and their ability to form 
extracellular matrix, as we observed in chapter three. 
HSP70 induction has been reported to promote degradation of the negative regulator 
of myelination, c-Jun, in neuregulin-associated demyelination (Li et al., 2012). 
Proteasome inhibition has also been reported to inhibit Schwann cells from inducing 
dedifferentiation markers such as P75 nerve growth factor receptor and glial 
fibrillary acidic protein both in vitro and in vivo (Lee et al., 2009). Heat-shock 
proteins also actively contribute to the myelination disorder Charcot-Marie-Tooth 
disease type 1A (CMT1A), which is caused by duplication or point mutations in 
peripheral myelin protein 22 (PMP22) (Rangaraju et al., 2008; Chittoor et al., 2013). 
In neuropathic Schwann cells, reduction in PMP22 degradation leads to formation of 
cytosolic aggregates. Induction of cytosolic HSP70 has shown to improve myelin 
formation and processing of PMP22 (Rangaraju et al., 2008). These studies suggest 
that perturbations in heat-shock protein levels and proteasome system in SMA 
Schwann cells can induce myelination deficits through myelin transcription factors 
regulation and degradation. 
In this chapter, I showed that proteomics is a powerful tool to identify differentially 
expressed proteins in Schwann cells from SMA mice and functional clustering of 
these proteins can reveal potential mechanisms contributing to SMA pathology. 
Ubiquitination pathway dysregulation, in particular UBA1 reduction, was shown to 
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be one of the mechanisms that causes intrinsic defects in Schwann cells from SMA 
mice. Therefore, targeting UPS components, specifically UBA1 can be considered as 




Chapter 6: General discussion 
6.1 Overview of results 
In this thesis I first developed an in vitro model system to allow the isolation of 
Schwann cells from postnatal SMA mice. This offers a solution to one major 
challenge in neurobiology by facilitating in vitro analyses of a sufficient number of 
purified myelin-competent Schwann cells from a mouse model of neuromuscular 
disease. Previous mouse Schwann cell protocols were not efficient for such 
quantitative studies in SMA mouse models. By undertaking modifications to the 
substrata, medium composition, number of pups, and the age of animals used, I 
obtained approximately 400,000 cells per preparation with 95-98% purity from 8-
day-old ‘Taiwanese’ SMA mice. I also showed that these Schwann cells were 
capable of inducing myelination responses in DRG neuron-Schwann cell co-cultures. 
In this study, three important questions were then addressed, using the new in vitro 
model system: 
1) Are there any intrinsic defects in SMA Schwann cells? 
I confirmed that SMN protein levels were significantly reduced in SMA-derived 
Schwann cells. I showed that Schwann cells from SMA mice developed normally 
pre-differentiation. In contrast, SMA-derived Schwann cells did not respond 
normally to myelination cues, as a significant reduction in expression levels of key 
myelin proteins was observed. Restoring SMN levels was shown to rescue these 
myelination defects, suggesting that deficient myelination was SMN-dependent. 
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2) Do intrinsic defects in Schwann cells contribute to SMA pathogenesis? 
Using co-cultures of wild-type DRG neurons with SMA-derived Schwann cells, I 
showed that neurons were abnormally myelinated. SMA-derived Schwann cells also 
promoted instability in neighbouring healthy neurons. I demonstrated that neurite 
instability was not due to the generation of a neurotoxic agent secreted from SMA 
Schwann cells. Rather, I showed that the extracellular matrix was disrupted in SMA 
Schwann cells both in vitro and in vivo, providing a possible explanation for the 
observed neurite instability.   
3) Can molecular pathways driving SMA Schwann cell defects be 
identified? 
Using label-free proteomics, 195 proteins were identified in SMA Schwann cells 
with > 20% up- or down-regulation in their expression levels compared to control 
Schwann cells. Functional clustering analyses revealed that the majority of these 
proteins are known pathological proteins contributing to myopathies and 
neurological disorders. Differentially expressed proteins were demonstrated to 
contribute to several cellular functions, including cell proliferation, death and 
assembly. I verified that apoptosis was increased in Schwann cells from SMA mice. 
Proteins contributing to glucogenesis and ubiquitination pathways were also shown 
to be modified in SMA-derived Schwann cells. Reduction in expression levels of 
UBA1 in SMA-derived Schwann cells verified the ubiquitination disruption 
observed in functional clustering analysis. Pharmacological inhibition of UBA1 in 
healthy Schwann cells reduced myelin protein expression and phenocopied Schwann 
cell defects in SMA mice. Thus, I showed that disruption to ubiquitination pathways 
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was responsible, at least in part, for intrinsic defects in Schwann cells from SMA 
mice. 
6.2 Contribution of cells and tissues other than motor neurons to 
SMA pathogenesis 
Although SMA is traditionally known as neuromuscular and lower motor neuron 
disease, it has become increasingly clear that other cells and tissues are also involved 
(Hamilton & Gillingwater, 2013). The identification of Schwann cell pathology in 
this thesis supports the hypothesis that it is not only motor neurons that are affected. 
The important finding of this study is that Schwann cell pathology can occur 
independently of axonopathy and neurodegeneration. Rather, I found that SMA 
Schwann cells induced neurite instability and contributed directly to defective 
myelination. Interestingly, Schwann cells appeared to promote neurite instability, at 
least in part, by producing a disrupted extracellular matrix. However, although 
intrinsic Schwann cell defects may contribute to SMA pathogenesis in mouse 
models, their relative contribution to the overall disease status of human patients 
with SMA remains unclear and will need further investigation. 
Several therapeutic approaches are currently under investigation, but there is still no 
cure for SMA. The identification of new target cells for SMN, such as Schwann 
cells, will hopefully lead to the design of more efficient and better-targeted 
treatments for the disease. Recently, it has been proposed that therapies which aimed 
to increase SMN levels, should be delivered systematically due to the involvement of 
non-neuromuscular tissues in SMA pathogenesis (Sleigh et al., 2011). However, 
different cell types and tissues have differential susceptibility to SMN reduction (the 
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threshold hypothesis of SMA) and therefore, it is important to achieve a maintenance 
level of SMN in all affected cells (Sleigh et al., 2011). Also the developmental time 
point in which SMN delivery could inhibit pathology is a key factor for efficient 
treatment. For instance, it has been reported that SMN delivery with scAAV9 at P1 
in SMAΔ7 mice improved lifespan to 250 days, whereas SMN administration at P10 
had little effect, indicating that earlier SMN replacement leads to better survival 
(Foust et al., 2010). Thus, differently affected cells may require delivery of therapy 
at different developmental time windows to achieve the optimal treatment for SMA. 
This study confirms an important role for SMN in regulating ubiquitination 
pathways. A recent study has shown that SMN reduction disrupts the ubiquitination 
pathway, and UBA1 in particular (Wishart et al., 2014). Beta-catenin was found to 
be a downstream mediator of UBA1-dependent pathology in spinal cord and muscle, 
but still unknown effectors mediated non-neuromuscular pathology (Wishart et al., 
2014). Similarly, I demonstrate that beta-catenin is not responsible for mediating 
ubiquitination pathway-dependent disruption in SMA Schwann cells. Therefore, 
SMA treatments targeting beta-catenin are unlikely to ameliorate Schwann cell 
pathology. However, targeting UBA1 would be likely to have therapeutic effects for 
Schwann cells as well as the neuromuscular system. 
6.3 In vitro analysis of peripheral neuropathies 
Several protocols have been proposed for the isolation and purification of Schwann 
cells from neonatal mice (Seilheimer et al., 1989; Dong et al., 1999; Nicholson et al., 
2001). However, these publications have not reported the number of Schwann cells 
they obtained and their ability to produce myelin. Recently Honkanen et al. 
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published a protocol in which they isolated 1.9-3.3 X 106 of 95% pure myelin-
competent Schwann cells from 12-15 4-day-old mouse pups (Honkanen et al., 2007). 
Using this protocol in ‘Taiwanese’ SMA mice, I showed that the number of Schwann 
cells obtained was not sufficient for quantitative analysis. I therefore developed the 
protocol in order to obtain higher number of Schwann cells, as well as using older 
pups to allow me to distinguish between healthy and SMA mice before pooling their 
sciatic nerves for experiments. 
The new protocol I have developed might now be considered useful for in vitro 
studies of Schwann cells in other peripheral neuropathies, such as Charcot-Marie-
Tooth disease. To my knowledge, most in vitro CMT studies have been performed 
either using DRG neuron-Schwann cell co-cultures from rat models (Nobbio et al., 
2006) or using mouse DRG explants (Liu et al., 2005). The potential of rat DRG 
neuron-Schwann cell co-culture is severely compromised by the lack of rat myelin 
mutants with the exception of the rat model of human CMT1A disease (Nobbio et 
al., 2006). In DRG explant culture models, neurons and Schwann cells are 
necessarily derived from the same animal and studies are thus restricted to a single 
genotype expressed by both neurons and Schwann cells. In order to dissect complex 
interactions between peripheral neuron and Schwann cell, co-cultures of mixed 
genotype are useful. For instance, in our study Schwann cells from SMA mice 
induce instability and abnormal myelination in healthy DRG neurons from wild-type 
mice, indicating that the myelination defects I observed are not just the consequence 
of neurodegeneration, a result that cannot have been determined by using DRG 
explant cultures. 
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6.4 Proteomic analysis in neurodegenerative disorders 
Proteomics, the large-scale analysis of protein expression, is routinely used to 
understand molecular alterations during development, pathogenesis and drug 
treatments (Tyers & Mann, 2003). The proteome is not as uniform and static as the 
genome (Adams, 2008). In addition, post-transcriptional modifications, such as 
methylation, phosphorylation, glycosylation and ubiquitination add extra complexity 
to the proteome (Jensen, 2006). Therefore, studying proteomics has been suggested 
to be more beneficial than genomic analysis to understand complex cellular functions 
and their alterations in development and pathologies (Adams, 2008). 
Proteomic analysis has previously been used in SMA studies. Proteomic analysis of 
embryonic stem (ES) cells derived from severe SMA mice revealed that SMN 
depletion activated cellular stress pathways, disrupted energy metabolism and 
cytoskeletal stability (Wu et al., 2011). Widespread molecular changes have also 
been observed by proteomic analysis of the hippocampus in SMA mice (Wishart et 
al., 2010). Proteomic analysis has also been used to identify drug targets and their 
potential side effects in SMA. Valproate treatment has reported to reduce collagen I 
synthesis, resulting in bone loss (Fuller et al., 2010). Label-free proteomics has also 
identified calreticulin and GRP75/mortalin as biomarkers for reporting on SMA 
disease progress in samples of muscle and skin (Mutsaers et al., 2013). In another 
study, protein biomarkers have been identified in plasma by iTRAQ proteomics in 
human patients (Finkel et al., 2012). Therefore, proteomic analysis is a powerful tool 
for identification of SMA biomarkers. In this study, I performed proteomics screen in 
isolated Schwann cells. Unlike previous proteomic screens, I used homogenous cell 
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population and therefore was able to identify cell type-specific molecular changes in 
SMA pathogenesis. In the system I have used, both control and SMA Schwann cells 
were extracted from the same litter, which introduced less variability to the 
proteomic results. These experimental refinements meant that I also obtained a larger 
coverage of proteins than in the previous proteomic studies discussed above. In order 
to interpret such a large amount of data, differentially expressed proteins were 
clustered using IPA analysis with respect to their known functions in biological 
systems (Wishart et al., 2010). Therefore, proteomic analysis combined with 
bioinformatics enabled me to identify the molecular pathways that may contribute to 
intrinsic defects in Schwann cells. This suggests that the same approach should 
perhaps now be used in other isolated cell populations affected in SMA to unravel 
the molecular pathways contributing to disease pathogenesis. 
Proteomic analysis has previously been shown to provide insights into other 
neurodegenerative disorders. For instance, the glial contribution to neuroprotection 
has recently been investigated in ALS primary cultured mouse astrocytes. Isotope 
labelling quantitative proteomics has been performed to identify secreted factors 
from astrocyte in response to motor neuron-derived angiogenin (ANG) stimulation 
(Skorupa et al., 2013). ANG induces astrocytes to secrete neuroprotective factors and 
its mutation has been observed in ALS patients (Skorupa et al., 2013). The proteomic 
analysis identified a set of astrocyte-derived proteins that may have a neuroprotective 
role and can slow ALS progression (Skorupa et al., 2013). Therefore, proteomic 
analysis is a powerful platform to study glial contribution not only in SMA but also 
in other neuromuscular disorders. 
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6.5 Ubiquitin-proteasome system disruption in neurodegeneration  
In section 6.2, I discussed how ubiquitination pathways were disrupted in SMA 
Schwann cells. However, SMA is not the only neurological disorder that exhibits 
ubiquitination-proteasome disruption. Several other neurodegenerative diseases are 
associated with the formation of ubiquitinated conjugates that are unable to be 
degraded by a compromised proteasome system and in response form aggregates in 
cell bodies (Rubinsztein, 2006).  Some examples of such ubiquitinated aggresomes 
are PMP22 aggregates in CMT1A (Fortun et al., 2006), neurofibrillary tangles in 
Alzheimer’s disease, Lewy bodies in Parkinson’s disease and Bunina bodies in 
amyotrophic lateral sclerosis (Shaw, 2005; Schmitt, 2006; Fortun et al., 2006). 
Duplication in the PMP22 gene in CMT1A leads to overexpression of PMP22 
protein. Faulty proteins are ubiquitinated, but excess PMP22 overloads the 
proteasome system, leading to disruption in Schwann cell intracellular sorting of 
PMP22 and other proteins. Interestingly, PMP22 aggresome formation induces 
demyelination that occurs before onset of neurodegeneration (Fortun et al., 2006).  It 
is still not known whether disruption to the ubiquitin-proteasome system in SMA 
Schwann cells forms any aggregates in the cytoplasm. Therefore, further work on the 
consequences of disruption in ubiquitination pathway in Schwann cells is required. 
6.6 Conclusion 
Taken together, I have shown here that Schwann cells may contribute to the 
pathogenesis of SMA. First, I demonstrate intrinsic defects in SMA Schwann cells, 
leading to abnormal myelination and neurite instability. Next, SMA Schwann cell 
defects have been shown to be independent of neuronal degeneration. Finally, I show 
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that ubiquitin homeostasis is disrupted in SMA Schwann cells, contributing to 
pathology via pathways independent of beta-catenin. These new insights extend our 
knowledge of SMA pathogenesis as a multi-system disorder and will hopefully lead 
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Appendix 1: Functional clustering revealed cellular growth and 
proliferation were significantly affected in Schwann cells from 
SMA mice 
Disease or function 
annotation 
P-value Molecules 
Proliferation of cells 1.10E-13 ADAM10, AKAP12, ALB, ALDH1A1, ANXA1, ANXA2, ANXA7, 
ASAH1, ATP5A1, ATP5B, CCT2, CDC42, CFL1, CLIC1, COL1A1, 
COL1A2, CRLF1, CTNNA1, CTSB, CTSD, CTTN, DBN1, DNAJA1, 
DNAJA2, DNM2, DSP, EEF1B2, EIF3C/EIF3CL, EIF4A1, FHL2, 
FLNA, FMR1, FN1, FSCN1, GNB1, GNB2L1, GPI, GSN, GSTP1, 
HADHA, HK1, HNRNPK, HNRNPM, HNRNPU, HSP90B1, HSPA5, 
HSPD1, IGF2R, ITGB1, JUP, LAMC1, LASP1, LEPRE1, LGALS1, 
LMNA, MTAP, MVP, NAP1L1, P4HA2, PCYOX1, PDCD6IP, PFN1, 
PGK1, PLEC, PRDX1, PRDX2, PRMT1, PSAP, PSMC1, RAB1A, 
RNH1, RPS4X, S100A10, S100A4, SEC23A, SERPINH1, SNCG, SND1, 
SOD1, SPTAN1, SPTBN1, SQSTM1, STAT3, SUGT1, SURF4, TCP1, 
TPP2, TXNDC5, TXNL1, TXNRD1, UBA1, UCHL1, VCP, VDAC1, 
YWHAG, YWHAQ 
Proliferation of 
breast cancer cell 
lines 
9.19E-08 ANXA2, ASAH1, CTSD, EEF1B2, EIF3C/EIF3CL, FN1, GNB2L1, 
HNRNPK, HSPA5, ITGB1, LGALS1, MTAP, PFN1, PRDX2, S100A4, 
SNCG, SND1, STAT3, UBA1, YWHAQ 
Proliferation of 
tumor cell lines 
3.38E-07 AKAP12, ALDH1A1, ANXA1, ANXA2, ANXA7, ASAH1, CDC42, 
COL1A1, CTSB, CTSD, CTTN, EEF1B2, EIF3C/EIF3CL, EIF4A1, 
FHL2, FLNA, FN1, FSCN1, GNB2L1, HK1, HNRNPK, HSPA5, IGF2R, 
ITGB1, JUP, LGALS1, MTAP, PDCD6IP, PFN1, PRDX2, PRMT1, 
S100A10, S100A4, SNCG, SND1, SOD1, SPTAN1, STAT3, TCP1, 
TPP2, UBA1, UCHL1, YWHAG, YWHAQ 
Metastasis of tumor 
cell lines 
2.69E-05 ASAH1, CTSB, CTTN, FN1, PRDX2, S100A4, SNCG, SND1 
Metastasis of breast 
cancer cell lines 
4.15E-05 CTSB, PRDX2, S100A4, SNCG, SND1 
Proliferation of 
carcinoma cell lines 
3.05E-04 ANXA1, ANXA2, FHL2, FSCN1, HK1, IGF2R, ITGB1, JUP, S100A10, 
SOD1, STAT3, UCHL1 
Neoplasia of tumor 
cell lines 
3.72E-04 ASAH1, CTSB, CTTN, FN1, JUP, PDCD6IP, PRDX2, S100A4, SNCG, 
SND1 
Proliferation of 9.08E-04 AKAP12, ALDH1A1, ANXA7, ASAH1, FSCN1, HK1, IGF2R, ITGB1, 
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Disease or function 
annotation 
P-value Molecules 






1.15E-03 ADAM10, STAT3 
Metastasis of 
carcinoma cell lines 
1.26E-03 CTTN, FN1, S100A4 
Colony formation of 
leukemia cell lines 
1.91E-03 ALDH1A1, CTSB, SQSTM1 
Colony formation of 
cells 
2.98E-03 AKAP12, ALDH1A1, ANXA1, ANXA7, CDC42, CTSB, CTSD, JUP, 
LEPRE1, S100A10, SOD1, SQSTM1, STAT3, SUGT1 
Colony formation of 
tumor cell lines 
3.31E-03 ALDH1A1, ANXA1, ANXA7, CTSB, CTSD, S100A10, SOD1, 
SQSTM1, STAT3 
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Appendix 2: Functional clustering revealed cell death and survival 
were significantly affected in Schwann cells from SMA mice 
Disease or function 
annotation 
P-value Molecules 
Cell death 7.22E-13 ADH5, AKAP12, ALB, ALDH1A1, ALDOA, ANXA1, ANXA2, 
ANXA5, ANXA7, AP2A2, ASAH1, ASS1, ATP5A1, CANX, CCT2, 
CCT8, CDC42, CFL1, COL1A1, CRLF1, CTNNA1, CTSB, CTSD, 
CTTN, DDAH2, DHX9, DNAJA1, DNM2, DSG1, DSP, EIF3C/EIF3CL, 
FHL2, FLNA, FN1, GFPT1, GLUD1, GNB2, GNB2L1, GPI, GSN, 
GSTP1, HADHA, HK1, HNRNPK, HSP90B1, HSPA4, HSPA5, HSPA9, 
HSPD1, HSPH1, HYOU1, IGF2R, ITGB1, JUP, LGALS1, LMNA, 
MAP1B, MDH1, MVP, NSF, PDCD6IP, PLEC, PRDX1, PRDX2, PSAP, 
PSMC1, Rpl10, RPLP0, RPS3, RTN4, S100A10, S100A4, SNCG, SND1, 
SOD1, SORBS2, SPTBN1, SQSTM1, STAT3, TCP1, TPP2, TUFM, 
TXNDC5, TXNRD1, UBA1, UCHL1, VCP, VDAC1, VDAC2, YWHAG, 
YWHAQ, YWHAZ 
Apoptosis 1.10E-12 ADH5, AKAP12, ALB, ALDH1A1, ALDOA, ANXA1, ANXA2, 
ANXA5, ANXA7, AP2A2, ASAH1, ASS1, CANX, CCT2, CDC42, 
CFL1, COL1A1, CRLF1, CTNNA1, CTSB, CTSD, CTTN, DDAH2, 
DHX9, DNM2, DSG1, DSP, EIF3C/EIF3CL, FHL2, FN1, GFPT1, 
GLUD1, GNB2, GNB2L1, GPI, GSN, GSTP1, HK1, HNRNPK, 
HSP90B1, HSPA4, HSPA5, HSPA9, HSPD1, HSPH1, HYOU1, IGF2R, 
ITGB1, JUP, LGALS1, LMNA, MAP1B, MDH1, PDCD6IP, PRDX1, 
PRDX2, PSAP, Rpl10, RPLP0, RPS3, RTN4, S100A10, S100A4, SNCG, 
SND1, SOD1, SORBS2, SPTBN1, STAT3, TCP1, TPP2, TXNDC5, 
UBA1, UCHL1, VCP, VDAC1, VDAC2, YWHAQ, YWHAZ 
Necrosis 6.60E-13 AKAP12, ALB, ALDH1A1, ALDOA, ANXA1, ANXA2, AP2A2, 
ASAH1, ASS1, ATP5A1, CCT2, CCT8, CDC42, COL1A1, CRLF1, 
CTNNA1, CTSB, CTSD, CTTN, DNM2, DSG1, DSP, EIF3C/EIF3CL, 
FHL2, FLNA, FN1, GFPT1, GLUD1, GNB2, GNB2L1, GPI, GSN, 
GSTP1, HADHA, HK1, HNRNPK, HSPA4, HSPA5, HSPA9, HSPD1, 
HSPH1, HYOU1, IGF2R, ITGB1, JUP, LGALS1, LMNA, MAP1B, 
MDH1, MVP, PDCD6IP, PLEC, PRDX1, PRDX2, PSAP, Rpl10, RPLP0, 
RPS3, RTN4, S100A10, S100A4, SND1, SOD1, SPTBN1, SQSTM1, 
STAT3, TCP1, TPP2, TUFM, TXNRD1, UBA1, UCHL1, VCP, VDAC1, 
VDAC2, YWHAG, YWHAQ, YWHAZ 
Cell death of tumor 
cell lines 
1.90E-11 AKAP12, ALB, ANXA2, AP2A2, ASAH1, ATP5A1, CCT2, CCT8, 
CDC42, COL1A1, CTSB, CTSD, CTTN, DNM2, DSG1, FN1, GNB2L1, 
GPI, GSN, GSTP1, HK1, HNRNPK, HSPA4, HSPA5, HSPA9, HSPD1, 
IGF2R, ITGB1, JUP, LGALS1, LMNA, PDCD6IP, PRDX1, PRDX2, 
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Disease or function 
annotation 
P-value Molecules 
PSAP, RPLP0, RPS3, RTN4, S100A4, SND1, SOD1, SQSTM1, STAT3, 
TCP1, TPP2, TUFM, TXNRD1, UCHL1, VCP, VDAC1, VDAC2, 
YWHAG, YWHAZ 
Apoptosis of tumor 
cell lines 
6.10E-09 AKAP12, ALB, ANXA2, AP2A2, CCT2, CDC42, COL1A1, CTSB, 
CTSD, CTTN, DNM2, DSG1, FN1, GNB2L1, GSN, GSTP1, HNRNPK, 
HSPA4, HSPA5, HSPA9, HSPD1, IGF2R, ITGB1, JUP, LGALS1, 
PDCD6IP, PRDX1, PSAP, RPLP0, RPS3, RTN4, S100A4, SND1, SOD1, 
STAT3, TCP1, UCHL1, VCP, VDAC1, VDAC2, YWHAZ 
Cell survival 2.84E-05 ASAH1, ASS1, CDC42, COL1A1, CTSB, DHX9, DNM2, EEF2, 
EIF3C/EIF3CL, FLNA, FN1, GLUD1, GNB2L1, GSTP1, HNRNPU, 
HSP90B1, HSPA4, HSPA5, HSPD1, HYOU1, IGF2R, ITGB1, JUP, 
LMNA, MVP, PRDX2, PSMA4, S100A4, SND1, SOD1, SQSTM1, 
STAT3, TCP1, TXNDC5, VCP, VDAC1, YWHAZ 
Cell viability 7.07E-05 ASAH1, ASS1, CDC42, COL1A1, CTSB, DNM2, EEF2, EIF3C/EIF3CL, 
FLNA, FN1, GLUD1, GNB2L1, GSTP1, HNRNPU, HSP90B1, HSPA5, 
HSPD1, HYOU1, IGF2R, ITGB1, LMNA, MVP, PRDX2, PSMA4, 
S100A4, SND1, SOD1, SQSTM1, STAT3, TCP1, TXNDC5, VCP, 
VDAC1, YWHAZ 
Neuronal cell death 2.13E-05 ASAH1, CDC42, CRLF1, CTSB, CTSD, FN1, GLUD1, GPI, HSPA5, 
HSPD1, HSPH1, HYOU1, ITGB1, LGALS1, MAP1B, PDCD6IP, 
PRDX2, RPS3, SOD1, STAT3, TCP1, UCHL1, YWHAZ 
Cell death of 
connective tissue 
cells 
1.44E-05 ASAH1, CDC42, CTSB, CTSD, EIF3C/EIF3CL, FLNA, FN1, GNB2, 
GPI, GSN, GSTP1, HSPA5, HSPD1, IGF2R, ITGB1, LMNA, Rpl10, 
STAT3, TPP2, UBA1, VCP, YWHAZ 
Cell viability of 
tumor cell lines 
2.24E-04 ASAH1, COL1A1, DNM2, EEF2, EIF3C/EIF3CL, FLNA, FN1, GLUD1, 
GNB2L1, GSTP1, HSP90B1, HSPA5, IGF2R, ITGB1, PRDX2, PSMA4, 
S100A4, SOD1, SQSTM1, STAT3, TCP1, VCP 
Apoptosis of 
neurons 
2.10E-05 ASAH1, CDC42, CRLF1, CTSB, FN1, GLUD1, GPI, HSPA5, HSPD1, 
HSPH1, HYOU1, LGALS1, MAP1B, PDCD6IP, PRDX2, RPS3, SOD1 
Cell death of 
fibroblast cell lines 
1.46E-04 ASAH1, CTSB, CTSD, EIF3C/EIF3CL, FN1, GNB2, GPI, GSN, GSTP1, 
HSPA5, HSPD1, ITGB1, Rpl10, UBA1, VCP, YWHAZ 
Cell death of kidney 
cells 
1.24E-04 ALB, CDC42, GFPT1, GNB2, GSN, GSTP1, HK1, HSPA5, HYOU1, 
ITGB1, SOD1, VCP, VDAC1, YWHAQ 
Cell death of 
cervical cancer cell 
lines 
1.27E-04 CTSB, HNRNPK, LMNA, PDCD6IP, PRDX2, SOD1, SQSTM1, STAT3, 
TCP1, TXNRD1, UCHL1, VCP, VDAC1 
cell death of kidney 
cell lines 
3.49E-04 CDC42, GNB2, GSN, GSTP1, HK1, HSPA5, HYOU1, ITGB1, SOD1, 
VCP, VDAC1, YWHAQ 
Cell death of colon 
cancer cell lines 
2.97E-04 AP2A2, CDC42, GSN, GSTP1, HSPD1, IGF2R, ITGB1, LMNA, 
SQSTM1, TXNRD1, VCP 
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Disease or function 
annotation 
P-value Molecules 
Cell death of 
neuroblastoma cell 
lines 
5.35E-05 ATP5A1, CCT2, CCT8, CDC42, ITGB1, PRDX2, SOD1, SQSTM1, 
STAT3, TCP1 
Cell death of central 
nervous system cells 
2.71E-03 ALB, CDC42, CTSD, HSPA5, HSPD1, HYOU1, MAP1B, RPS3, SOD1, 
TCP1 
Cell death of 
cerebral cortex cells 
1.18E-03 CDC42, CTSD, HSPA5, HSPD1, HYOU1, MAP1B, RPS3, SOD1, TCP1 
Cell death of 
fibroblasts 
3.39E-03 CDC42, CTSD, FLNA, GPI, IGF2R, ITGB1, LMNA, STAT3, TPP2 
Cellular degradation 6.70E-04 CTSB, CTSD, PSAP, PSMC1, SOD1, SQSTM1, STAT3, UCHL1 
Cell death of 
carcinoma cell lines 
2.95E-03 AP2A2, CTTN, GPI, HK1, HSPA5, SOD1, STAT3, UCHL1 
Cell death of 
lymphoma cell lines 
2.95E-03 ALB, ANXA2, LGALS1, RPLP0, STAT3, TPP2, YWHAG, YWHAZ 
Degeneration of 
neurons 
2.14E-03 CTSB, CTSD, PSAP, PSMC1, SOD1, STAT3, UCHL1 
Apoptosis of 
prostate cancer cell 
lines 
3.71E-03 AKAP12, FN1, HSPA5, HSPD1, ITGB1, LGALS1, STAT3 
Cell death of 
pheochromocytoma 
cell lines 
2.57E-03 CDC42, PSAP, RPS3, SOD1, STAT3, VCP 
Cell viability of 
brain cancer cell 
lines 
2.27E-04 DNM2, EEF2, GLUD1, HSPA5, STAT3 
Cell viability of 
myeloma cell lines 




3.16E-03 CDC42, PSAP, RPS3, SOD1, STAT3 
Cell death of 
endothelial cell lines 
2.62E-03 CTSD, FN1, HYOU1, SOD1 
Delay in apoptosis 
of fibroblast cell 
lines 
1.72E-03 FN1, GSN 
Killing of cervical 
cancer cell lines 
4.03E-03 GSTP1, HNRNPK 
Cell death 7.22E-13 ADH5, AKAP12, ALB, ALDH1A1, ALDOA, ANXA1, ANXA2, 
ANXA5, ANXA7, AP2A2, ASAH1, ASS1, ATP5A1, CANX, CCT2, 
CCT8, CDC42, CFL1, COL1A1, CRLF1, CTNNA1, CTSB, CTSD, 
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Disease or function 
annotation 
P-value Molecules 
CTTN, DDAH2, DHX9, DNAJA1, DNM2, DSG1, DSP, EIF3C/EIF3CL, 
FHL2, FLNA, FN1, GFPT1, GLUD1, GNB2, GNB2L1, GPI, GSN, 
GSTP1, HADHA, HK1, HNRNPK, HSP90B1, HSPA4, HSPA5, HSPA9, 
HSPD1, HSPH1, HYOU1, IGF2R, ITGB1, JUP, LGALS1, LMNA, 
MAP1B, MDH1, MVP, NSF, PDCD6IP, PLEC, PRDX1, PRDX2, PSAP, 
PSMC1, Rpl10, RPLP0, RPS3, RTN4, S100A10, S100A4, SNCG, SND1, 
SOD1, SORBS2, SPTBN1, SQSTM1, STAT3, TCP1, TPP2, TUFM, 
TXNDC5, TXNRD1, UBA1, UCHL1, VCP, VDAC1, VDAC2, YWHAG, 
YWHAQ, YWHAZ 
Apoptosis 1.10E-12 ADH5, AKAP12, ALB, ALDH1A1, ALDOA, ANXA1, ANXA2, 
ANXA5, ANXA7, AP2A2, ASAH1, ASS1, CANX, CCT2, CDC42, 
CFL1, COL1A1, CRLF1, CTNNA1, CTSB, CTSD, CTTN, DDAH2, 
DHX9, DNM2, DSG1, DSP, EIF3C/EIF3CL, FHL2, FN1, GFPT1, 
GLUD1, GNB2, GNB2L1, GPI, GSN, GSTP1, HK1, HNRNPK, 
HSP90B1, HSPA4, HSPA5, HSPA9, HSPD1, HSPH1, HYOU1, IGF2R, 
ITGB1, JUP, LGALS1, LMNA, MAP1B, MDH1, PDCD6IP, PRDX1, 
PRDX2, PSAP, Rpl10, RPLP0, RPS3, RTN4, S100A10, S100A4, SNCG, 
SND1, SOD1, SORBS2, SPTBN1, STAT3, TCP1, TPP2, TXNDC5, 
UBA1, UCHL1, VCP, VDAC1, VDAC2, YWHAQ, YWHAZ 
Necrosis 6.60E-13 AKAP12, ALB, ALDH1A1, ALDOA, ANXA1, ANXA2, AP2A2, 
ASAH1, ASS1, ATP5A1, CCT2, CCT8, CDC42, COL1A1, CRLF1, 
CTNNA1, CTSB, CTSD, CTTN, DNM2, DSG1, DSP, EIF3C/EIF3CL, 
FHL2, FLNA, FN1, GFPT1, GLUD1, GNB2, GNB2L1, GPI, GSN, 
GSTP1, HADHA, HK1, HNRNPK, HSPA4, HSPA5, HSPA9, HSPD1, 
HSPH1, HYOU1, IGF2R, ITGB1, JUP, LGALS1, LMNA, MAP1B, 
MDH1, MVP, PDCD6IP, PLEC, PRDX1, PRDX2, PSAP, Rpl10, RPLP0, 
RPS3, RTN4, S100A10, S100A4, SND1, SOD1, SPTBN1, SQSTM1, 
STAT3, TCP1, TPP2, TUFM, TXNRD1, UBA1, UCHL1, VCP, VDAC1, 
VDAC2, YWHAG, YWHAQ, YWHAZ 
Cell death of tumor 
cell lines 
1.90E-11 AKAP12, ALB, ANXA2, AP2A2, ASAH1, ATP5A1, CCT2, CCT8, 
CDC42, COL1A1, CTSB, CTSD, CTTN, DNM2, DSG1, FN1, GNB2L1, 
GPI, GSN, GSTP1, HK1, HNRNPK, HSPA4, HSPA5, HSPA9, HSPD1, 
IGF2R, ITGB1, JUP, LGALS1, LMNA, PDCD6IP, PRDX1, PRDX2, 
PSAP, RPLP0, RPS3, RTN4, S100A4, SND1, SOD1, SQSTM1, STAT3, 
TCP1, TPP2, TUFM, TXNRD1, UCHL1, VCP, VDAC1, VDAC2, 
YWHAG, YWHAZ 
Delay in apoptosis 
of fibroblast cell 
lines 
6.10E-09 AKAP12, ALB, ANXA2, AP2A2, CCT2, CDC42, COL1A1, CTSB, 
CTSD, CTTN, DNM2, DSG1, FN1, GNB2L1, GSN, GSTP1, HNRNPK, 
HSPA4, HSPA5, HSPA9, HSPD1, IGF2R, ITGB1, JUP, LGALS1, 
PDCD6IP, PRDX1, PSAP, RPLP0, RPS3, RTN4, S100A4, SND1, SOD1, 
STAT3, TCP1, UCHL1, VCP, VDAC1, VDAC2, YWHAZ 
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Disease or function 
annotation 
P-value Molecules 
Killing of cervical 
cancer cell lines 
2.84E-05 ASAH1, ASS1, CDC42, COL1A1, CTSB, DHX9, DNM2, EEF2, 
EIF3C/EIF3CL, FLNA, FN1, GLUD1, GNB2L1, GSTP1, HNRNPU, 
HSP90B1, HSPA4, HSPA5, HSPD1, HYOU1, IGF2R, ITGB1, JUP, 
LMNA, MVP, PRDX2, PSMA4, S100A4, SND1, SOD1, SQSTM1, 
STAT3, TCP1, TXNDC5, VCP, VDAC1, YWHAZ 
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Appendix 3: Functional clustering revealed molecular transport 
was significantly affected in Schwann cells from SMA mice 





7.44E-09 ALB, ANXA1, ANXA2, ANXA6, AP2A1, AP2A2, ASAH1, ATP5A1, 
ATP5B, CANX, CDC42, CFL1, CLIC1, COL1A1, DNAJA1, DNAJA2, 
FMR1, FN1, GDI2, GSN, HNRNPA3, HSPA9, IGF2R, ITGB1, JUP, 
KPNB1, LASP1, LGALS1, MAP1B, MYO1C, NPC2, NSF, PCYOX1, 
PDIA4, PSAP, RAB1A, RAB6A, RTN4, SEC23A, SEPT2, SNCG, 
SOD1, SPTBN1, SQSTM1, STAT3, USO1, VDAC1, VDAC2, YWHAZ 
Transport of protein 2.29E-11 AP2A1, AP2A2, CFL1, COL1A1, DNAJA1, DNAJA2, GDI2, HSPA9, 
IGF2R, JUP, KPNB1, MAP1B, NSF, RAB1A, RAB6A, SEC23A, SOD1, 
SPTBN1, SQSTM1, STAT3, USO1 
Secretion of 
molecule 
1.71E-04 ANXA1, ANXA2, ANXA6, ASAH1, CANX, CDC42, FN1, GSN, 





CFL1, DNAJA1, DNAJA2, DNM2, JUP, KPNB1, SPTBN1, STAT3 
Import of protein 8.10E-06 CFL1, DNAJA1, DNAJA2, JUP, KPNB1, SPTBN1, STAT3 






















Appendix 4: IPA analysis showed protein trafficking was 
significantly affected in Schwann cells from SMA mice 
Disease or function 
annotation 
P-value Molecules 
Transport of protein 2.29E-11 AP2A1, AP2A2, CFL1, COL1A1, DNAJA1, DNAJA2, GDI2, HSPA9, 
IGF2R, JUP, KPNB1, MAP1B, NSF, RAB1A, RAB6A, SEC23A, 
SOD1, SPTBN1, SQSTM1, STAT3, USO1 
Internalization of 
protein 
7.23E-06 CFL1, DNAJA1, DNAJA2, DNM2, JUP, KPNB1, SPTBN1, STAT3 
Import of protein 8.10E-06 CFL1, DNAJA1, DNAJA2, JUP, KPNB1, SPTBN1, STAT3 
Secretion of protein 8.60E-04 ANXA1, ANXA2, CANX, CDC42, MYO1C, PDIA4, SEC23A 
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Appendix 5: Functional clustering indicated cellular assembly and 
organisation were significantly affected in Schwann cells from 
SMA mice 





1.13E-08 ACTR3 ADD1, AKAP12, ALDOA, ANXA1, CANX, CAPG, CAPZB, 
CDC42, CFL1, CORO1C, CTTN, DBN1, DNM2, DSP, EPB41L2, FHL2, 
FLNA, FMR1, FN1, FSCN1, GOLGB1, GORASP2, GSN, ITGB1, JUP, 
KPNB1, LAMC1, LASP1, MAP1B, PFN1, PLS3, PRMT1, RAB6A, 




8.50E-08 ACTR3, ADD1, AKAP12, ALDOA, ANXA1, CANX, CAPG, CAPZB, 
CDC42, CFL1, CORO1C, CTTN, DBN1, DNM2, DSP, EPB41L2, FHL2, 
FLNA, FMR1, FN1, FSCN1, GSN, ITGB1, JUP, KPNB1, LAMC1, 
LASP1, MAP1B, PFN1, PLS3, PRMT1, RTN4, S100A4, SEPT2, SOD1, 
SPTAN1, SPTBN1, STAT3, TLN1, UCHL1 
Microtubule 
dynamics 
1.93E-05 ACTR3, AKAP12, CANX, CAPG, CAPZB, CDC42, CFL1, CTTN, 
DBN1, DNM2, DSP, FLNA, FMR1, FN1, FSCN1, GSN, ITGB1, 
KPNB1, LAMC1, LASP1, MAP1B, PFN1, PRMT1, RTN4, S100A4, 
SEPT2, SOD1, SPTBN1, STAT3, TLN1, UCHL1 
Organization of 
organelle 
2.18E-10 ALDOA, ANXA2, CAPZB, CDC42, CFL1, COL1A1, COL1A2, 
COL3A1, CTNNA1, DBN1, DSP, FLNA, FN1, GOLGB1, GORASP2, 




5.08E-05 ACTR3, AKAP12, CAPG, CAPZB, CDC42, CFL1, CTTN, DBN1, 
DNM2, FLNA, FMR1, FN1, FSCN1, ITGB1, LAMC1, LASP1, MAP1B, 
PFN1, PRMT1, RTN4, S100A4, SEPT2, SPTBN1, UCHL1 
Development of 
cytoplasm 
3.41E-07 ACTR3, ADD1, ANXA1, Cald1, CAPZB, CDC42, CFL1, CORO1C, 
CTSD, CTTN, FLNA, FN1, GNB1, GPI, GSN, ITGB1, MAP1B, 
PDCD6IP, PFN1, STAT3 
Formation of 
filaments 
3.38E-07 ACTR3, ADD1, Cald1, CAPZB, CDC42, CFL1, CTTN, FN1, GNB1, 




2.96E-07 ACTR3, ADD1, Cald1, CAPZB, CDC42, CFL1, CORO1C, CTTN, 




3.44E-11 ALDOA, ANXA2, CDC42, CFL1, COL1A1, COL1A2, COL3A1, DBN1, 
DSP, FLNA, FN1, ITGB1, JUP, P4HA1, PLS3, SERPINH1, SOD1 
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Disease or function 
annotation 
P-value Molecules 
Formation of actin 
filaments 
7.56E-06 ACTR3, ADD1, Cald1, CDC42, CFL1, CTTN, FN1, GNB1, GPI, GSN, 
ITGB1, PDCD6IP, PFN1, STAT3 
Outgrowth of 
neurites 
5.97E-04 ADAM10, CDC42, CORO1B, FN1, ITGB1, LGALS1, MAP1B, PSAP, 
RTN4, S100A4, SOD1, SPTBN1, STAT3, YWHAZ 
Neuritogenesis 2.74E-03 ACTR3, CAPZB, CDC42, DBN1, FMR1, ITGB1, LAMC1, MAP1B, 
PFN1, PRMT1, RTN4, SEPT2, SPTBN1, UCHL1 
Morphogenesis of 
neurites 
7.95E-04 ACTR3, CAPZB, CDC42, DBN1, FMR1, ITGB1, LAMC1, MAP1B, 
PFN1, PRMT1, RTN4, SEPT2 
Quantity of 
filaments 
1.79E-07 CDC42, CFL1, DNM2, DSP, FN1, GNB2L1, MAP1B, PLEC, 
SERPINH1, SPTAN1, STAT3 
Quantity of cellular 
protrusions 




3.53E-05 AKAP12, CDC42, CFL1, CORO1C, EPB41L2, FLNA, FN1, FSCN1, 
SEPT2, SPTAN1, TLN1 
Assembly of cell-
cell contacts 









5.31E-07 ALDOA, CDC42, CFL1, DBN1, FLNA, FN1, ITGB1, JUP, PLS3 
Reorganization of 
cytoskeleton 
1.74E-04 AKAP12, CDC42, CFL1, DSP, FLNA, FN1, JUP, PLS3, SPTAN1 
Formation of actin 
stress fibers 
1.18E-03 Cald1, CDC42, FN1, GNB1, GPI, ITGB1, PDCD6IP, PFN1, STAT3 
Formation of 
plasma membrane 
1.21E-03 CDC42, CTNNA1, DNM2, FMR1, ITGB1, JUP, LAMC1, RTN4, 
YWHAG 
Quantity of actin 
stress fibers 
1.78E-07 CDC42, CFL1, DNM2, FN1, GNB2L1, PLEC, SPTAN1, STAT3 
Organization of 
cellular membrane 




4.21E-05 CTSB, DNAJA1, HSPA4, PSAP, SOD1, SQSTM1, UCHL1 
Formation of 
vesicles 
1.50E-04 ANXA2, ANXA5, AP2A2, DNM2, FLNA, NSF, PDCD6IP 
Polymerization of 
filaments 
1.59E-04 ACTR3, ADD1, CAPZB, CDC42, CFL1, GSN, MAP1B 
Stabilization of 
filaments 
1.69E-04 CFL1, CTTN, DSP, FLNA, FMR1, MAP1B, STAT3 
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Disease or function 
annotation 
P-value Molecules 
Formation of focal 
adhesions 
7.25E-04 AKAP12, Cald1, CDC42, FN1, GNB1, ITGB1, NSF 
Formation of 
lamellipodia 
1.39E-03 ACTR3, CAPZB, CDC42, CFL1, DNM2, FN1, LASP1 
Formation of 
filopodia 
1.80E-03 ACTR3, AKAP12, CDC42, FN1, FSCN1, ITGB1, MAP1B 
Organization of 
collagen fibrils 
1.10E-06 ANXA2, COL1A1, COL1A2, COL3A1, P4HA1, SERPINH1 
Quantity of focal 
adhesions 
4.33E-06 Cald1, FLNA, FN1, GNB2L1, ITGB1, SPTAN1 
Fusion of cellular 
membrane 
2.06E-05 ANXA1, ANXA7, MYO1C, NSF, PSAP, USO1 
Fusion of vesicles 5.68E-05 ANXA1, ANXA2, ANXA7, MYO1C, NSF, VCP 
Organization of 
plasma membrane 
1.92E-04 CAPZB, CDC42, CFL1, CTNNA1, DSP, SPTBN1 
Reorganization of 
actin cytoskeleton 
5.04E-04 AKAP12, CDC42, CFL1, FLNA, FN1, SPTAN1 
Polymerization of 
actin filaments 
8.09E-04 ACTR3, ADD1, CDC42, CFL1, GSN 
Rearrangement of 
cytoskeleton 




8.66E-04 CAPZB, DSP, FMR1, JUP, SOD1 
Retraction of 
cellular protrusions 
1.90E-03 CDC42, FN1, GPI, GSN, MAP1B 
Quantity of plasma 
membrane 
projections 
2.73E-03 CANX, CDC42, FN1, MAP1B, SOD1 
Growth of Golgi 
cisternae 
6.73E-08 GOLGB1, NSF, USO1, VCP 
Formation of actin 
cytoskeleton 
1.25E-05 CORO1C, FLNA, FN1, ITGB1 
Formation of 
podosomes 
7.03E-05 Cald1, CDC42, CTTN, GSN 
Disruption of cell-
cell contacts 
1.68E-04 ANXA1, GNB2L1, ITGB1, SOD1 
Disruption of 
cytoskeleton 
3.40E-04 GSN, ITGB1, LMNA, PLEC 
Formation of actin 4.88E-04 ADD1, Cald1, CDC42, FSCN1 
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6.77E-04 GOLGB1, GORASP2, RAB6A, SURF4 
Reorganization of 
filaments 
6.77E-04 CDC42, DSP, JUP, PLS3 
Formation of 
desmosomes 
1.27E-06 DSG1, DSP, JUP 
Stabilization of 
actin filaments 
2.60E-04 CFL1, CTTN, FLNA 
Formation of 
fibronectin matrix 
3.35E-04 FN1, ITGB1, PDCD6IP 
Size of focal 
adhesions 
6.40E-04 Cald1, FLNA, NSF 
Transport of 
mitochondria 
6.40E-04 MAP1B, SOD1, UCHL1 
Length of dendritic 
spines 
7.71E-04 CDC42, DBN1, FMR1 
Organization of 
cellular protrusions 
7.71E-04 CAPZB, CFL1, FSCN1 
Organization of 
actin stress fibers 
1.26E-03 FN1, ITGB1, PLS3 
Trafficking of 
vesicles 
1.46E-03 ANXA5, AP2A2, RAB6A 
Release of granules 3.06E-03 FN1, LGALS1, NSF 
Extension of 
peripheral lamellae 
1.18E-04 GSN, ITGB1 
Fusion of vesicle 
membrane 
1.18E-04 ANXA7, PSAP 
Stabilization of 
hemidesmosomes 
1.18E-04 ITGB1, PLEC 
Transport of 
nucleus 
1.18E-04 FN1, GPI 
Assembly of axon 
initial segments 
3.51E-04 SPTAN1, SPTBN1 
Quantity of 
podosomes 
3.51E-04 Cald1, CDC42 
Retraction of 
filopodia 
3.51E-04 CDC42, GSN 
Binding of actin 6.97E-04 EPB41L2, YWHAZ 
Formation of basal 6.97E-04 ITGB1, LAMC1 
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6.97E-04 DSP, JUP 
Retraction of 
pseudopodia 
6.97E-04 FN1, GPI 
Depolymerization 
of actin 
1.15E-03 CFL1, PLEC 
Quantity of 
hemidesmosomes 
1.15E-03 ITGB1, PLEC 




2.39E-03 ANXA2, PDCD6IP 
Binding of 
ribosome 
3.16E-03 EEF1B2, HSPA5 
Elongation of actin 
filaments 
3.16E-03 INF2, PFN1 
Fusion of liposome 3.16E-03 ANXA1, ANXA2 
Localization of 
vesicles 
3.16E-03 CTTN, MYO1C 
Modification of 
cytoskeleton 
3.16E-03 GSN, S100A4 
Quantity of 
membrane ruffles 
3.16E-03 ADD1, SORBS2 
Size of dendritic 
trees 
3.16E-03 ITGB1, RTN4 
Formation of 
caveolae 




Appendix 6: List of publications, posters and presentations 
List of Publications 
Hunter G., Aghamaleky Sarvestany A., Roche S.L., Symes R.C., Gillingwater T.H., 
2014. SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal 
muscular atrophy. Hum Mol Genet. (In press) 
Aghamaleky Sarvestany A., Hunter G., Tavendale A., Lamont D.J., Llavero 
Hurtado M., Graham L., Wishart T.M., Gillingwater T.H., Label-free quantitative 
profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann 
cell defects in spinal muscular atrophy (In press)  
Anatomical Society Summer Meeting 2013-Talk 
Intrinsic defects in Schwann cells in spinal muscular atrophy 
Euan MacDonald Centre Post-Graduate Seminar 2013-Talk 
Intrinsic defects in Schwann cells in spinal muscular atrophy 
Edinburgh University Neuroscience Day 2013 
Intrinsic, SMN-dependent defects in Schwann cells in spinal muscular atrophy 
(SMA) 
 
 
